



European Dermatology Forum

EDF-Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) Part I

Developed by the Guideline Subcommittee “Atopic Eczema” of the
European Dermatology Forum

Subcommittee Members:

Prof. Dr. Andreas Wollenberg, Munich (Germany)
Dr. Sébastien Barbarot, Nantes (France)
Prof. Dr. Thomas Bieber, Bonn (Germany)
PD Dr. Stephanie Christen-Zaech, Lausanne (CH)
Prof. Dr. Mette Deleuran, Aarhus (Germany)
Dr. A Fink-Wagner, Konstanz (Germany)
Prof. Dr. Uwe Gielert, Gießen (Germany)
Prof. Dr. Giampiero Girolomoni, Verona (Italy)
Prof. Dr. Susanne Lau, Berlin (Germany)
Prof. Dr. Antonella Muraro, Padova (Italy)

Prof. Dr. Magdalena Czarnecka-Operacz, Poznan (Poland)
Prof. Dr. Torsten Schäfer, Immenstadt (Germany)
Prof. Dr. Peter Schmidt-Grendelmeier, Davos (Switzerland)
Prof. Dr. Dagmar Simon, Bern (Switzerland)
Prof. Dr. Zsuzsanna Szalai, Budapest (Hungary)
Prof. Dr. Jacek C. Szepietowski, Wrocław (Poland)
Prof. Dr. Alain Taieb, Bordeaux (France)
Prof. Dr. Antonio Torrelo, Madrid (Spain)
Prof. Dr. Thomas Werfel, Hanover (Germany)
Prof. Dr. Johannes Ring, Munich (Germany)

Members of EDF Guideline Committee:

Prof. Dr. Werner Aberer, Graz (Austria)
Prof. Dr. Martine Bagot, Paris (France)
Prof. Dr. Nicole Basset-Seguin, Paris (France)
Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany)
Prof. Dr. Lasse Braathen, Bern (Switzerland)
Prof. Dr. Sergio Chimenti, Rome (Italy)
Prof. Dr. Alexander Enk, Heidelberg (Germany)
Prof. Dr. Claudio Feliciani, Parma (Italy)
Prof. Dr. Claus Garbe, Tübingen (Germany)
Prof. Dr. Harald Gollnick, Magdeburg (Germany)
Prof. Dr. Gerd Gross, Rostock (Germany)
Prof. Dr. Michael Hertl, Marburg (Germany)
Prof. Dr. Dimitrios Ioannides, Thessaloniki (Greece)
Prof. Dr. Gregor Jemec, Roskilde (Denmark)
Prof. Dr. Lajos Kemény, Szeged (Hungary)
Dr. Gudula Kirtschig, Tübingen (Germany)
Prof. Dr. Robert Knobler, Vienna (Austria)
Prof. Dr. Annegret Kuhn, Muenster (Germany)
Prof. Dr. Marcus Maurer, Berlin (Germany)
Prof. Dr. Dieter Metze, Muenster (Germany)
Prof. Dr. Kai Munte, Rotterdam (Netherlands)

Prof. Dr. Gillian Murphy, Dublin (Ireland)
Prof. Dr. Alexander Nast, Berlin (Germany)
Prof. Dr. Martino Neumann, Rotterdam (Netherlands)
Prof. Dr. Tony Ormerod, Aberdeen (United Kingdom)
Prof. Dr. Mauro Picardo, Rome (Italy)
Prof. Dr. Annamari Ranki, Helsinki (Finland)
Prof. Dr. Johannes Ring, Munich (Germany)
Prof. Dr. Berthold Rzany, Berlin (Germany)
Prof. Dr. Rudolf Stadler, Minden (Germany)
Prof. Dr. Sonja Ständer, Münster (Germany)
Prof. Dr. Wolfram Sterry, Berlin (Germany)
Prof. Dr. Eggert Stockfleth, Bochum (Germany)
Prof. Dr. Alain Taieb, Bordeaux (France)
Prof. Dr. George-Sorin Tiplica, Bucharest (Romania)
Prof. Dr. Elke Weisshaar, Heidelberg (Germany)
Prof. Dr. Sean Whittaker, London (United Kingdom)
Prof. Dr. Fenella Wojnarowska, Oxford (United Kingdom)
Prof. Dr. Andreas Wollenberg, Munich (Germany)
Prof. Dr. Christos Zouboulis, Dessau (Germany)
Prof. Dr. Dr. Torsten Zuberbier, Berlin (Germany)

Chairman of EDF Guideline Committee:

Prof. Dr. Alexander Nast, Berlin (Germany)

Expiry date: 31.01.2021

Consensus based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children

Part I

Wollenberg A¹, Barbarot S², Bieber T³, Christen-Zaech S⁴, Deleuran M⁵, Fink-Wagner A⁶, Gieler U⁷, Girolomoni G⁸, Lau S⁹, Muraro A¹⁰, Czarnecka-Operacz M¹¹, Schäfer T¹², Schmid-Grendelmeier P¹³, Simon D¹⁴, Szalai Z¹⁵, Szepietowski JC¹⁶, Taïeb A¹⁷, Torrelo A¹⁸, Werfel T¹⁹, Ring J²⁰

For the European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients' Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS)

Correspondence to:
Prof. Dr. med. Dr. h.c. Andreas Wollenberg
Department of Dermatology and Allergology
Ludwig-Maximilian University
Frauenlobstr. 9-11, D-80337 Munich
Email: wollenberg@lrz.uni-muenchen.de

¹ Department Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany and Klinik Thalkirchner Straße, Munich, Germany

² Department of Dermatology, Centre Hospitalier Universitaire CHU Nantes, Nantes, France

³ Department of Dermatology and Allergy, and Christine Kühne-Center for Allergy Research and Education, University Bonn, Bonn, Germany

⁴ Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

⁵ Department Dermatology, Aarhus University Hospital, Aarhus, Denmark

⁶ Patient representative, European Federation of Allergy and Airways Diseases Patients' Associations (EFA) corporate Relations and Fundraising Manager and Co-Founder of Global Allergy and Asthma Patient Platform (GAAPP), Konstanz, Germany

⁷ Department of Dermatology and Dept. of Psychosomatics and Psychotherapy, University of Gießen and Marburg GmbH, Gießen, Germany

⁸ Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy

⁹ Pediatric Pneumology and Immunology, Universitätsmedizin Berlin, Germany

¹⁰ Centro di Specializzazione Regionale per lo Studio e la Cura delle Allergie e delle Intolleranze Alimentari presso l'Azienda Ospedaliera, Università di Padova, Italy

¹¹ Department of Dermatology, Medical University, Poznan, Poland

¹² Dermatological Practice, Immenstadt, Germany

¹³ Allergy Unit, Department of Dermatology, University of Zurich, Switzerland and Christine Kühne Center for Allergy research and Education CK-CARE, Davos, Switzerland

¹⁴ Department Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

¹⁵ Department of Dermatology, Heim Pál Children's Hospital, Budapest, Hungary

¹⁶ Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland

¹⁷ Department of Dermatology & Pediatric Dermatology, Hôpital St André, Bordeaux, France

¹⁸ Department of Dermatology, Hospital Niño Jesus, Madrid, Spain

¹⁹ Department Dermatology and Allergy, Hannover Medical School, Hannover, Germany

²⁰ Department Dermatology and Allergy Biederstein, Technische Universität München, Munich, Germany and Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos

Declaration of Conflict of Interest

A. Wollenberg has been an advisor, speaker or investigator for ALK Abelló, Almirall, Anacor, Astellas, Beiersdorf, Bencard, Bioderma, Chugai, Galderma, Glaxo SmithKline, Hans Karrer, LEO Pharma, L'Oreal, Maruho, MedImmune, Novartis, Pfizer, Pierre Fabre, Regeneron and Sanofi.

S.Barbarot has been an advisor, speaker or investigator for Bioderma, La Roche Posay, Sanofi-Genzyme, Novalac, Ferring, Abbvie, Novartis, Janssen.

T. Bieber has been advisor, speaker or investigator for Abbvie, Allmirall, Anacor, Astellas, Bayer, Celgene, Chugai, Daiichi-Sankyo, Galderma, Glaxo SmithKline, Leo Pharma, Novartis, Pfizer, Pierre-Fabre, L'Oréal, La Roche-Posay, Regeneron, and Sanofi.

S. Christen-Zaech has been an advisor, speaker or investigator for Galderma, L'Oreal, La RochePosey, Pierre Fabre, Permamed, Procter and Gamble, and Sanofi-Genzyme.

M. Deleuran has been an advisor, speaker or investigator for AbbVie, Leo Pharma, MEDA, Pierre-Fabre, L'Oréal, La Roche-Posay, Pfizer, Regeneron and Sanofi.

A. Fink-Wagner has been working with, or an advisor or speaker for ALTANA, Novartis, Nycomed, Hoffmann-La Roche and Teva.

U. Gieler has been has been advisor or speaker for Allmirall, Astellas, Bayer, Celgene, Galderma, Glaxo SmithKline, Leo Pharma, Lilly, Novartis, Pfizer, Pierre-Fabre, La Roche-Posay and Sanofi -Aventis.

G. Girolomoni has been an advisor, speaker or investigator for AbbVie, Abiogen, Allmirall, Amgen, Bayer, Biogen, Boehringer Ingelheim, Celgene, Eli-Lilly, Galderma, Hospira, Janssen, Leo Pharma, Menlo therapeutics, Merck, MSD, Mundipharma, Novartis, Otsuka, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi and Sun Pharma

S. Lau has received grants from Allergopharma and Symbiopharm, and a honorarium from Merck as member of a drug monitoring committee, ALK and DBV Technologies.

A. Muraro has has been a speaker for Meda, Nestlé and Stallergenes.

M. Czarnecka-Operacz has been an advisor, speaker or investigator for Allergopharma, Allmiral, Bioderma, Berlin Chemie, Mennarini, Novartis, Pierre Fabre, Galderma, Janssen and Leo Pharma.

T. Schäfer has been speaker for Abbott, Bencard, Dr Pfleger, Norvatis and Syneron-Candela.

P. Schmid-Grendelmeier has been an advisor or speaker for ALK-Abello, Allergopharma, La Roche-Posay, MEDA, Novartis, Sanofi and Stallergenes.

D. Simon has been an advisor, speaker or investigator for Roche, Novartis, Galderma, Glaxo SmithKline, Merz Pharma (Schweiz), Almirall, Sanofi, and Eli Lilly.

Z. Szalai has been advisor for Pfizer, speaker or investigator for Bayer, Novartis, Pierre Fabre, Sanofi, Leo.

J.C. Szepietowski has been a Consultant and Advisor for AbbVie, Celgene, Dignity Sciences, Leo Pharma, Novartis, Pierre-Fabre and Sandoz; Investigator for AbbVie, Actelion, Amgen, GSK, Janssen, Merck, Novartis, Regeneron, Takeda, Trevi; Speaker for AbbVie, Actavis, Astellas, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly.

A. Taïeb has been an advisor for Anacor, Bioderma, Chugai, Galderma, Roche and Pierre Fabre.

1 A. Torrelo has been advisor, speaker or investigator for AbbVie, Anacor, Astellas, Bayer, Beiersdorf AG,
2 Galderma, Meda, Novartis, Pierre Fabre.

3
4 T. Werfel has received support for research projects from AbbVie, Astellas, Janssen/JNJ, Meda,
5 Regeneron/Sanofi, Takeda, Ziarco, and has been an advisor for AbbVie, Allmiral, LEO Pharma, Lilly,
6 MSD, Novartis, Regeneron/Sanofi, Roche, Stallergen and Ziarco.

7
8 J. Ring has been advisor, speaker or investigator for ALLERGIKA, ALK Abello, Almirall-Hermal, Anacor,
9 Astellas, Bencard/Allergy Therapeutics, Galderma, GSK-Stiefel, LEO Pharma, Meda, MSD, Novartis,
10 Phadia-ThermoFisher, and Sanofi.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 Table R1 (online repository)

Assignment of guideline sections to draft authors

Part I

Introduction	(Andreas Wollenberg & Johannes Ring)
Method of guideline formation	(Andreas Wollenberg & Johannes Ring)
Patient perspective	(Antje Fink-Wagner, patient representative)
General measures and avoidance strategies	(Susanne Lau & Thomas Werfel)
Basic emollient treatment and bathing	(Jacek Szepietowski & Alain Taieb)
Dietary intervention	(Antonella Muraro & Johannes Ring)
Topical anti-inflammatory therapy	(Thomas Bieber & Giampiero Girolomoni)
Phototherapy	(Alain Taieb & Magda Operacz)
Antipruritic therapy	(Jacek Szepietowski & Uwe Gieler)

Part II

Antimicrobial therapy	(Peter Schmid-Grendelmeier & Stephanie Christen-Zäch)
Systemic anti-inflammatory treatment	(Mette Deleuran & Andreas Wollenberg)
Other systemic treatment	(Dagmar Simon & Antonio Torrelo)
Allergen specific immunotherapy	(Magda Operacz & Johannes Ring)
Complementary medicine	(Torsten Schaefer & Johannes Ring)
Psychosomatic counselling	(Uwe Gieler & Zsuzsanna Szalai)
Educational interventions	(Zsuzsanna Szalai & Sebastien Barbarot)
Conclusion and future options	(Andreas Wollenberg & Johannes Ring)

Table R2: Members of the guideline panels (role in the guidelines development, discipline, institution)

Name	Role in the guideline development, discipline / content expertise, institution / geographic location	Institutions represented
Expert panel		
Sebastien Barbarot	Expert panel member; Assistant Professor of Dermatology, Department of Dermatology, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France	European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Thomas Bieber	Expert panel member; Professor of Dermatology, Department of Dermatology and Allergy, and Christine Kühne-Center for Allergy Research and Education, University Bonn, Bonn, Germany	European Dermatology Forum (EDF), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Stephanie Christen-Zäch	Expert panel member; Pediatric dermatologist, Head of Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	European Society for Pediatric Dermatology (ESPD), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Mette Deleuran	Expert panel member; Professor of Dermatology and Head; Department Dermatology, Aarhus University Hospital, Aarhus, Denmark	European Dermatology Forum (EDF), European Society for Pediatric Dermatology (ESPD), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Antje Fink-Wagner	Expert panel member; Patient representative; EFA corporate Relations and Fundraising Manager and Co-Founder of GAAPP, Konstanz, Germany	European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Global Allergy and Asthma Patient Platform (GAAPP)
Uwe Gieler	Expert panel member; Professor of Psychosomatics and Dermatology, Department of Dermatology and Dept. of Psychosomatics and	European Dermatology Forum (EDF), European Academy of

	Psychotherapy, University of Gießen and Marburg GmbH, Gießen, Germany	Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Giampiero Girolomoni	Expert panel member; Professor of Dermatology, Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy	European Dermatology Forum (EDF) European Academy of Dermatology and Venerology (EADV)
Susanne Lau	Expert panel member; Professor of Pediatric Allergy, Pediatric Pneumology and Immunology, Universitätsmedizin Berlin, Germany	European Academy of Allergy and Clinical Immunology (EAACI)
Antonella Muraro	Expert panel member; Professor of Allergy, Food Allergy Referral Centre , Veneto Region; Department of Women and Child Health , Padua University Hospital, Padua, Italy	European Academy of Allergy and Clinical Immunology (EAACI)
Magda Czarnecka-Operacz	Expert panel member; Professor of Dermatology and Head; Department of Dermatology, Medical University, Poznan, Poland	European Dermatology Forum (EDF); European Union of Medical Specialists (UEMS); European Academy of Allergy and Clinical Immunology (EAACI)
Torsten Schaefer	Expert panel member; Dermatologist, Dermatological Practice, Immenstadt, Germany	European Academy of Allergy and Clinical Immunology (EAACI)
Peter Schmid-Grendelmeier	Expert panel member; Professor of Dermatology and Allergy, Allergy Unit, Department of Dermatology, University of Zurich, Switzerland and Christine Kühne Center for Allergy research and Education CK-CARE, Davos, Switzerland	European Academy of Allergy and Clinical Immunology (EAACI), European Academy of Dermatology and Venerology (EADV)
Dagmar Simon	Expert panel member; Professor of Dermatology, Department Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland	European Academy of Dermatology and Venerology (EADV); European Task Force on Atopic Dermatitis (ETFAD); European Academy of Allergy and Clinical Immunology (EAACI)
Zsuzsanna Szalai	Expert panel member; Dermatologist and Pediatrician, Head, Department of Dermatology, Heim Pál Children's Hospital, Budapest, Hungary	European Society for Pediatric Dermatology (ESPD), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Jacek Szepietowski	Expert panel member; Professor of Dermatology, Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland	European Dermatology Forum (EDF), European Academy of Dermatology and Venerology (EADV); European Society for Dermatology and Psychiatry (ESDaP)
Alain Taieb	Expert panel member; Professor of Dermatology, Department of Dermatology & Pediatric Dermatology, Hôpital St André, Bordeaux, France	European Dermatology Forum (EDF), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Antonio Torrelo	Expert panel member; Professor of Pediatric Dermatology, Department of Dermatology, Hospital Niño Jesus, Madrid, Spain	European Society for Pediatric Dermatology (ESPD), European Task Force on Atopic Dermatitis (ETFAD)
Thomas Werfel	Expert panel member; Professor of Dermatology, Department Dermatology and Allergy, Hannover Medical School, Hannover, Germany	European Dermatology Forum (EDF), European Academy of Allergy and Clinical Immunology (EAACI), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD)
Steering group		
Johannes Ring	Chairman, moderation of the consensus conference; Professor emeritus of Dermatology and Allergy; Klinik für Dermatologie, Allergologie und Venerologie, Technical University Munich; Munich, Germany and Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos	European Dermatology Forum (EDF), European Academy of Allergy and Clinical Immunology (EAACI), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD),

		Global Allergy and Asthma European Network (GA2LEN)
Andreas Wollenberg	Organization, drafting and writing of the guideline text and figures; Consultant Dermatologist and Professor of Dermatology, Department Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany and Klinik Thalkirchner Straße, Munich, Germany	European Dermatology Forum (EDF), European Society for Pediatric Dermatology (ESPD), European Academy of Dermatology and Venerology (EADV), European Task Force on Atopic Dermatitis (ETFAD), European Academy of Allergy and Clinical Immunology (EAACI)

1 List of Abbreviations

2	AAD	American Academy of Dermatology
3	AD	Atopic dermatitis
4	AE	Atopic eczema
5	AEGIS	3-trimethylsilylpropyl-dimethyloctadecyl ammonium chloride
6	AH	Antihistamines
7	AGREE	Appraisal of Guidelines Research and Evaluation
8	APT	Atopy patch test
9	ASIT	Allergen-specific Immunotherapy
10	AZA	Azathioprine
11	BB-UVB	Broadband ultraviolet B
12	BCC	Basal Cell Carcinoma
13	BO	Borage oil
14	CAM	Complementary alternative medicine
15	CAP-FEIA	CAP Fluorescence Immunoassay
16	CHM	Chinese herbal medicine
17	DBPC	Double-blind placebo-controlled
18	DBPCFC	Double-blind placebo-controlled food challenge
19	DHA	Docosahexaenoic acid
20	EADV	European Academy of Dermatology and Venereology
21	EASI	Eczema Area and Severity Score, a signs score
22	EAT	Enquiring About Tolerance
23	EC	Eczema coxsackium
24	EC-MPS	Enteric-coated mycophenolate sodium
25	EDF	European Dermatology Forum
26	EFA	European Federation of Allergy and Airways Diseases Patients'
27		Associations
28	EH	Eczema herpeticum
29	EPO	Evening primrose oil
30	ETFAD	European Task Force on Atopic Dermatitis
31	EU	European Union
32	EV	Eczema vaccinatum
33	FA	Food allergy
34	FTU	Fingertip unit
35	GAAPP	Global Allergy and Asthma Patient Platform
36	HBD	Human- β -defensin
37	HDM	House Dust Mite
38	HTA	Health Technology Assessment
39	H1R	Histamin 1 receptor
40	IA	Immunoabsorption
41	ICAM1	Intercellular Adhesion Molecule 1
42	IGA	Investigators Global Assessment, a signs score
43	IgE	Immunoglobulin E
44	IgG	Immunoglobulin G
45	IL	Interleukin
46	IVIG	Intravenous immunoglobulins
47	IFN- α	Interferon alpha
48	IFN- γ	Interferon gamma

1	JAK	Janus kinase
2	LEAP	Learning Early About Peanut Allergy
3	LTC4	Leukotriene C4
4	LTD4	Leukotriene D4
5	LTE4	Leukotriene E4
6	MCV	Molluscum contagiosum virus
7	MMF	Mycophenolat Mofetil
8	MTX	Methotrexate
9	mTLSS	modified Total Lesion Symptom Score
10	NB-UVB	Narrow band Ultraviolet B
11	OFC	Oral food challenge
12	OTC	Over the counter
13	PDE 4	Phosphodiesterase 4
14	PE	Patient education
15	PO-SCORAD	Patient-oriented Scoring of Atopic Dermatitis
16	PUVA	Psoralen and ultraviolet A
17	RCT	Randomized controlled trial
18	ROS	Reactive oxygen species
19	SASSAD	Six Area Six Signs Atopic Dermatitis score
20	SCC	Squamous Cell Carcinoma
21	SCIT	Subcutaneous Immunotherapy
22	SCORAD	Scoring of Atopic Dermatitis, a composite score
23	SLIT	Sublingual Immunotherapy
24	SPT	Skin prick test
25	TCI	Topical calcineurin inhibitors
26	TCS	Topical corticosteroids
27	TPMT	Thiopurine methyltransferase
28	TSH	Thyroid-stimulating hormone
29	Th1	T helper 1 cells
30	Th2	T helper 2 cells
31	Th17	T helper 17 cells
32	UV-light	Ultraviolet light
33	VOCs	Volatile organic compounds
34	VZV	Varicella-zoster Virus
35	QoL	Quality of life
36	TSLP	Thymic stromal lymphopoietin
37		

Abstract

This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus based guideline, taking available evidence from other guidelines, systematic reviews, and published studies in to account.

This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions.

Management of AE must consider the individual clinical variability of the disease, highly standardized treatment rules are not recommended. Basic therapy is focused on treatment of disturbed barrier function by hydrating and lubricating topical treatment, besides further avoidance of specific and unspecific provocation factors. Topical anti-inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive therapy for long term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are preferred in sensitive skin areas and for long term use. Topical phosphodiesterase inhibitors may be a treatment alternative when available. Adjuvant therapy includes UV irradiation, preferably with UVB 311 nm or UVA1. Pruritus is targeted with the majority of the recommended therapies, but some patients may need additional antipruritic therapy. Antimicrobial therapy, systemic anti-inflammatory treatment, immunotherapy, complementary medicine and educational intervention will be addressed in part II of the guideline.

Key words: Atopic eczema, atopic dermatitis, pruritus, immunomodulation, emollients

1	Table of contents
2	
3	Part I
4	Introduction
5	Method of guideline formation
6	Patient perspective
7	General measures and avoidance strategies
8	Basic emollient treatment and bathing
9	Dietary intervention
10	Topical anti-inflammatory therapy
11	Phototherapy
12	Antipruritic therapy
13	
14	Part II
15	Antimicrobial therapy
16	Systemic anti-inflammatory treatment
17	Other systemic treatment
18	Allergen specific immunotherapy
19	Complementary medicine
20	Psychosomatic counselling
21	Educational interventions
22	Conclusion and future options
23	

1 Introduction

Atopic eczema (AE; atopic dermatitis, eczema, “Neurodermitis” in German speaking countries, endogenous eczema, neurodermatitis) is an inflammatory, pruritic, chronic or chronically relapsing skin disease occurring often in families with other atopic diseases (bronchial asthma and/ or allergic rhinoconjunctivitis). AE is one of the most common non-communicable skin diseases which affects up to 20% of children and 2-8% of adults in most countries of the world. In many instances AE begins in childhood, while severe cases may persist in adulthood. About one third of adult cases develop in adulthood. AE is often the first step in the development of other atopic diseases, such as allergic rhinoconjunctivitis or asthma and food allergy (FA).

Though several diagnostic criteria have been proposed over time, the classical Hanifin & Rajka criteria are still the most widely used criteria worldwide (1). There is no pathognomonic laboratory biomarker for diagnosis of AE. The most typical feature, the elevation of total or allergen-specific IgE levels in serum or the detection of IgE-mediated sensitization in skin tests, is not present in all individuals suffering from AE; the term “intrinsic” (non-IgE-associated) AE has been introduced to distinguish the latter group from “extrinsic” (IgE-associated) forms of AE (2). The controversy in terminology is going on until today, and has practical implications regarding avoidance strategies for AE management.

Apart from a strong genetic influence (80% concordance in monozygous twins, 20% in heterozygous twins), there are other characteristic features in pathophysiology. These include an immune deviation towards the T helper 2 (Th2) pathway in the initiation phase with consequent increased IgE production; an increased production of mediators from various inflammatory cells, a deficient skin barrier function (“dry” skin) due to abnormal lipid metabolism and epidermal structural protein formation of filaggrin and protease inhibitors; an abnormal microbial colonization with pathogenic organisms such as *Staphylococcus aureus* or *Malassezia* sp. (compared to *Staphylococcus epidermidis* in normal individuals) and subsequently increased susceptibility to skin infection; and an obvious, strong psychosomatic influence.

After establishing the diagnosis of AE, the overall disease severity must be determined by evaluating both objective signs and subjective symptoms. As signs-only scores are lacking the subjective part of pruritus and sleep disturbance, composite scores assessing signs and symptoms must be used to assess overall disease severity (3). The classical composite score is the “Scoring of Atopic Dermatitis” (SCORAD) developed by the European Task Force of Atopic Dermatitis (ETFAD) (4). AE with a SCORAD above 50 is regarded as severe, while SCORAD values below 25 are considered as mild AE (3, 5). The Patient-oriented SCORAD (PO-SCORAD) is a tool for assessing AE severity independent of the physician, and the results correlate well with SCORAD (6). In contrast, the Eczema Area and Severity Score (EASI) is a signs-only score assessing visible lesions only, but not the subjective symptoms. The Patient-Oriented Eczema Measures for Eczema (POEM) are a symptoms-only score to measure subjective symptoms, but not objective signs in clinical trials. The Investigators Global Assessment (IGA) is frequently used, but more a global assessment than a validated score. In contrast to SCORAD, POEM and EASI, it is based on a single

1 global assessment by the investigator only. The HOME group is an initiative of
2 methodologists, industry representatives and physicians interested in outcome measures
3 for AE, which has done considerable work in recommending instruments for measurement
4 of the previously identified domains of AE such as signs, symptoms, quality of life and long
5 term control (7).

6 Most AE cases can be regarded as mild, whereas less than 10% of patients suffer from
7 severe eczematous skin lesions. This percentage of severe cases seems to be higher in the
8 adult AE population (8). This guideline covers most of the important and relevant strategies
9 for management of AE.

10

11

Methods

The guideline committee decided that these guidelines should strictly concentrate on therapeutic regimens and omit longer chapters on clinical entity, diagnosis or pathophysiology of the disease. This is a consensus-based S2k guideline, though it has an additional strong focus on evidence from the literature. Consensus was achieved among the nominated members of the European interdisciplinary expert group.

Base of the guideline

This is an update of the 2012 guideline on atopic dermatitis (8, 9). The former, first version of this guideline had been based on the evidence-based national guideline from Germany (10), the HTA report (11), as well as the position paper of the ETFAD (12), which were compared and assessed. The former committee had decided that all these documents fulfilled enough criteria to be used as the base of the first version of the European Guidelines on Treatment of Atopic Eczema (8, 9).

Data base and literature search

For this consensus-based guideline, no systematic literature review has been performed. During the kick-off meeting in Copenhagen in 2015, subgroups of two authors were determined among the expert panel to be responsible for the draft of specific sections of the guideline by virtue of their clinical and scientific expertise (Table R1). Discrepancies between the two respective authors were escalated to the steering committee. The subgroups were in charge of the search for best available evidence, the summary thereof and of critically appraising the evidence to inform the drafted recommendations. Specific inclusion or exclusion criteria for the selection of the evidence (such as the limitation to a certain study design) were not defined and the authors were encouraged to include the 'best available evidence'.

Data were included only, if a reference had been published as a full paper in a peer reviewed journal by March 2017, but not based on an abstract or a conference presentation only.

Classification of presented studies with regard to study type

To give the reader a general impression of the quality of the evidence presented in this guideline, grades of evidence were assigned using the system employed in the 2012 version of the guideline (table 1) (8, 9). These need to be interpreted with caution, however, as the literature search that was undertaken followed a targeted rather than systematic approach.

Recommendation levels (table 2) were given only for those therapies available in Europe by September 2017, though the label did not have to specifically include AE as a licensed indication. Therapies not available in Europe by September 2017 could be mentioned in the manuscript, but no formal therapeutic recommendation would be given for these. High level evidence with a potential to significantly change current treatment paradigms published after

these deadlines could be included upon vote during the final meeting of the guideline committee in Geneva in 2017.

The expert panel tried to use standardized language for the recommendations given, but would prefer a consensus vote on non-standardized language over standardized language, if the highly variable clinical presentation of AE would suggest that a non-standardized wording be more useful in clinical reality from a patient's or physicians perspective (see table 3 for standardized wording of recommendations).

Consensus process

The committee designated all recommendation statements, as well as some especially important areas as those requiring consensus. Consensus conferences were held in Copenhagen in October 2015, in Vienna in September 2016 and in Geneva in September 2017. Johannes Ring acted as the moderator during all face-to-face meetings.

All sections with recommendations were discussed within the whole group and consensus was defined as approval by at least 75 % of the panel members. All consented recommendations are marked with grey boxes.

External review

According to the EDF standard operation procedure, all EDF members were invited to review the guidelines prior to the last internal review. The comments of the participating societies were forwarded to the chapter authors and considered during the last internal review.

Update of the guidelines

These guidelines will require updating approximately every three years, but advances in medical sciences may demand an earlier update.

Target group

This guideline has been prepared for physicians, especially dermatologists, pediatricians, allergists, general practitioners and all specialists taking care of patients suffering from AE. Patients and relatives should also be able to get reliable information and advice with regard to evidence-based therapeutic modalities.

AE management from a patient's perspective

Due to the variety of different AE therapies and different individual reactions, patients and their caregivers need clear and easy to understand strategies for their individual needs in therapy, and in order to become comfortable to take over responsibility for the treatment of their chronic condition. Patients and caregivers need to be trained to understand and apply the existing therapeutic options and best disease management immediately after a diagnosis of AE. Health Care Professionals need to be reimbursed for education, as the training of patients and caregivers is an imperative prerequisite for the essential concordance between the patient and the treating physician. Free access to care and medication is essential from a patient's perspective. A multidisciplinary approach including psychological advice is needed to overcome the painful, itching and stigmatizing flare-ups and their impact on quality of life. Rehabilitation may play a key role.

Patients and caregivers should be able to identify their individual symptoms, become aware of the need and benefit of sufficient amounts of basic management (topical treatment, avoidance of specific and unspecific trigger factors) and to understand certain needs of anti-inflammatory treatment based on topical glucocorticosteroids (TCS) and topical calcineurin inhibitors (TCI). This will lead to a fast and effective short-term management of exacerbations, as well as long term control by proactive therapy. Movement of patients and caregivers towards unapproved complementary alternative medicine (CAM) and non-compliance often result in worsening of the disease and should be avoided.

Cases of severe AE should be discussed openly and in detail between the treating physician or multidisciplinary team and the patient or caregiver, since many patients cannot overlook the therapeutic options, even if they have access to transparent guidelines. Patients and caregivers should actively be involved in therapeutic decisions at all stages in order to achieve therapeutic success.

Patients with a not well controlled AE should be informed about new therapeutic options and possible side effects. Guidelines for patients and caregivers should be in place.

General measures and avoidance strategies

The identification of individual trigger factors is crucial in the management of AE and their avoidance allows longer phases of remission or total clearance of symptoms. It is important to differentiate between the genetic predisposition towards hypersensitive, dry skin with barrier dysfunction – largely corresponding to ichthyosis vulgaris – which cannot be "cured" and the inflammatory skin lesions which can very well be treated and disappear.

In avoidance recommendations, one must distinguish between primary, secondary and tertiary prevention measures. Among provocation factors, specific and non-specific elicitors must be distinguished.

Non-specific provocation factors

Numerous factors and substances from the environment can irritate the sensitive skin of patients with AE and can elicit eczema flares. They may be physical, like mechanic irritants (e.g. wool), chemical (acids, bleaches, solvents, water) or biological (allergens, microbes) in nature. Information on unspecific irritants and their role in aggravating AE is a crucial prerequisite for long-term management of patients with AE. Here also the adequate skin care and hygiene procedures in cleansing and dressing have to be discussed with the patient (see also, "Educational program, eczema school").

Negative effects of air pollutants upon the development and maintenance of AE, like tobacco smoke or volatile organic compounds (VOCs) in indoor environments and traffic exhaust in the outdoor air must be mentioned. There is evidence from epidemiological trials that exposure to indoor chemicals, such as formaldehyde, increases skin barrier disturbance (13); a mixture of volatile organic compounds has been shown to increase the intensity of atopy patch test reactions to aero-allergens in patients with AE (14).

Exposure to traffic exhaust has been shown to be associated with an increased risk to develop AE in pre-school children (15, 16). Moreover, diesel exhaust particles may favor alopecia and skin scratching, and thus worsen AE (17).

Exposure to environmental tobacco smoke measured as urinary cotinin / creatinin ratio was associated with a significant elevated risk to develop AE which was especially pronounced in children of parents with an atopic background (18). The prevalence of smoking was higher in severe AE, as shown in a recent cross sectional study investigating the entire Danish population (19). A systematic review of 86 studies confirmed the association of smoking and AE in adolescents and adults in all continents of the earth (20). It remains unclear, however, if smoking is a provocation factor in AE or if the burden of AE leads to more frequent smoking habits (20).

Avoidance strategies regarding tobacco smoke as well as traffic exhaust exposure in young children have been introduced in the recent S3 Guideline for primary prevention of atopic diseases in Germany (21).

Specific allergen avoidance

Aeroallergens

Aeroallergens can elicit eczematous skin lesions in sensitized patients with AE, which can be explained by increased permeability of the skin for inhalant allergens in patients with skin barrier defects (22). Positive atopy patch tests are associated with specific IgE and positive histories of flare-ups of AE to seasonal allergens (23).

Many airborne allergens eliciting AE are derived from house dust mites (HDM) of the species *Dermatophagoides pteronyssinus* and *D. farinae*. The enzymatic activity of major mite allergens is found to destroy tight junctions of the epithelial cells in the bronchial mucosa and may thus also deteriorate the skin barrier dysfunction in patients with AE (24).

House dust mites are living in a complex eco-system consisting of air humidity, temperature and presence of organic material. They accompany humans and are most commonly present in dust from mattresses or bedroom floors. Normal cleaning measures help only little in decreasing house dust mite allergens present in settled and airborne dust indoors. Encasings of mattresses and beddings protect humans from house dust mites in mattresses. There are also mite-proof pyjamas ("eczema overalls"). Some studies are showing a clear-cut benefit from house dust mite avoidance strategies in the improvement of AE (25, 26). A recent meta-analysis was not in favor of house dust mite avoidance in established AE (27). Rehabilitation programs in mite-free environments – like in alpine climate – have shown to lead to significant and long-lasting improvement of AE (28).

Pollen in the outdoor air also can elicit flares of AE as has been shown in a nested case control study in pre-school children (29). A challenge of sensitized patients with grass pollen in a challenge chamber led to exacerbation of AE in winter in a proof-of-concept study (30). Pollen avoidance is difficult under everyday conditions in most parts of Europe except when air conditioning with pollen filters is used in the indoor environment. In high altitude mountain climate pollen counts are usually lower than in the average living areas.

Animal epithelia

Many patients are aware that contact with animals may lead to a deterioration of skin symptoms. While in former times avoidance of pets was a central feature in primary prevention recommendations for atopy, this has been modified as follows: cat epithelia exposure is regarded by most authors as a risk factor, so it should be avoided (31, 32). There is no evidence that dogs increase the risk of AE in children; recent studies suggest that dogs might even protect from AE, possibly due to exposure to non-pathogenic microbes (33-35). Once a patient is sensitized to a pet and shows symptoms after contact, avoidance is necessary.

Furthermore, the exposure towards bacteria is increased if dogs live in a household, which may have a protective effect in terms of primary prevention and immune regulation. However, if AE has developed, there may be a risk of bacterial superinfection if skin lesions are present and dogs have a close contact to the patient (36). *Staphylococcus aureus*, which heavily colonizes the lesions of AE, produces extracellular proteases, which cause barrier breakdown in the skin and thus facilitate the uptake of allergens and specific sensitization.

Dietary Recommendations

See chapter "Dietary intervention"

Vaccinations

It is a common misconception that AE patients and especially children diagnosed with AE should avoid routine vaccinations. There is no evidence, that recommended vaccinations in infancy and early childhood have an impact on the development of AE or other atopic diseases (37). All children diagnosed with AE should be vaccinated according to the local or national vaccination plan. Vaccinations should not be administered during acute flares – in those cases two weeks of well-conducted TCS therapy followed by a normal vaccination procedure are recommended (37). Patients on immunosuppressive therapy with cyclosporine or related drugs should consult a specialist before live vaccination is performed (37). The only exception from this rule has been the intracutaneous smallpox vaccination with an attenuated live vaccine, which is contraindicated in AE patients due to risk of life-threatening eczema vaccinatum (38). A safe and effective alternative regimen with a highly attenuated MVA vaccine may circumvent these problems for AE patients in the future (39).

Clothing and textiles - contact allergens

Smooth clothing and avoidance of irritating fabrics and fibers is essential in the avoidance of primary skin irritation. Silk garments with an AEGIS-coating are lightweight and comfortable to wear, but do not improve eczema severity over standard of care treatment (40). Too occlusive clothing inducing heat sensations should be avoided.

Obviously, contact allergens relevant to the patient should also be avoided. This is of special relevance if type IV allergy to ingredients of emollients has been diagnosed by classical patch tests. Emulsifiers, fragrances and preservatives are the main cause of contact allergy to cosmetics (41).

Occupational aspects

Special recommendations must be given in individual counseling programs regarding the choice of profession. There is common consensus that occupations involving contact with strongly sensitizing substances should be avoided by patients with AE (42). Professions with skin irritating tasks are not recommended to atopic individuals with a history of persistent or relapsing hand eczema. The risk of contact sensitization is slightly increased in patients with AE (43).

Summary of evidence

There is some evidence that house dust mite avoidance strategies, especially encasings, can reduce house dust mite and house dust allergen content in indoor air and therefore

1 improve AE. The latter is controversial, since a recent meta-analysis would not confirm this
2 effect. (2b)

3 There is evidence that house dust mite avoidance and high altitude climate may give benefit
4 to patients suffering from AE. (2b, 3b)

5 There is a rationale for using protective clothes (eczema overalls), although good studies
6 are missing. (-)

7 In spring and summertime pollen exposure may exacerbate AE in the air-exposed skin
8 areas. (-)

9 Vaccination does neither improve nor worsen the natural course of AE (2a).

10 **Recommendations**

11 Pollen avoidance measures can be recommended during the pollen season. (-, D)

12 House dust mite avoidance measures may be tried in selected cases. (-, D)

13 When classical patch tests are positive, relevant contact allergens should be avoided. (-, D)

14 All children diagnosed with AE should be vaccinated according to the national vaccination
15 plan (2a, B).

16

Basic therapy of disturbed skin barrier function and emollient therapy (“skin care”)

Emollient therapy and skin care

Dry skin is one of the characteristic symptoms of AE. There is now scientific evidence in humans and mice of genetically driven skin barrier anomalies that facilitate allergen penetration into the skin with an increased proneness to irritation and subsequent cutaneous inflammation. Filaggrin deficiency is the best-defined anomaly, which gives rise to a deficiency in small water binding molecules resulting from normal filaggrin catabolism (44). Besides that, a lack of stratum corneum intercellular lipids and an inadequate ratio between compounds (cholesterol, essential fatty acids, ceramides) enhance trans-epidermal water loss leading to epidermal micro-fissuring. Barrier disruption leads to inflammation, and protease-antiprotease imbalance is a crucial intermediate step (45).

Cleansing and bathing

The skin must be cleansed thoroughly, but gently and carefully to get rid of crusts and mechanically eliminate bacterial contaminants in the case of bacterial super-infection. Cleansers with or without antiseptics (the duration of action of antiseptics is very limited, thus mechanical cleansing is probably more important) in non-irritant and low allergen formulas available in various galenic forms (syndets, aqueous solutions) may be used. It is easier to perform this first stage of gentle cleansing of skin on the nappy mattress rather than directly in the bathtub in infants (3). A further cleansing followed by a rapid rinse is performed in the bath (27-30°C). The short duration of the bath (only 5 minutes) and the use of bath oils (2 last minutes of bathing) are aimed at avoiding epidermal dehydration. Topical emollients are preferentially applied directly after a bath or a shower following gentle drying when the skin is still slightly humid (see next section on emollient therapy).

Adding antiseptics such as sodium hypochlorite to the bath-water is an additional option for treatment of AE because of its bacterial count inhibiting activities (46, 47). A study showed that children bathing in 0,005% bleach experienced an improvement of their AE (47, 48). In a recent study sodium hypochlorite baths did not show superiority to water baths concerning the severity of AE, but allowed a reduction in topical corticosteroid and antibiotic usage (49). Salt baths may be beneficial because of removing the dead keratin material (50). Salt baths are useful especially in heavily impetiginized or ichthyotic skin. A recent study suggested usage of fragrance-free baby oil as a soap substitute, especially in populations where specially designed emollients are not affordable (51).

Bath oils are a valuable addition for skin care especially in babies and children. Bath additives containing potentially allergenic proteins such as from peanut or colloidal oat should be avoided in the most vulnerable age group before the age of 2 (3) It should be emphasized that most bath oils commercially available in Europe are practically free of these protein allergens.

Recommendations

Adding antiseptics such as sodium hypochlorite to the bath-water may be useful for treatment of AE (1b, A).

Emollient therapy

By tradition, emollients are defined as topical treatment with vehicle-type-substances lacking active ingredients. These emollients are extremely helpful for AE patients, and contain usually a humectant (promoting stratum corneum hydration, such as urea or glycerol) and an occludent (reducing evaporation, such as petrolatum). Recently, marketing of non-medicated “emollients” containing active ingredients have softened the delineation of emollients from topical drugs. Throughout this guideline, “emollients” are defined as “topical formulations with vehicle-type-substances lacking active ingredients”, whereas “emollients plus” refers to “topical formulations with vehicle-type substances and additional active, non-medicated substances”.

The direct sole use of emollients on inflamed skin is poorly tolerated and it is better to treat the acute flare first. Emollients are the mainstay of management. Hydration of the skin is usually maintained by at least twice daily application of moisturizers with a hydrophilic base, e.g. 5% urea (52). According to the acuity of the skin condition, lipophilic bases are also helpful. The use of barrier ointments, bath oil, shower gel, emulsions or micellar solutions enhancing the barrier effect is also recommended. The cost of high quality (low in contact allergens) emollient therapies often restrict their use because such therapies are considered to be non-prescription drugs (except for e.g. Finland and Switzerland, where prescription and reimbursement are usual) and the quantities required are usually high (up to 100 g per week in young children, and up to even 500 g in adults). The use of pure oil products such as coconut oil instead of emulsions will dry out the skin, increase the transepidermal water loss and is therefore not recommended.

The applied amount of topicals may also follow the fingertip unit rule: A fingertip unit (FTU) is the amount of ointment expressed from a tube with a 5-mm diameter nozzle and measured from the distal skin-crease to the tip of the index finger (~0.5 g); this is an adequate amount for application to two adult palm areas, which is approximately 2% of an adult body surface area (53).

A better molecular and biochemical knowledge of the skin in AE should provide access to barrier improving topical agents. There is increasing evidence-based proof for the use of emollients (54).

Ingredients and possible risks of emollients

Urea may cause irritation and kidney dysfunction in infants and should be avoided in this age group, whereas toddlers should be treated with lower concentrations than adults (3). Glycerol seems better tolerated (less smarting effect) than urea plus sodium chloride (55). Usually, the recommendation is to use emollients immediately after bathing and soft pad drying. A small study suggests that an emollient applied alone without bathing may have a longer duration as measured by capacitance (56).

Propylene glycol is easily irritating in young children aged less than two years and should not be used for toxicity reasons in these young children. There is concern that the large preventive use of emollients containing intact proteins such as peanut allergens (57) or colloidal oat meal (58) may increase the risk of skin sensitization and allergy. Only emollient preparations devoid of proteinaceous allergens and haptens known to cause contact allergy frequently (such as lanolin/wool wax alcohol or methylisothiazolinone) should be used, especially in the most vulnerable age group before the age of two years.

Emollients containing tannin- and ammonium bituminosulphonate (ichthammol) may be a useful addition to the basic treatment regimen, especially in mild disease or if TCS treatment is not possible from a patient's perspective, e.g. corticophobia (steroid phobia) (59).

Sole use of emollients without sufficient topical anti-inflammatory therapy involves a considerable risk for disseminated bacterial and viral infection of AE, which is already increased in AE patients (60).

Emollients “plus”

In the last years, several non-medicated products for topical treatment of AE are available on the market, which contain active ingredients, but are neither fulfilling the definition of nor needing a license as a topical drug. These products may contain for example saponins, flavonoids and riboflavins from protein free oat plantlet extracts, or bacterial lysates from *Aquaphilus dolomiae* or *Vitreoscilla filiformis* (61). These lysates both improve AE lesions and influence the skin microbiome of AE patients (62, 63). In vitro and clinical research data from different laboratories have provided some background information on molecular targets and possible mode of action of these active emollients “plus” (64-66).

Evidence of emollient efficacy

Certain moisturizers could improve skin barrier function in AE and reduce skin susceptibility to irritants. It was clearly demonstrated that long-term emollient therapy improves AE-associated xerosis (67). Simple stand-alone emollient application for one week may improve mild to moderate AE (68). A comparative study showed that an over-the-counter moisturizer could be as clinically effective as more expensive barrier creams in the management of mild to moderate childhood AE (69). Another study in adult AE patients suggested an effect of coconut oil on staphylococcus aureus carriage (70). In addition, the daily use of emollients from birth may significantly reduce the incidence of AE in a high-risk population (71, 72). As the major limitation of these two promising trials is their relatively short duration of half a year, longer trials are currently performed.

Evidence of steroid sparing effects of emollients

1. Short-term (3-6 weeks)

Several studies in children (54, 73) and one in a mixed children-adult population (74) showed a variable but consistent evidence of short-term steroid sparing effect in mild to moderate AE.

2. *Long-term-maintenance therapy*

Maintenance of stable disease can be obtained with emollients used twice weekly or more frequently in a subset of patients, after an induction of remission with topical corticosteroids. Several studies showed comparable results for intermittent emollient therapy and time to relapse, using comparable study designs in adults and children (75, 76).

Recommendations

Emollients should be prescribed in adequate amounts and these should be used liberally and frequently, in a minimum amount of 250 g per week for adults (3b,C).

Emollient bath oils and soap substitutes should also be used. Emollients with a higher lipid content are preferable in winter time (3b,C).

A regular use of emollient has a short and long term steroid sparing effect in mild to moderate AE. An induction of remission with topical corticosteroids or topical calcineurin inhibitors is required first (2a,B).

Dietary intervention

Food allergens, pre- and probiotics

Food allergy has been well documented in approximately one third of children with moderate-severe AE (77). Among food allergens, cow's milk, hen's egg, peanut, soy, nuts and fish are most frequently responsible for AE exacerbation in young children, with age-dependent variations in causally incriminated food (78). In older children, adolescents and adults pollen associated food allergy should be taken into account (79, 80).

Response patterns to food allergens

Three different clinical reaction patterns in patients with AE have been described, depending on the type of symptoms and their time of onset (78, 81).

Immediate-type, non-eczematous reactions are usually IgE mediated, occur within 2 hours after the administration of the allergen, with skin manifestations such as urticaria, angioedema, flush, and pruritus or other immediate type reactions of the gastrointestinal tract, the respiratory tract, or the cardiovascular system in the sense of anaphylaxis. Cutaneous manifestations occur in 74% of patients. In addition, children might develop a transient morbilliform rash 6 to 10 hours after the initial immediate reaction, disappearing within a few hours and considered as "late-phase" IgE-mediated response (81, 82).

Isolated eczematous delayed-type reactions typically occur 6 to 48 hours after the administration of the allergen with flares of eczema on predilection sites of AE, suggestive for a non-anaphylactic pattern.

A combination of the two above-mentioned patterns with an immediate-type reaction followed by an eczematous delayed-type reaction has been described in approximately 40% of children (83).

Sensitization to food can be identified by means of a detailed clinical history in combination with in vivo tests (skin prick tests, prick-prick tests) and in vitro tests (serum specific IgE). In addition, patch tests proved to be useful for studying delayed food-related skin responses. In vitro tests are valuable when skin prick tests (SPT), cannot be applied (e.g. dermatographism or UV- and drug induced skin hypo-reactivity, eczema at the test site, lack of compliance for SPT in infancy, etc.). Moreover, in vitro specific IgE to food allergens gives better quantitative data for the grade of sensitization which helps to estimate the probability of the risk of a clinical reaction (although precise decision points are not available) and it offers the opportunity to test single recombinant allergens which may have a better diagnostic specificity than testing with food extracts for some foods (e.g. omega-5-gliadin in wheat allergy, Gly m 4 in pollen-related soy allergy).

Atopy patch test (APTs) are performed with self-made food material using a 1/10 dilution in saline of the fresh food applied for 24-48 hours on non-lesional skin (84). Food APT is not standardized for routine use. So far, APTs have demonstrated to improve the accuracy of skin testing in the diagnosis of allergy to cow's milk, eggs, cereals, and peanuts in patients with AE (85-88). Whereas immediate-type reactions are associated with SPT positivity,

1 delayed reactions are related to positive responses to APTs. However, double-blind
2 placebo-controlled food challenge (DBPCFC) remains the “gold standard” for the diagnosis
3 of FA (89).

4 Oral food challenge (OFC) should always be performed under medical supervision with
5 emergency equipment available, particularly after long-lasting elimination of the culprit food.
6 Practically, OFC should be performed according to standardized protocols considering
7 variables associated with food matrix, doses and time intervals (90). In AE the major flaw is
8 that DBPCFC might not offer the opportunity to exclude placebo reactions or coincidental
9 influences of other trigger factors of AE during the prolonged challenge period. Therefore in
10 AE the evaluation of delayed reactions after 24 hours or 48 hours by trained personal is
11 mandatory (83). Challenge tests based on repeated exposure to food enable the
12 assessment of delayed adverse responses (83).

13 Unfortunately, the effects of dietary interventions on the course of AE have been studied
14 only in a few controlled studies. In a systematic review (11) eight randomised, controlled
15 studies examining the effect of an elimination diet on existing AE were identified and
16 summarized in the following way: a) Elimination diets are difficult to carry out even in a
17 motivating atmosphere during a clinical study. b) The drop-out-rate in AE studies is
18 particularly high in studies on diets. c) There is no convincing evidence that a milk- or egg-
19 free elimination diet is beneficial in general, when unselected groups of patients with AE
20 were studied. d) There is no evidence for a benefit in the use of elementary or few food
21 restricted diets in unselected patients with AE.

22 A Cochrane systematic review based on nine randomized controlled trials concluded that
23 eliminating egg from the diet in those who had positive specific IgE to eggs proved beneficial
24 (91). The American Academy of Dermatology recommended egg restriction in the subset of
25 patients with AE who were found to be clinically allergic to eggs (92), but this approach
26 should also be followed for other food allergens proven relevant in individual patients.

27 Although progress has been considerable, there are no simple strategies to prevent the
28 development of AE and food allergy in infants. The recent publication of randomized trials,
29 such as the Learning Early About Peanut Allergy (LEAP) (93) and Enquiring About
30 Tolerance (EAT) (94) studies, have given some support to the notion that early oral ingestion
31 of food may protect from sensitization and allergy later in life. The oral introduction early in
32 the first year of life at a “window of opportunity“ of time between 4 and 6 months of age may
33 actually protect children by facilitating the induction of tolerance (95). Epidemiological
34 studies have shown a significant association between the diversity of foods given in the first
35 year of life and protection from atopic eczema (96).

37 **Pre- and probiotics**

38 Probiotics such as lactobacillus mixtures have been studied in AE, and have been shown to
39 induce improvement (97). Other studies failed to show significant effects (98, 99). In a study
40 with 800 infants the effect of a prebiotic mixture was investigated and found to have
41 beneficial effects in preventing the development of AE (100).

Non-pathogenic bacterial strains like *Vitreoscilla filiformis* or *Aquaphilus dolomiae* have been used as sources for bacterial lysates for topical therapy of AE (see chapter: Topical therapy).

Previous systematic reviews on probiotics for the treatment of AE have consistently concluded a lack of effect in children (101). On the basis of the existing literature, with only one group showing positive results in a controlled study, the guideline group decided not to give a recommendation for treatment with lactobacilli in AE. It may well be that a preventive effect of pre- or probiotic mixtures will be shown in the future; consultation of the S3 guideline on “prevention on allergy” is recommended (21).

Summary of evidence

Food sensitization occurs in about 50 % of children with severe AE. The relevance can be evaluated by oral provocation tests, best performed as double-blind placebo-controlled food challenge. (1a)

Food allergy plays a role for disease exacerbation in 30 % of AE children, most often against basic foods such as hen’s egg or cow’s milk. Pollen-associated food allergy can occur in all ages. (2a)

Food elimination diets represent a major impairment in quality of life and are not easy to perform. (2a)

There is evidence that elimination of basic foods in food allergic children can improve the AE. (1a)

The persistence of food allergy can be evaluated by oral provocation after 1 or 2 years. (3a)

There are no long-term studies to the effect of food elimination diets in AE. (-)

There is conflicting data on prevention or improvement of AE during uptake of pro-biotics such as lactobacillus preparations (1b).

Recommendations

Patients with moderate to severe AE should observe a therapeutic diet eliminating those foods that elicited clinical early or late reactions upon controlled oral provocation tests. (2b, B)

Primary prevention of food allergy associated AE is recommended with exclusive breast milk feeding until 4 months of age. (2-3,C)

If breast milk is lacking in low risk children (general population), conventional cow’s milk formula is recommended. (2-3,C)

If breast milk is lacking in high-risk children (one first degree relative with physician diagnosed allergic symptoms), a documented hypoallergenic formula is recommended. (1, B)

Introduction of complementary foods is recommended between 4 and 6 months of age in low and high-risk children irrespective of an atopic heredity. (1-2, B)

A certain diversity of foods selected should be observed during the introduction between 4 and 6 months of age (1, D)

1 **Topical anti-inflammatory therapy**

3 **Topical treatment: overall principles**

4 Effective topical therapy depends on three fundamental principles: sufficient strength,
5 sufficient dosage and correct application (3). Many formulations are available especially for
6 corticosteroids, and the choice of formulation has a strong impact on the efficacy of the
7 resulting drug. Topical treatment should always be applied on hydrated skin, especially
8 when using ointments. Patients with acute, oozing and erosive lesions and children
9 sometimes do not tolerate standard topical application, and may first be treated with 'wet
10 wraps' until the oozing stops. Wet wrap medications are highly effective in acute AE and
11 improve tolerance. The use of wet-wrap dressings with diluted corticosteroids for up to 14
12 days (usual is rather up to 3 days) may be a safe crisis intervention treatment of severe
13 and/or refractory AE with temporary systemic bioactivity of the corticosteroids as the only
14 reported serious side effects (102-105). However, this treatment approach is not
15 standardized yet, and the evidence that it is more effective than conventional treatment with
16 topical steroids in AE is not of high quality. Simple or occlusive medications in less sensitive
17 skin areas and for brief time periods may also increase efficacy and speed up lesion
18 resolution. Even without wet wraps, topical therapy may be time consuming, and deserves
19 attention. One well-conducted treatment per day is usually sufficient but acute flares may
20 require a few days with higher treatment frequency.

21 By tradition, anti-inflammatory topical therapy has been administered to lesional skin only
22 and has been stopped or tapered down once visible lesions were cleared. This traditional,
23 reactive approach has now an alternative, which is the proactive treatment concept.
24 Proactive therapy is defined as a combination of predefined, long-term, anti-inflammatory
25 treatment applied usually twice a week to previously affected areas of skin in combination
26 with liberal use of emollients on the entire body and a predefined appointment schedule for
27 clinical examinations (106). The proactive regimen is started after all lesions have
28 successfully been treated by a regular anti-inflammatory therapy (by either steroids or topical
29 calcineurin-inhibitors) in addition to ongoing emollient application on previously unaffected
30 skin. Clinical trial data are available for a number of steroid products as well as for tacrolimus
31 ointment (107), but topical steroids are usually approved only for a very limited period of
32 time such as a few weeks. Studies investigating topical steroids for proactive treatment are
33 usually conducted only for 16 weeks, whereas studies with tacrolimus ointment have shown
34 good results for 52 weeks in both children and adults. The duration of the proactive
35 management is usually adapted to the severity and persistence of the disease (108). The
36 applied amount of anti-inflammatory topicals should also follow the fingertip unit rule (see
37 chapter: Emollient therapy).

39 **Glucocorticosteroids**

40 Topical glucocorticosteroids (TCS) are a first-line anti-inflammatory treatment, applied on
41 inflammatory skin according to the needs (pruritus, sleeplessness, new flare). Numerous
42 substances are available in a variety of formulations. Anti-inflammatory effects in AE were

1 reported by different investigators (109, 110). With mild disease activity, a small amount of
2 topical corticosteroid twice to thrice weekly (monthly amounts in the mean range of 15 g in
3 infants, 30 g in children and up to 60–90 g in adolescents and adults, roughly adapted to
4 affected body surface area), associated with a liberal use of emollients generally allows a
5 good maintenance. Such monthly amounts of even potent topical steroids usually do not
6 have adverse systemic or local effects. Twice weekly application of fluticasone or
7 methylprednisolone aceponate significantly reduced the risk of relapses of AE in a proactive
8 strategy (109-112).

9 Several factors should be considered when choosing a topical corticosteroid, including
10 potency, galenic formulation, patient age and body area to which the medication will be
11 applied. The potency of topical corticosteroids is grouped by potency according to Niedner
12 from mild (group I) to super-potent (group IV) (113). Prescribers should know this
13 classification, as they should know that the US-American classification is different and
14 ranges from VII (weakest) to I (strongest). In France, this classification is even different.
15 Super potent TCS (group IV) are not recommended for AE treatment, especially not in
16 children (3). Potent and very potent corticosteroids of group III and IV are more likely to
17 cause depression of adrenal function than group I and II treatments, but their systemic
18 effects will decrease more quickly due to more rapid restitution of the skin barrier (114).
19 Treatment of the face and especially the eyelid region should be restricted to mild TCS
20 (group I and II). Children should be treated with less potent TCS than adults. In addition, there
21 are different generations of substances, which may differ in their risk-benefit ratio.

22 Itch is the key symptom for evaluation of response to treatment, and tapering should not be
23 initiated before the itch has largely improved. Two applications per day may be necessary
24 to reduce the itch, but one well-conducted, correctly dosed treatment per day may be
25 sufficient (115, 116). Dose tapering is usually applied to avoid withdrawal rebound, although
26 no controlled studies have demonstrated its usefulness. Tapering strategies consist of
27 switching to a less potent corticosteroid, or keeping a more potent one while reducing the
28 frequency of application (intermittent regimen). The most constructive way to spare steroids
29 and avoid steroid-related side-effects is to use them intensively during the acute flares (3).
30 Continuous emollient skin care combined with early anti-inflammatory intervention is also
31 very important to stabilize the disease and prevent flares (117).

32 Side-effects of topical corticosteroids comprise a variety of skin changes mostly in the sense
33 of skin atrophy – except from contact allergy to glucocorticosteroid substances. The skin
34 changes manifest as thinning of the skin, development of teleangiectasias (rubeosis
35 stericoidica), spontaneous scars (“pseudocicatrices stellaires”, ecchymosis, striae distensae
36 (stretch marks). A “dirty neck” (cutis punctata linearis colli) and hypertrichosis may develop.
37 In infants, inappropriate use of TCS in the diaper area can lead to granuloma gluteale
38 infantum or even iatrogenic Cushing’s disease. The risk of ocular complications by topical
39 corticosteroids seems to be low. Development of glaucoma or cataract has been described
40 after systemic glucocorticosteroid application (118).

41 The use of potent topical corticosteroids in sensitive skin areas (face, neck, folds) should be
42 limited in time to avoid skin atrophy (119). Monitoring by physical examination for cutaneous
43 side effects during long term use of potent topical corticosteroids is very important. The
44 special aspects and potential adverse effects of topical corticosteroids in pregnancy have

1 been recently reviewed (120). The application of topical corticosteroids to the eyelids and
2 periorbital region, even over longer periods of time in adults with AE was not associated to
3 the development of glaucoma or cataracts (118). Application of very potent topical
4 corticosteroids even for brief time periods may result in the drug becoming systemically
5 available and potent enough to induce adrenal gland suppression (121).

6 In the face a special skin condition called rosacea-like perioral dermatitis is often started by
7 inappropriate, long term use of TCS. The skin seems to become “addicted” to TCS (“red
8 face syndrome” or „corticosteroid addiction syndrome“). This is characterized by rosacea
9 like disease with persistent erythema, burning and stinging sensation. It has been reported
10 mostly on the face and genital area of women primarily in the setting of long-term
11 inappropriate use of potent topical corticosteroids (122).

12 Patient fear of side effects of corticosteroids (corticophobia) is quite common and should be
13 recognized and adequately addressed to improve adherence and avoid undertreatment
14 (123-125).

15 The simultaneous combination of topical corticosteroids with topical calcineurin inhibitors at
16 the same site does not seem to be useful. At least in pediatric patients with severe AE, the
17 efficacy and safety profile of pimecrolimus cream 1% combined with fluticasone were similar
18 to that of fluticasone alone (126). Treating sensitive body areas such as the face with topical
19 calcineurin inhibitors while treating other affected body areas with a topical corticosteroid
20 may be a useful and cost effective strategy. Initial treatment with topical corticosteroids may
21 be considered in patients with acute flare to minimize topical calcineurin inhibitor site
22 reactions (108).

24 **Summary of evidence**

25 Topical corticosteroids have a significant effect improving skin lesions compared to vehicle.
26 (1b)

27 The efficacy of topical glucocorticosteroids can be increased by using wet wraps. (1b)

28 **Recommendations**

29 Topical corticosteroids are important anti-inflammatory drugs to be used in AE, especially in
30 the acute phase. (-, D)

31 Topical corticosteroids with an improved risk-benefit ratio are recommended in AE. (-, D)

32 Diluted topical corticosteroids may be used under wet wraps for short-term periods in acute
33 AE to increase their efficacy. (1b, A)

34 Proactive therapy, e.g. twice weekly application in the long-term follow-up, may help to
35 reduce relapses. (1b, A)

36 Proactive therapy with TCS may be used safely for at least 20 weeks, which is the longest
37 duration of trials (1b, A).

38 Patient fear of side effects of corticosteroids (corticophobia) should be recognized and
39 adequately addressed to improve adherence and avoid undertreatment. (4C)

1 **Topical calcineurin inhibitors**

2 Two topical calcineurin inhibitors (TCI), tacrolimus ointment and pimecrolimus cream, are
3 licensed for AE treatment. The efficacy of both formulations has been demonstrated against
4 vehicle in clinical trials for short-term (127, 128) and long-term use (129, 130). In addition,
5 proactive tacrolimus ointment therapy has been shown to be safe and effective for up to 1
6 year in reducing the number of flares and improving the quality of life in both adults and
7 children (131, 132). The anti-inflammatory potency of 0.1% tacrolimus ointment is similar to
8 a corticosteroid with intermediate potency (133, 134), whereas the latter is clearly more
9 effective than 1.0% pimecrolimus cream (135).

10 The efficacy of long-term monotherapy with tacrolimus ointment has been shown in children
11 and adults (133, 134, 136). Less data are available for children under 2 years of age (137,
12 138). Pimecrolimus cream has been studied in infants and children in a combination regimen
13 with topical corticosteroids (139, 140), the latter being given if a flare occurred. Both topical
14 calcineurin inhibitors are approved in the EU from 2 years of age and above. High quality
15 long-term safety data have recently been published on a 4-year tacrolimus and 5-year
16 pimecrolimus studies (141, 142). The cost effectiveness of proactive therapy with tacrolimus
17 has been demonstrated for moderate AE and is even higher in severe AE in a recent study
18 on adult patients (143), whereas the cost effectiveness of first-line treatment with topical
19 calcineurin inhibitors has not been demonstrated conclusively. However, in children with AE,
20 twice-weekly treatment with tacrolimus 0.03% ointment has been observed to reduce the
21 number of flares and to prolong flare free intervals, and may be cost-saving in children with
22 moderate or severe AE (144, 145).

23 In addition, the long-term, effective treatment of patients with AE may have a beneficial effect
24 also on respiratory symptoms and serum IgE (146). In adults, long-term treatment with 0.1%
25 tacrolimus ointment appears to be at least as effective as a corticosteroid regimen for the
26 trunk and extremities and more effective in the face and neck area. Both topical tacrolimus
27 and corticosteroids decrease skin recall activity, and decrease serum IgE in patients with
28 treatment response.

29 Safety data of both topical calcineurin inhibitors have been reported in many clinical trials
30 and registries, demonstrating the safety of these drugs in daily routine use. The most
31 frequently observed side effect is a transient warmth, tingling or burning sensation at the
32 application site during the first days of application (127, 135). It starts about 5 min after each
33 application of the drug and may last up to 1 h, but intensity and duration typically disappear
34 within few days (147). Some patients experience a transient worsening of skin conditions.
35 These side effects are more common with tacrolimus ointment than with pimecrolimus
36 cream and when they are applied on acutely inflamed skin. In some patients they are severe
37 enough to induce prompt treatment discontinuation. Initial treatment with topical
38 corticosteroids should thus be considered in patients with acute flare to minimize these site
39 reactions (108).

40 Generalized viral infections such as eczema herpeticum or eczema molluscatum have been
41 observed during topical calcineurin inhibitor treatment (148, 149), but a high number of
42 clinical trials failed to demonstrate an increased frequency or showed only a transient
43 increase (reviewed in (150-153)). In contrast to corticosteroids, none of the topical

calcineurin inhibitors induces skin atrophy (154, 155). This favours their use over topical corticosteroids in delicate body areas such as the eyelid region, the perioral skin, the genital area, the axilla region or the inguinal fold and for topical long-term management. Clinical and preclinical data do not indicate an increased risk of lymphoma (156). In contrast, severe AE as such may carry an independent significant risk for lymphoma (156). The use of topical calcineurin inhibitors is also not associated with increased risk of non-melanoma skin cancer, other malignancies or photocarcinogenicity (142, 157-161). However, given that the long-term use of cyclosporine is associated with an increased photocarcinogenicity risk in solid organ transplant patients, UV protection e.g. with sunscreens has been advised (3). The use of topical calcineurin inhibitors under wet wraps or on erosive lesions may increase systemic absorption.

Clinicians should be aware of the black-box warning on the use of topical calcineurin inhibitors, and may discuss this with patients to improve adherence.

Summary of evidence

TCl have a significant effect compared to vehicle in short-term and long-term treatment of AE. (1b)

Tacrolimus 0,1% ointment is more potent than pimecrolimus cream. (1b)

Tacrolimus ointment and to lesser extent pimecrolimus cream may cause burning sensation and transiently worsen AE especially when given on acutely inflamed skin. (1a)

TCl do not cause skin atrophy, glaucoma or cataract. (1a)

Recommendations

Topical calcineurin inhibitors (TCl) are important anti-inflammatory drugs to be used in AE. (-, D)

Instead of treating acute flares with TCl, initial treatment with topical corticosteroids before switching to a TCl should be considered. (-, D).

TCl are especially indicated in sensitive skin areas (face, intertriginous sites, anogenital area). (1b, A)

Proactive therapy with twice weekly application of tacrolimus ointment may reduce relapses. (1b, A)

Effective sun protection should be recommended in patients treated with TCl. (-, D)

Upcoming topical therapies

Topical selective phosphodiesterase 4 inhibitors

Crisaborole is a topical phosphodiesterase 4 inhibitor effective in the treatment of AE lesions, which has recently been approved for treatment of mild to moderate AE in patients 2 years of age and older in the United States of America (162, 163). Study data published have focused on treatment of individual skin lesions using global eczema scores, as well as on safety aspects, but do not include SCORAD data or EASI data of the patients treated.

1 From the published data of the global scores and the individual items of an eczema score,
2 a relatively low efficacy of crisaborole is probable (162). The efficacy of crisaborole is
3 significantly higher than the efficacy of its vehicle. However, the efficacy of crisaborole in
4 comparison to TCI or TCS is difficult to determine. Crisaborole ointment is currently not
5 licensed in Europe.

6 Other topical phosphodiesterase 4 inhibitors under investigation include OPA-15406 and
7 E6005 (164, 165).

9 **Topical Janus-Kinase (JAK) inhibitors**

10 First promising phase II clinical trial data with the topical JAK- inhibitor tofacitinib have been
11 published (166), but the topical development program was halted. Further similar
12 compounds are in the pipeline for topical as well as for systemic therapy, but none is
13 currently licensed in Europe.

Phototherapy

As most patients affected by AE improve during the sunny summer season, artificial UV radiation is frequently employed in the treatment of AE. On the contrary, a small group of patients will exacerbate following UV radiation.

A recent study has confirmed that 74% of patients affected by mild-moderate AE had complete resolution during summer holidays, 16% had improvement and only 9% had no modification of AE severity, confirming the seasonality of the disease, with improvement during summertime and worsening in the other seasons: Seaside holidays produced a significantly greater improvement than mountains holidays, with complete resolution of the disease in 91% versus 11% of patients ($P<0.01$) (167). While this difference cannot be explained on the sole basis of UV exposure, these data support the hypothesis on the positive effect of UV radiation on AE.

Photobiology of AE treatment

Various pathways and means through which the energy of UV radiation from natural or artificial sources is ultimately transformed into biologic effects within the skin have been suggested, including cutaneous sensory nerves, neuropeptides, neurotrophins, and certain nerve-related receptors (168). In general the effects of UV-light sources on the skin act immunosuppressive, immunomodulating, anti-inflammatory as well as antipruritic, which is obviously an overlapping effect. The known mechanisms of action target immunomodulation through apoptosis of inflammatory cells, inhibition of Langerhans cells and alteration of cytokine production (169). In addition, UV has an antimicrobial effect reducing the colonization of *S. aureus*, (170) due to its anti-inflammatory effect and improves skin barrier (171). A different explanation could be supported by the role of Vitamin D: a recent study demonstrated that a 2-week course of heliotherapy significantly improved vitamin D balance by increasing serum calcidiol concentration, and caused a marked healing of AE (172). Suppression of Th2 associated cytokines such as IL-5, 13 and 31 have been observed under UVA1 therapy (169). Induction of apoptosis of T-helper cells most probably are related to generation of reactive oxygen species (ROS) (173, 174). Depletion and loss of function of antigen-presenting cells within the epidermis and dermis support immunosuppression via UV light source. Reduction of ICAM1 expression on keratinocytes has been observed and further enhanced via IL-10 induced reduction of γ -IFN (175, 176).

Light sources and current treatment regimen for AE

Heliotherapy uses the exposure to natural sun light under controlled conditions and is part of the therapeutic treatment in so called “climate therapy” at low altitude (Dead Sea) predominantly with UVA (177), at sea level or at high altitude (e.g. Davos) with predominantly UVB (178). The dose in heliotherapy is slowly increased by increasing the time of sun exposure in moderate increments.

The following alternative modalities of UV treatment have been used in AE: UVB (mostly narrowband (NB-UVB) of 311-313 nm and less frequently broadband (BB-UVB), UVA (especially UVA1 of 340-400 nm), combined UVAB, and photochemotherapy where UV can be combined with previous oral or topical administration of photosensitizing drugs such as psoralens - the PUVA photochemotherapy regimen, but the long-term risks of skin cancer noted in psoriasis have drastically limited this modality in Europe. In contrast, classical broad-spectrum UVB phototherapy does not show increased risk for BCC and SCC (179, 180).

Other light therapies have been introduced. Short wave visible light (> 380 nm) ("Blue light") may have some effects, as indicated in uncontrolled pilot studies (181). There are no controlled studies for this modality. Photopheresis is used in some centers for treatment of selected cases. Positive effects in patients with severe refractory AE have been described. Other devices such as 308 nm monochromatic excimer laser expand the therapeutic options in patients with localized and therapy-resistant AE even though they can treat only limited surfaces (182, 183). Pulsed-dye laser for the treatment of chronic AE is still experimental (184).

Currently the mainstay for phototherapy in Europe is NB-UVB and UVA1. Following concerns relative to PUVA, long-term risks of UV-light therapies have to be considered in particular in children and even more in adults who have received systemic immunosuppressants. Until now, no clinical studies have shown an increase of non-melanoma skin cancer with NB-UVB and UVA1 (185, 186). The benefit/risk ratio of UVA1 medium-high dose (>20-70 J/cm²) is considered as better than that of high or low dose (187-190). Comparison of middle-high UVA1 and NB-UVB does not show significant differences with regard to efficacy and tolerability.

Taking into account the individual tolerability, NB-UVB has been indicated for chronic moderate forms of AE (191) and is currently preferred to BB-UVB because it is less erythemogenic, while high dose UVA1 has been prescribed for more severe phases (192). Furthermore, as highlighted in a recent study, there is a small but significant proportion of psoriasis and AE patients who do not tolerate NB-UVB but demonstrate an excellent clinical response to BB-UVB (193).

Practical aspects of AE treatment

In practice, the choice of a certain UV treatment is limited by the availability of the phototherapy equipment: e.g. UVA1 devices are expensive to buy and to maintain. The biggest drawbacks of UV therapy are that the patient must travel between 3 and 5 times per week and for 6-12 weeks to a site that offers this therapy. In addition, UV light does not effectively treat hairy areas as scalp and skin folds. As a rule, phototherapy is not indicated in the acute stage of AE (except UVA1, which is also effective in managing AE flares), but is more apt to treat chronic, pruritic, lichenified forms and should not be prescribed in those patients who experience a worsening of AE during sun exposure.

At the beginning of phototherapy, a co-medication of topical steroids and emollients should be considered to prevent a possible flare-up. UV therapy has to comply with special

requirements with regard to personnel, documentation, UV protection especially of the eyes, contraindications and technical aspects.

In practice, when prescribed, phototherapy is usually a part of a total treatment plan, i.e. a second-level treatment used especially in adults and much less in children. Phototherapy can improve and even clear AE; it can decrease bacterial colonization and reduce the strength and/or the amount of topical anti-inflammatory drugs needed, but the beneficial effects vary from person to person.

Summary of evidence

Narrow-band UVB has a better safety and efficacy profile compared to broad-band UVB. (1a)

Medium-dose UVA1 is similar in efficacy to narrow-band UVB. (1b)

High-dose UVA1 is more effective in severe phases of AE. (1b)

All UV treatments pose theoretically a long-term risk for development of skin aging and skin cancer, which is best demonstrated for PUVA. (2a)

New devices such as 308 nm excimer laser or visible blue light therapy may expand therapeutic options, but have not been assessed properly in AE. (-)

Recommendations

Medium-dose UVA1 and narrow-band UVB are recommended for treatment of AE in adult patients. (1b, A)

Narrow-band UVB is preferred over broad-band UVB for AE treatment if available. (1a, A)

Co-treatment with topical steroids and emollients should be considered at the beginning of phototherapy to prevent flare-up. (C)

PUVA therapy is not a first choice therapy for safety profile reasons. (1b, A)

New devices such as 308 nm excimer laser are not recommended for treatment of AE patients. (-,D)

Though phototherapy is rarely used in pre-pubertal children, it is not contraindicated; its use depends rather on feasibility and equipment (NB-UVB). (-,D)

1 **Anti-pruritic therapy**

2

3 Itch is the most important clinical symptom in AE, with particular impact on emotional
4 dimensions of perception as compared to other pruritic dermatoses (194, 195). Concerning
5 pruritus accompanying AE, only few studies investigated the antipruritic effect only. Pruritus
6 was in most studies part of the total symptom score, such as in SCORAD or PO-SCORAD
7 (4, 6). For example, topical and systemic corticosteroids, topical calcineurin inhibitors,
8 cyclosporine and UV-irradiation have significant influence on pruritus while only single
9 studies specifically investigated the relief of pruritus intensity.

10 Antipruritic therapy in AE is multidimensional treating the symptom itself, the contributing
11 factors such as dry skin, inflammation and the related scratch lesions. Therefore, several
12 general measures can also be recommended (see: “Basic Therapy” and “Psychosomatic
13 counseling”).

14

15 **Topical Therapy**

16 ***Glucocorticosteroids***

17 Topical corticosteroids have anti-inflammatory activity rather than acting as direct anti-
18 pruritic agents (196). However, several studies described the anti-inflammatory effect of
19 topical corticosteroids in AE, in which pruritus was one parameter among others studied.
20 Recent meta-analysis revealed 6 RCT with topical corticosteroids (desonide hydrogel
21 0.05%, clobetasole propionate lotion, fluticasone propionate 0.05% cream, prednicarbate
22 0.25% ointment, hydrocortisone 1% and methylprednisolone aceponate 0.1% cream) and
23 showed that those agents significantly reduce itch in AE patients by 34% in comparison to
24 the vehicle usage (197). Topical corticosteroids have a rapid antipruritic effect and can also
25 be used in “proactive” therapy (108).

26 ***Calcineurin inhibitors***

27 Topical calcineurin inhibitors relieve significantly pruritus in AE. Itch is completely relieved
28 after the first days of treatment both in adults and children. 22 RCTs were meta-analysed
29 (16 – pimecrolimus 1% cream, 3 – tacrolimus 0.3% ointment, 1 – tacrolimus 0.1% ointment,
30 1 – tacrolimus 0.03% and 1- tacrolimus 0.01% ointment). Topical calcineurin inhibitors
31 appeared to reduce AE itch significantly by 36% compared to vehicle application (197).
32 Pimecrolimus blocks via TRPV1 the re-accumulation and synthesis of substance P (SP), a
33 major mediator of pruritus in inflammatory skin lesions.

34 ***Antihistamines***

35 5% doxepin cream exhibited antipruritic effects in 3 controlled studies in AE; one RCT
36 assessed the efficacy of cromoglycate 4% lotion (197). The meta-analysis of those studies
37 documented that the use of topical antihistamines markedly reduced itch of AE by 27% in
38 patients in comparison to the vehicle. However, topical doxepin therapy is not licensed and
39 not used in any European country due to an increased risk of contact allergy, especially
40 when the treatment exceeds eight days.

Cannabinoid receptor agonist

Topical cannabinoid receptor agonists have been described to exhibit antipruritic and analgesic properties. One cosmetic product containing the cannabinoid agonist N-palmitoylethanolamin was used in a multicenter, large cohort, open label study as adjuvant treatment in AE (74). 2456 patients including over 900 children applied the cream twice daily. Pruritus and the need to use corticosteroids were reduced up to 60%.

Opioid receptor antagonists

One double-blind, vehicle-controlled, randomized cross-over trial was performed with topical μ -opioid receptor antagonist nalmefene. The drug was used during two 7-days periods separated by the wash-out period. The study did not show significant efficacy in reducing the itch intensity in AE (198).

Polidocanol

Case series described the efficacy of a combination of the anaesthetic polidocanol and 5% urea (199). In children with AE, the combination showed a pruritus improvement of 30% in comparison with an emollient (200). Polidocanol is not licensed for AE in Europe, but OTC products are available.

Anesthetics

Local anaesthetics such as benzocaine, lidocaine, as well as a mixture of prilocaine and lidocaine are widely used as short-term effective topical antipruritics. In experimental studies, the antipruritic effect of local anaesthetics was demonstrated in AE (201). None of these substances is licensed for AE in Europe, but some OTC products are available.

Capsaicin

Capsaicin, is a naturally occurring alkaloid and the principal pungent of hot chilli peppers. Capsaicin binds to the TRPV1 ion channel, which is present on many itch-mediating C-fibers. Capsaicin has been advocated to be antipruritic in various dermatoses. Concerning AE, experimental studies (202) and case series (203) report on clear itch reduction. No controlled study has been published.

Summary of evidence

There is evidence that topical corticosteroids are effective in the initial phase of AE exacerbation to control pruritus. (1a)

There is evidence that topical calcineurin inhibitors are effective in AE until clearance of eczema to control pruritus. (1a)

There is not enough RCT evidence to demonstrate the efficacy of topical antihistamines, including doxepin in the treatment of AE itch. (1a)

There is no evidence from RCTs that the topical cannabinoid receptor agonist N-palmitoylethanolamin is effective as an adjuvant antipruritic therapy in AE. (4)

There is no evidence that the topical μ -opioid receptor antagonist nalmefene is effective in the management of pruritus in AE. (2b)

There is no evidence that topical anaesthetics and capsaicin is an effective adjuvant antipruritic therapy in AE. (4)

Recommendations

Topical corticosteroids are recommended to control pruritus in the initial phase of AE exacerbation. (1a,A)

Topical calcineurin inhibitors are recommended to control pruritus in AE until clearance of eczema. (1a,A)

Topical polidocanol may be used to reduce pruritus in AE patients. (-,D)

Routine clinical use of topical antihistamines including doxepin, topical cannabinoid receptor agonists, topical μ opioid receptor antagonists or topical anaesthetics, cannot be recommended as an adjuvant antipruritic therapy in AE. (4,C)

There is not enough data available to recommend the use of capsaicin in management of itch in AE patients. (4,B)

UV therapy

UV irradiation relieves pruritus in AE, which has been demonstrated in several studies. A recent systematic review of 19 available RCTs suggests the usage of narrow-band UVB and UVA1 as the most effective in the treatment of AE, including reduction of itch intensity (204). There is no “anti-itch-specific” data for UV therapy available, which would differ from the general recommendations for UV treatment of AE. (See chapter “UV therapy”).

Recommendations

There is evidence that UV-therapy can be used in AE to relief pruritus. Narrow-band UVB and UVA1 seem to be most preferable treatment modalities. (2a,B)

Systemic therapy

Antihistamines

Antihistamines (AH) have been used for decades, in an attempt to relieve pruritus in patients with AE. However, only a few randomized controlled trials have been conducted and they have in the majority shown only a weak or no effect in decreasing pruritus (205-213). According to a Cochrane search, randomized controlled trials investigating the efficacy of AH monotherapy in eczema patients are lacking (214).

The first generation of sedative AH such as hydroxyzine, clemastine fumarate and dimethindene maleate may allow a better sleep in acute situations with exacerbations of eczema (evidence level D). A significant, but clinically small, antipruritic effect of fexofenadine 60 mg twice daily has been described (215). An effect on itch of a high dosage of 20 to 40 mg cetirizine daily has been observed, but this effect was primarily attributed to sedation (211). In the recent meta-analysis of antipruritics in AE (197) only one RCT study on systemic AH fulfilled the criteria for inclusion and did not show significant improvement of itch in comparison to placebo (211).

In general, AH are safe to use, also for a long period of time (216). There are limited evidence-based data for the antipruritic effect of AH (H1-antagonists) in AE in general, and the effect of both first and second generation AH on pruritus in patients suffering from AE is very limited. AH may decrease urticaria when associated with AD, but this is rarely seen in clinical reality. The ETAC pediatric cetirizine studies showed an effect of AH on food induced urticaria (217). (See also chapter “Other systemic treatment”)

Apremilast

The oral inhibitor of phosphodiesterase 4 (PDE4) apremilast is discussed in part II of the guideline (see chapter “other systemic treatment”).

Leukotriene receptor antagonists

The leukotriene receptor antagonists zafirlukast and zileuton are discussed in part II of the guideline (see chapter “other systemic treatment”).

Opioid receptor antagonists

The μ -opioid receptor antagonist nalmeferene was applied in controlled, randomized studies in AE. A dosage of 10 mg and 20 mg each once per day showed significant relief of pruritus in three studies (218-220). In open label trials and one double-blind, placebo-controlled study trial, the only orally active μ -opioid antagonist naltrexone 25 - 150 mg per day showed considerable antipruritic effects (221, 222). Common side effects include anxiety, arthralgia, dizziness, drowsiness, fatigue, vomiting and headache. None of these substances is currently licensed for treatment of AE itch.

Selective serotonin reuptake inhibitors

The antipruritic effect of the selective serotonin reuptake inhibitors paroxetine and fluvoxamine was investigated in an open label trial in dermatological patients. A few patients with pruritus due to AE were included, who responded with considerable reduction of pruritus. In these patients, the pruritus was reduced about half in intensity (maximal antipruritic effect score, 45.0 \pm 7.1%) (223).

Cyclosporine A

See chapter “Systemic Immunosuppression”

Intravenous Immunoglobulin therapy

See chapter “Other systemic treatment”

Mycophenolate mofetil

See chapter “Systemic Immunosuppression”

Nemolizumab

See chapter “Biologics”

Summary of evidence

There is conflicting evidence regarding efficacy of antihistamines (H1-antagonists) for treatment of pruritus in AE, with the majority of studies showing only a weak or no effect on

1 pruritus. Antihistamines in general, and especially second generation agents, show a good
2 safety profile. (1b)

3 The opioid receptor antagonists naltrexone and nalmeferene may reduce itch in AE patients.
4 Common side effects include anxiety, arthralgia, dizziness, drowsiness, fatigue, vomiting
5 and headache. (1b)

6 The selective serotonin reuptake inhibitors paroxetine and fluvoxamine may be effective in
7 the treatment of AE-induced itch. Side effects include constipation, diarrhea, dizziness,
8 drowsiness, ejaculatory and erectile dysfunction, decreased libido, insomnia, nausea and
9 headache. (4)

10 **Recommendations**

11 There is not enough evidence to support the general use of both first and second generation
12 H1R-antihistamines for treatment of pruritus in AE. These may be tried for treatment of
13 pruritus in AE patients, if standard treatment with TCS and emollients is not sufficient. (1b,
14 A)

15 Long term use of sedative antihistamines in childhood may affect sleep quality and is
16 therefore not recommended. (-,D)

17 The opioid receptor antagonists naltrexone and nalmeferene are not recommended for routine
18 treatment of itch in AE patients. (-,D)

19 The selective serotonin reuptake inhibitors paroxetine and fluvoxamine are not
20 recommended for routine treatment of itch in AE patients. (4,C)

Tables

Table 1 Grades of evidence

- 1a) Meta-analysis of randomized clinical trials (RCT)
 - 1b) Single RCTs
 - 2a) Systematic review of cohort studies
 - 2b) Single cohort studies and RCTs of limited quality
 - 3a) Systematic review of case control studies
 - 3b) Single case control study
 - 4) Case series, case cohort studies or cohort studies of limited quality
- Recommendations (see Table 2) were classified based on the grade of evidence.

Table 2 Classification of strength of recommendation

Recommendation strength	Evidence grade
A	1a, 1b
B	2a, 2b, 3a, 3b
C	4
D	Expert opinion

Table 3 Language of recommendations

Wording in standard situations	Free text explanation
must be used	This intervention should be done in all patients, unless there is a real good reason not to do it
should be used	Most expert physicians would do it this way, but some would prefer other possible action
may be used	It would be correct to do this intervention, but it would also be correct not to do it; the choice depends largely on the specific situation
is possible	Most expert physicians would do something else, but it would not be wrong to do it
may be used in selected patients only	This intervention is not adequate for most patients, but for some patients there may be a reason to do it
is not recommended	Most expert physicians would not choose this intervention, but some specific situation may justify its use
must not be used	This intervention is inadequate in most situations

Table 4: Topical drugs for treatment of atopic eczema

	TCS class II	TCS class III	Tacrolimus	Pimecrolimus
overall recommendation	+ default treatment	+ short term flare treatment	+ long term maintenance	+ children, facial lesions
most important side effects	skin atrophy teleangiectasia striae distensae	skin atrophy teleangiectasia striae distensae	initial burning/stinging	initial burning/stinging
suitable for long term treatment	sometimes	no	yes	yes
suitable for proactive therapy	yes ♦	yes ♦	yes*	no
suitable for children > 2 years of age	yes	sometimes, see text	yes*	yes*
suitable for babies < 2 years of age	yes	diluted use	yes ♦	yes ♦
suitable during pregnancy	yes	yes	possible with strict indication ♦	possible with strict indication ♦
suitable during lactation	yes	yes	possible with strict indication ♦	possible with strict indication ♦

♦ off label use

* licensed use

Table 5: Upcoming topical drugs for treatment of atopic eczema

	Substance code	Target	Substance class	Development phase	Registration status	Trial data	Adverse drug effect signals	Recommendation
Crisaborole	AN2728	phosphodiesterase 4	PDE4 blocker	IV	app. USA	more effective than vehicle, no comparative study	application site pain	
	OPA-15406	phosphodiesterase 4	PDE4 blocker					
	E6005	phosphodiesterase 4	PDE4 blocker					

♦ see full text

PDE: phosphodiesterase; app: approved;

Treatment recommendation for atopic eczema: adult

- For every phase, *additional* therapeutic options should be considered
- Add antiseptics / antibiotics in cases of superinfection
- Consider compliance and diagnosis, if therapy has insufficient effect
- Refer to guideline text for restrictions, especially for treatment marked with ¹
- Licensed indication are marked with ², off-label treatment options are marked with ³

SEVERE: SCORAD >50 / or persistent eczema	Hospitalization; systemic immuno-suppression: cyclosporin A ² , short course of oral glucocorticosteroids ² , dupilumab ^{1,2} , methotrexate ³ , azathioprin ³ , mycophenolate mofetil ³ , PUVA ¹ , alitretinoin ^{1,3}
MODERATE: SCORAD 25-50 / or recurrent eczema	Proactive therapy with topical tacrolimus ² or class II or class III topical glucocorticosteroids ³ , wet wrap therapy, UV therapy (UVB 311 nm, medium dose UVA1), psychosomatic counseling, climate therapy
MILD: SCORAD <25 / or transient eczema	Reactive therapy with topical glucocorticosteroids class II ² or depending on local cofactors: topical calcineurin inhibitors ² , antiseptics incl. silver ² , silver coated textiles ¹
BASELINE Basic Therapy	Educational programmes, emollients, bath oils, avoidance of clinically relevant allergens (encasings, if diagnosed by allergy tests)

Treatment recommendation for atopic eczema: children

- For every phase, *additional* therapeutic options should be considered
- Add antiseptics / antibiotics in cases of superinfection
- Consider compliance and diagnosis, if therapy has insufficient effect
- Refer to guideline text for restrictions, especially for treatment marked with ¹
- Licensed indication are marked with ², off-label treatment options are marked with ³

SEVERE: SCORAD >50 / or persistent eczema	Hospitalization, systemic immuno-suppression: cyclosporin A ³ , methotrexate ³ , azathioprin ³ , mycophenolate mofetil ^{1,3}
MODERATE: SCORAD 25-50 / or recurrent eczema	Proactive therapy with topical tacrolimus ² or class II or III topical glucocorticosteroids ³ , wet wrap therapy, UV therapy (UVB 311 nm) ¹ , psychosomatic counseling, climate therapy
MILD: SCORAD <25 / or transient eczema	Reactive therapy with topical glucocorticosteroids class II ² or depending on local cofactors: topical calcineurin inhibitors ² , antiseptics incl. silver, silver coated textiles ¹
BASELINE Basic Therapy	Educational programmes, emollients, bath oils, avoidance of clinically relevant allergens (encasings, if diagnosed by allergy tests)

1 References:

- 2 1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol (Stockh) Suppl.*
3 1980;92:44-7.
- 4 2. Wuthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. *Epidemiology,*
5 *natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. J*
6 *Investig Allergol Clin Immunol.* 2003;13(1):1-5. Epub 2003/07/17.
- 7 3. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task
8 force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.
9 *Journal of the European Academy of Dermatology and Venereology : JEADV.* 2016;30(5):729-47. Epub
10 2016/03/24.
- 11 4. European Task Force on Atopic Dermatitis. Severity Scoring of Atopic Dermatitis: The SCORAD
12 Index. *Dermatology.* 1993;186:23-31.
- 13 5. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the
14 SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology.*
15 1997;195(1):10-9. Epub 1997/01/01.
- 16 6. Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, et al. Patient-Oriented
17 SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. *Allergy.*
18 2011;66(8):1114-21. Epub 2011/03/19.
- 19 7. Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, et al. Towards global consensus on
20 outcome measures for atopic eczema research: results of the HOME II meeting. *Allergy.* 2012;67(9):1111-7.
21 Epub 2012/08/01.
- 22 8. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment
23 of atopic eczema (atopic dermatitis) Part II. *Journal of the European Academy of Dermatology and*
24 *Venereology : JEADV.* 2012;26(9):1176-93. Epub 2012/07/21.
- 25 9. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment
26 of atopic eczema (atopic dermatitis) part I. *Journal of the European Academy of Dermatology and*
27 *Venereology : JEADV.* 2012;26(8):1045-60. Epub 2012/07/19.
- 28 10. Werfel T, Aberer W, Augustin M, Biedermann T, Folster-Holst R, Friedrichs F, et al. [Atopic
29 dermatitis: S2 guidelines]. *J Dtsch Dermatol Ges.* 2009;7 Suppl 1:S1-46. *Neurodermitis S2-Leitlinie.*
- 30 11. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health*
31 *Technol Assess.* 2000;4(37):1-191.
- 32 12. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. ETFAD/EADV eczema task
33 force 2009 position paper on diagnosis and treatment of atopic dermatitis. *Journal of the European*
34 *Academy of Dermatology and Venereology : JEADV.* 2010;24(3):317-28. Epub 2009/09/08.
- 35 13. Eberlein-König B, Przybilla B, Kuhn I, Pechak J, Gebefugi I, Kleinschmidt J, et al. Influence of
36 airborne nitrogen dioxide or formaldehyde on parameters of skin function and cellular activation in
37 patients with atopic eczema and control subjects. *The Journal of allergy and clinical immunology.*
38 1998;101(1 Pt 1):141-3.
- 39 14. Huss-Marp J, Eberlein-König B, Breuer K, Mair S, Ansel A, Darsow U, et al. Influence of short-term
40 exposure to airborne Der p 1 and volatile organic compounds on skin barrier function and dermal blood
41 flow in patients with atopic eczema and healthy individuals. *Clinical and experimental allergy : journal of*
42 *the British Society for Allergy and Clinical Immunology.* 2006;36(3):338-45.
- 43 15. Kathuria P, Silverberg JI. Association of pollution and climate with atopic eczema in US children.
44 *Pediatr Allergy Immunol.* 2016;27(5):478-85. Epub 2016/02/05.
- 45 16. Morgenstern V, Zutavern A, Cyrys J, Brockow I, Koletzko S, Kramer U, et al. Atopic diseases, allergic
46 sensitization, and exposure to traffic-related air pollution in children. *Am J Respir Crit Care Med.*
47 2008;177(12):1331-7.
- 48 17. Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, et al. The aryl hydrocarbon
49 receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin.
50 *Nature immunology.* 2017;18(1):64-73. Epub 2016/11/22.

- 1 18. Kramer U, Lemmen CH, Behrendt H, Link E, Schafer T, Gostomzyk J, et al. The effect of
2 environmental tobacco smoke on eczema and allergic sensitization in children. *Br J Dermatol*.
3 2004;150(1):111-8.
- 4 19. Andersen YM, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction,
5 ischemic stroke, and cardiovascular death in patients with atopic dermatitis. *The Journal of allergy and*
6 *clinical immunology*. 2016;138(1):310-2 e3. Epub 2016/03/15.
- 7 20. Kantor R, Kim A, Thyssen JP, Silverberg JL. Association of atopic dermatitis with smoking: A
8 systematic review and meta-analysis. *J Am Acad Dermatol*. 2016;75(6):1119-25 e1. Epub 2016/08/21.
- 9 21. Schafer T, Bauer CP, Beyer K, Bufer A, Friedrichs F, Gieler U, et al. S3-Guideline on allergy prevention:
10 2014 update: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the
11 German Society for Pediatric and Adolescent Medicine (DGKJ). *Allergo journal international*.
12 2014;23(6):186-99. Epub 2014/01/01.
- 13 22. Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and
14 molecular immunologic mechanisms in patients with atopic dermatitis. *The Journal of allergy and clinical*
15 *immunology*. 2016;138(2):336-49. Epub 2016/08/09.
- 16 23. Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wuthrich B, et al. The prevalence of
17 positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic
18 eczema: a European multicenter study. *Allergy*. 2004;59(12):1318-25. Epub 2004/10/28.
- 19 24. Takai T, Ikeda S. Barrier dysfunction caused by environmental proteases in the pathogenesis of
20 allergic diseases. *Allergol Int*. 2011;60(1):25-35. Epub 2010/12/22.
- 21 25. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-
22 mite allergen avoidance on atopic dermatitis. *Lancet*. 1996;347(8993):15-8.
- 23 26. Ricci G, Patrizi A, Specchia F, Menna L, Bottau P, D'Angelo V, et al. Effect of house dust mite
24 avoidance measures in children with atopic dermatitis. *Br J Dermatol*. 2000;143(2):379-84. Epub
25 2000/08/22.
- 26 27. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, et al. House dust mite
27 reduction and avoidance measures for treating eczema. *The Cochrane database of systematic reviews*.
28 2015;1:CD008426. Epub 2015/01/20.
- 29 28. Fieten KB, Weststrate AC, van Zuuren EJ, Bruijnzeel-Koomen CA, Pasmans SG. Alpine climate
30 treatment of atopic dermatitis: a systematic review. *Allergy*. 2015;70(1):12-25. Epub 2014/08/19.
- 31 29. Kramer U, Weidinger S, Darsow U, Mohrenschlager M, Ring J, Behrendt H. Seasonality in symptom
32 severity influenced by temperature or grass pollen: results of a panel study in children with eczema. *J Invest*
33 *Dermatol*. 2005;124(3):514-23.
- 34 30. Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A, et al. Exacerbation of atopic
35 dermatitis on grass pollen exposure in an environmental challenge chamber. *The Journal of allergy and*
36 *clinical immunology*. 2015;136(1):96-103 e9. Epub 2015/06/06.
- 37 31. Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. *Curr Probl Dermatol*.
38 2011;41:1-34. Epub 2011/05/18.
- 39 32. Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L. Pet exposure and risk of atopic
40 dermatitis at the pediatric age: a meta-analysis of birth cohort studies. *The Journal of allergy and clinical*
41 *immunology*. 2013;132(3):616-22 e7. Epub 2013/05/29.
- 42 33. Apfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema: population-based cross-sectional
43 study in Germany. *Allergy*. 2011;66(2):206-13. Epub 2010/09/02.
- 44 34. Lappalainen MH, Huttunen K, Roponen M, Remes S, Hirvonen MR, Pekkanen J. Exposure to dogs is
45 associated with a decreased tumour necrosis factor-alpha-producing capacity in early life. *Clinical and*
46 *experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2010;40(10):1498-
47 506. Epub 2010/07/17.
- 48 35. Thorsteinsdottir S, Thyssen JP, Stokholm J, Vissing NH, Waage J, Bisgaard H. Domestic dog exposure
49 at birth reduces the incidence of atopic dermatitis. *Allergy*. 2016;71(12):1736-44. Epub 2016/07/08.
- 50 36. Kettleson EM, Adhikari A, Vesper S, Coombs K, Indugula R, Roponen T. Key determinants of the
51 fungal and bacterial microbiomes in homes. *Environ Res*. 2015;138:130-5. Epub 2015/02/24.

37. Wollenberg A, Vogel S, Renner ED. [Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases]. *Hautarzt*. 2010;61(11):985-93; quiz 94. Epub 2010/10/23. Impfungen bei Neurodermitis und anderen chronisch entzündlichen Hauterkrankungen.
38. Wollenberg A, Engler R. Smallpox, vaccination and adverse reactions to smallpox vaccine. *Curr Opin Allergy Clin Immunol*. 2004;4:271-5.
39. Darso U, Sbornik M, Rombold S, Katzer K, von Sonnenburg F, Behrendt H, et al. Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2016;30(11):1971-7. Epub 2016/10/25.
40. Thomas KS, Bradshaw LE, Sach TH, Batchelor JM, Lawton S, Harrison EF, et al. UK Dermatology Clinical Trials Network's CLOTHES Trial Team. Silk garments plus standard care compared with standard care for treating eczema in children: A randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial). *PLoS Med*. 2017;14(4):e1002280.
41. Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2015 29:1071-81.
42. Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. In: Kanerva L, Elsner P, Wahlberg JE, Maibach HI, editors. *Handbook of Occupational Dermatology*. Berlin, Germany: Springer; 2000. p. 3–16.
43. Thyssen JP, Linneberg A, Engkilde K, Menne T, Johansen JD. Contact sensitization to common haptens is associated with atopic dermatitis: new insight. *Br J Dermatol*. 2012;166(6):1255-61. Epub 2012/01/31.
44. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet*. 2006;38(4):441-6.
45. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. *J Exp Med*. 2009;206(5):1135-47.
46. Ryan C, Shaw RE, Cockerell CJ, Hand S, Ghali FE. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. *Pediatric dermatology*. 2013;30(3):308-15. Epub 2013/04/27.
47. Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. *J Dermatol*. 2013;40(11):874-80. Epub 2013/10/12.
48. Huang JT, Abrams M, Tloughan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics*. 2009;123(5):e808-14. Epub 2009/05/01.
49. Hon KL, Tsang YC, Lee VW, Pong NH, Ha G, Lee ST, et al. Efficacy of sodium hypochlorite (bleach) baths to reduce *Staphylococcus aureus* colonization in childhood onset moderate-to-severe eczema: A randomized, placebo-controlled cross-over trial. *The Journal of dermatological treatment*. 2016;27(2):156-62. Epub 2015/08/14.
50. Ludwig G. [On the topical effect of sea water tub-baths with and without addition of an oil emulsion]. *Z Haut Geschlechtskr*. 1968;43(16):683-8. Über Lokalwirkungen von Meerwasser-Wannenbadern mit und ohne Zusatz einer Öl-Emulsion.
51. Hlela C, Lunjani N, Gumede F, Kakande B, Khumalo NP. Affordable moisturisers are effective in atopic eczema: A randomised controlled trial. *S Afr Med J*. 2015;105(9):780-4. Epub 2015/10/03.
52. Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. *Immunology and allergy clinics of North America*. 2010;30(3):351-68. Epub 2010/07/31.
53. Gelmetti C, Wollenberg A. Atopic dermatitis - all you can do from the outside. *Br J Dermatol*. 2014;170 Suppl 1:19-24. Epub 2014/04/12.
54. Grimalt R, Mengeaud V, Cambazard F, Study Investigators G. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology*. 2007;214(1):61-7.

- 1 55. Loden M, Andersson AC, Anderson C, Bergbrant IM, Frodin T, Ohman H, et al. A double-blind study
2 comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. *Acta dermato-*
3 *venereologica*. 2002;82(1):45-7.
- 4 56. Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing
5 regimens on skin hydration in atopic dermatitis. *Pediatric dermatology*. 2009;26(3):273-8.
- 6 57. Lack G, Fox D, Northstone K, Golding J, Avon Longitudinal Study of P, Children Study T. Factors
7 associated with the development of peanut allergy in childhood. *The New England journal of medicine*.
8 2003;348(11):977-85.
- 9 58. Boussault P, Léauté-Labrèze C, Saubusse E, Maurice-Tison S, Perromat M, Roul S, et al. Oat
10 sensitization in children with atopic dermatitis: prevalence, risks and associated factors. . *Allergy*.
11 2007;62:1251-6.
- 12 59. Boyd AS. Ichthammol revisited. *International journal of dermatology*. 2010;49(7):757-60. Epub
13 2010/07/14.
- 14 60. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic
15 aspects and clinical management. *The Journal of allergy and clinical immunology*. 2003;112(4):667-74. Epub
16 2003/10/18.
- 17 61. Mandeau A, Aries MF, Boe JF, Brenk M, Crebassa-Trigueros V, Vaissiere C, et al. Rhealba(R) oat
18 plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune
19 inflammatory mediators. *Planta medica*. 2011;77(9):900-6. Epub 2011/01/18.
- 20 62. Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, et al. Effects of nonpathogenic gram-
21 negative bacterium *Vitreoscilla filiformis* lysate on atopic dermatitis: a prospective, randomized, double-
22 blind, placebo-controlled clinical study. *Br J Dermatol*. 2008 159:1357-63.
- 23 63. Bianchi P, Theunis J, Casas C, Villeneuve C, Patrizi A, Phulpin C, et al. Effects of a New Emollient-
24 Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis.
25 *Pediatric dermatology*. 2016;33(2):165-71. Epub 2016/03/24.
- 26 64. Aries MF, Hernandez-Pigeon H, Vaissiere C, Delga H, Caruana A, Leveque M, et al. Anti-
27 inflammatory and immunomodulatory effects of *Aquaphilus dolomiae* extract on in vitro models. *Clinical,*
28 *cosmetic and investigational dermatology*. 2016;9:421-34. Epub 2016/11/24.
- 29 65. Mahe YF, Perez MJ, Tacheau C, Fanchon C, Martin R, Rousset F, et al. A new *Vitreoscilla filiformis*
30 extract grown on spa water-enriched medium activates endogenous cutaneous antioxidant and
31 antimicrobial defenses through a potential Toll-like receptor 2/protein kinase C, zeta transduction pathway.
32 *Clinical, cosmetic and investigational dermatology*. 2013;6:191-6. Epub 2013/09/17.
- 33 66. Fostini AC, Georgescu V, Decoster CJ, Girolomoni G. A cream based on *Aquaphilus dolomiae*
34 extracts alleviates non-histaminergic pruritus in humans. *European journal of dermatology : EJD*.
35 2017;27(3):317-8. Epub 2017/04/18. A cream based on *Aquaphilus dolomiae* extracts alleviates non-
36 histaminergic pruritus in humans.
- 37 67. Boralevi F, Saint Aroman M, Delarue A, Raudsepp H, Kaszuba A, Bylaite M, et al. Long-term
38 emollient therapy improves xerosis in children with atopic dermatitis. *Journal of the European Academy of*
39 *Dermatology and Venereology : JEADV*. 2014;28(11):1456-62. Epub 2013/11/26.
- 40 68. Angelova-Fischer I, Neufang G, Jung K, Fischer TW, Zillikens D. A randomized, investigator-blinded
41 efficacy assessment study of stand-alone emollient use in mild to moderately severe atopic dermatitis
42 flares. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2014;28 Suppl 3:9-15.
43 Epub 2014/04/08.
- 44 69. Miller DW, Koch SB, Yentzer BA, Clark AR, O'Neill JR, Fountain J, et al. An over-the-counter
45 moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the
46 treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. *J Drugs*
47 *Dermatol*. 2011;10(5):531-7. Epub 2011/05/03.
- 48 70. Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of
49 coconut and virgin olive oils in adult atopic dermatitis. *Dermatitis*. 2008;19(6):308-15.
- 50 71. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient
51 enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *The Journal of*
52 *allergy and clinical immunology*. 2014;134(4):818-23. Epub 2014/10/06.

- 1 72. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer
2 to neonates prevents development of atopic dermatitis. *The Journal of allergy and clinical immunology*.
3 2014;134(4):824-30 e6. Epub 2014/10/06.
- 4 73. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical
5 corticosteroids in childhood atopic dermatitis: a randomized comparative study. *Pediatr Allergy Immunol*.
6 2008;19(7):614-8.
- 7 74. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an
8 emollient containing N-palmitoylethanolamine (ATOPA study). *Journal of the European Academy of*
9 *Dermatology and Venereology* : JEADV. 2008;22(1):73-82.
- 10 75. Åkerström U, Reitamo S, Langeland T, Berg M, Rustad L, Korhonen L, et al. Comparison of
11 Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind
12 Controlled Multicentre Clinical Trial. *Acta dermato-venereologica*. 2015;95(5):587-92.
- 13 76. Mengeaud V, Phulpin C, Bacquey A, Boralevi F, Schmitt AM, Taieb A. An innovative oat-based sterile
14 emollient cream in the maintenance therapy of childhood atopic dermatitis. *Pediatric dermatology*.
15 2015;32(2):208-15. Epub 2014/12/23.
- 16 77. Eigenmann P, Sicherer S, Borkowski T, Cohen B, Sampson H. Prevalence of IgE-mediated food
17 allergy among children with atopic dermatitis. *Pediatrics*. 1998;101:E8.
- 18 78. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology,
19 epidemiology, diagnosis, and management. *The Journal of allergy and clinical immunology*. 1999;104(3 Pt
20 2):S114-22. Epub 1999/09/14.
- 21 79. Breuer K, Wulf A, Constien A, Tetau D, Kapp A, Werfel T. Birch pollen-related food as a provocation
22 factor of allergic symptoms in children with atopic eczema/dermatitis syndrome. *Allergy*. 2004;59:988-94
- 23 80. Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic
24 dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. *The Journal of*
25 *allergy and clinical immunology*. 1999;104(2 Pt 1):466-72. Epub 1999/08/19.
- 26 81. Breuer K, Heratizadeh A, Wulf A, Baumann U, Constien A, Tetau D, et al. Late eczematous reactions
27 to food in children with atopic dermatitis. *Clinical and experimental allergy : journal of the British Society*
28 *for Allergy and Clinical Immunology*. 2004;34(5):817-24.
- 29 82. Sampson HA. The evaluation and management of food allergy in atopic dermatitis. *Clin Dermatol*.
30 2003;21(3):183-92. Epub 2003/06/05.
- 31 83. Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rance F, Turjanmaa K, et al. Eczematous
32 reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. *Allergy*. 2007;62(7):723-8.
- 33 84. Niggemann B, Reibel S, Wahn U. The atopy patch test (APT)-- a useful tool for the diagnosis of food
34 allergy in children with atopic dermatitis. *Allergy*. 2000;55(3):281-5. Epub 2001/02/07.
- 35 85. Turjanmaa K, Darsow U, Niggemann B, Rancé F, Vanto T, Werfel T. EAACI/GA2LEN Position Paper:
36 Present status of the atopy patch test – position paper of the Section on Dermatology and the Section on
37 Pediatrics of the EAACI. *Allergy*. 2006;61:1377-84.
- 38 86. Niggemann B. The role of the atopy patch test (APT) in diagnosis of food allergy in infants and
39 children with atopic dermatitis. *Pediatr Allergy Immunol*. 2001;12 Suppl 14:37-40.
- 40 87. Roehr CC, Reibel S, Ziegler M, Sommerfeld C, Wahn U, Niggemann B. Atopy patch tests, together
41 with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic
42 dermatitis. *The Journal of allergy and clinical immunology*. 2001;107:548-53.
- 43 88. Darsow U, Ring J. Airborne and dietary allergens in atopic eczema: a comprehensive review of
44 diagnostic tests. *Clin Exp Dermatol*. 2000;25(7):544-51.
- 45 89. Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C, et al. EAACI
46 food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. *Allergy*.
47 2014;69(8):1008-25. Epub 2014/06/10.
- 48 90. Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, Blanco C, Ebner C, Hourihane J, et al.
49 Standardization of food challenges in patients with immediate reactions to foods--position paper from the
50 European Academy of Allergology and Clinical Immunology. *Allergy*. 2004;59(7):690-7. Epub 2004/06/08.
- 51 91. Bath-Hextall F, Delamere F, Williams H. Dietary exclusions for improving established atopic eczema
52 in adults and children systematic review. *Allergy*. 2009;64:258-64.

- 1 92. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic
2 dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American
3 Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice
4 Guidelines". *J Am Acad Dermatol*. 2004;50(3):391-404. Epub 2004/02/28.
- 5 93. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of
6 peanut consumption in infants at risk for peanut allergy. *The New England journal of medicine*.
7 2015;372(9):803-13. Epub 2015/02/24.
- 8 94. Perkin MR, Logan K, Tseng A, Raji B, Ayis S, Peacock J, et al. Randomized Trial of Introduction of
9 Allergenic Foods in Breast-Fed Infants. *The New England journal of medicine*. 2016;374(18):1733-43. Epub
10 2016/03/05.
- 11 95. Muraro A, Halken S, Arshad SH, Beyer K, Dubois AE, Du Toit G, et al. EAACI food allergy and
12 anaphylaxis guidelines. Primary prevention of food allergy. *Allergy*. 2014;69(5):590-601. Epub 2014/04/05.
- 13 96. Roduit C, Frei R, Loss G, Buchele G, Weber J, Depner M, et al. Development of atopic dermatitis
14 according to age of onset and association with early-life exposures. *The Journal of allergy and clinical
15 immunology*. 2012;130(1):130-6 e5. Epub 2012/04/24.
- 16 97. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic
17 eczema. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical
18 Immunology*. 2000;30(11):1604-10. Epub 2000/11/09.
- 19 98. Fölster-Holst R, Müller F, Schnopp N, Abeck D, Kreiselmaier I, Lenz T, et al. Prospective, randomized
20 controlled trial on *Lactobacillus rhamnosus* in infants with moderate to severe atopic dermatitis. *Br J
21 Dermatol*. 2006;155:1256-61.
- 22 99. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of
23 probiotic *Lactobacillus* strains in children with atopic dermatitis. *The Journal of allergy and clinical
24 immunology*. 2003;111(2):389-95. Epub 2003/02/18.
- 25 100. Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. *Expert
26 review of clinical immunology*. 2012;8(1):17-9. Epub 2011/12/14.
- 27 101. Cuello-Garcia CA, Brozek JL, Fiocchi A, Pawankar R, Yepes-Nunez JJ, Terracciano L, et al. Probiotics
28 for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. *The
29 Journal of allergy and clinical immunology*. 2015;136(4):952-61. Epub 2015/06/06.
- 30 102. Schnopp C, Holtmann C, Stock S, Remling R, Folster-Holst R, Ring J, et al. Topical steroids under wet-
31 wrap dressings in atopic dermatitis--a vehicle-controlled trial. *Dermatology*. 2002;204(1):56-9.
- 32 103. Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-Lopez JJ, Feito Rodriguez M, Herranz-Pinto P.
33 Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-
34 analysis. *Br J Dermatol*. 2016. Epub 2016/11/20.
- 35 104. Kohn LL, Kang Y, Antaya RJ. A randomized, controlled trial comparing topical steroid application to
36 wet versus dry skin in children with atopic dermatitis (AD). *J Am Acad Dermatol*. 2016. Epub 2016/06/05.
- 37 105. Janmohamed SR, Oranje AP, Devillers AC, Rizopoulos D, van Praag MC, Van Gysel D, et al. The
38 proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic
39 dermatitis: A prospective, randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol*. 2014.
- 40 106. Wollenberg A, Frank R, Kroth J, al. e. Proactive therapy of atopic eczema – an evidence-based
41 concept with a behavioral background. *J Dtsch Dermatol Ges* 2009. 2009;7: 117–21.
- 42 107. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis--an emerging concept. *Allergy*.
43 2009;64(2):276-8.
- 44 108. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic
45 eczema. *Ann Dermatol*. 2012;24(3):253-60. Epub 2012/08/11.
- 46 109. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for
47 reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol*. 2002;147(3):528-37.
- 48 110. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, et al. Twice weekly
49 fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic
50 dermatitis: randomised, double blind, parallel group study. *BMJ*. 2003;326(7403):1367.
- 51 111. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of
52 moderate to severe atopic dermatitis in adults with topical fluticasone propionate. *The Netherlands Adult
53 Atopic Dermatitis Study Group*. *Br J Dermatol*. 1999;140(6):1114-21.

- 1 112. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic
2 dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment
3 with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol*. 2008;158(4):801-
4 7.
- 5 113. Niedner R. Therapie mit systemischen Glukokortikoiden. *Hautarzt*. 2001;52:1062-71.
- 6 114. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by
7 superpotent topical steroids. *J Am Acad Dermatol*. 1993;29(3):501-3.
- 8 115. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the
9 treatment of atopic dermatitis of childhood. *Pediatric dermatology*. 1984;1(3):246-53.
- 10 116. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis.
11 *Clin Dermatol*. 2003;21(3):193-200.
- 12 117. Eichenfield LF, Hanifin JM, Beck LA, Lemanske RF, Jr., Sampson HA, Weiss ST, et al. Atopic dermatitis
13 and asthma: parallels in the evolution of treatment. *Pediatrics*. 2003;111(3):608-16.
- 14 118. Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical
15 corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. *J Am Acad Dermatol*.
16 2011;64(2):275-81.
- 17 119. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review.
18 *Drug Saf*. 2015;38(5):493-509.
- 19 120. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids
20 in pregnancy. *The Cochrane database of systematic reviews*. 2015(10):CD007346.
- 21 121. van Velsen SG, De Roos MP, Haeck IM, Sparidans RW, Bruijnzeel-Koomen CA. The potency of
22 clobetasol propionate: serum levels of clobetasol propionate and adrenal function during therapy with
23 0.05% clobetasol propionate in patients with severe atopic dermatitis. *The Journal of dermatological*
24 *treatment*. 2012;23(1):16-20.
- 25 122. Hajar T, Leshem YA, Hanifin JM, Nedorost ST, Lio PA, Paller AS, et al. A systematic review of topical
26 corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. *J*
27 *Am Acad Dermatol*. 2015;72(3):541-9 e2.
- 28 123. Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C, et al. Topical
29 corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. *Br J Dermatol*.
30 2011;165(4):808-14.
- 31 124. Lee JY, Her Y, Kim CW, Kim SS. Topical Corticosteroid Phobia among Parents of Children with Atopic
32 Eczema in Korea. *Ann Dermatol*. 2015;27(5):499-506.
- 33 125. Müller SM, Tomaschett D, Euler S, Vogt DR, Herzog L, Itin P. Topical Corticosteroid Concerns in
34 Dermatological Outpatients: A Cross-Sectional and Interventional Study. *Dermatology*. 2016;232(4):444-52.
- 35 126. Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1%
36 to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a
37 randomized, double-blind trial. *The Journal of dermatological treatment*. 2010;21(3):157-66.
- 38 127. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos J, et al. A short-term trial of tacrolimus
39 ointment for atopic dermatitis. *The New England journal of medicine*. 1997;337:816-21.
- 40 128. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin
41 macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. *Arch Dermatol*. 1998;134:805-9.
- 42 129. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year
43 of tacrolimus ointment monotherapy in adults with atopic dermatitis. *The European Tacrolimus Ointment*
44 *Study Group. Arch Dermatol*. 2000;136(8):999-1006. Epub 2000/08/05.
- 45 130. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, et al. Pimecrolimus
46 cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology*.
47 2002;205(3):271-7.
- 48 131. Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, et al. Proactive treatment of atopic
49 dermatitis in adults with 0.1% tacrolimus ointment. *Allergy*. 2008;63(6):742-50.
- 50 132. Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, et al. Proactive disease
51 management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized,
52 multicentre, comparative study. *Br J Dermatol*. 2008;159(6):1348-56.

133. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. *The Journal of allergy and clinical immunology*. 2002;109:547-55.
134. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. *The Cochrane database of systematic reviews*. 2015(7):CD009864. Epub 2015/07/02.
135. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. *The Journal of dermatological treatment*. 2010;21(3):144-56.
136. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. *The Journal of allergy and clinical immunology*. 2002;109(3):539-46.
137. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. *Arch Dermatol*. 2003;139(9):1184-6.
138. Reitamo S, Mandelin J, Rubins A, Remitz A, Makela M, Cirule K, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. *International journal of dermatology*. 2009;48(4):348-55.
139. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *J Pediatr*. 2003;142(2):155-62.
140. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. *J Am Acad Dermatol*. 2002;46:495-504.
141. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. *Br J Dermatol*. 2008;159(4):942-51.
142. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. *Pediatrics*. 2015;135(4):597-606. Epub 2015/03/25.
143. Wollenberg A, Sidhu MK, Odeyemi I, Dorsch B, Koehne-Volland R, Schaff M, et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol*. 2008;159(6):1322-30. Epub 2008/09/11.
144. Thaci D, Chambers C, Sidhu M, Dorsch B, Ehlken B, Fuchs S. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2010;24(9):1040-6.
145. Healy E, Bentley A, Fidler C, Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. *Br J Dermatol*. 2011;164(2):387-95.
146. Mandelin JM, Remitz A, Virtanen HM, Malmberg LP, Haahtela T, Reitamo S. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. *The Journal of dermatological treatment*. 2010;21(3):167-70.
147. Bornhövd EC, Burgdorf WHC, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. *Curr Opin Investig Drugs*. 2002;3:708-12.
148. Lübke J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. *Dermatology*. 2000;201(3):249-51.
149. Wetzel S, Wollenberg A. Eczema molluscatum in tacrolimus treated atopic dermatitis. *European journal of dermatology : EJD*. 2004;14(1):73-4.
150. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics*. 2002;110(1 Pt 1):e2.
151. Lubbe J. Secondary infections in patients with atopic dermatitis. *Am J Clin Dermatol*. 2003;4(9):641-54.

- 1 152. Bornhovd E, Wollenberg A. Topische Immunmodulatoren zur Ekzembehandlung. *Allergo J*
2 2003;12:456–62.
- 3 153. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. A multicentre,
4 randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults
5 with moderate to severe atopic dermatitis. *Br J Dermatol*. 2005;152(6):1282-9.
- 6 154. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not
7 affect collagen synthesis: Results of a single-center randomized trial. *J Invest Dermatol*. 1998;111:396-8.
- 8 155. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical
9 ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a
10 randomized, double-blind controlled study. *Br J Dermatol*. 2001;144:507-13.
- 11 156. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in
12 patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. *J*
13 *Am Acad Dermatol*. 2015;72(6):992-1002.
- 14 157. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, et al. Review of the potential
15 photo-carcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology
16 Forum. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2005;19(6):663-71.
- 17 158. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin
18 inhibitors and skin cancer in adults. *Dermatology*. 2007;214(4):289-95.
- 19 159. Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts
20 and controversies. *Clin Dermatol*. 2010;28(1):52-6. Epub 2010/01/20.
- 21 160. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association Between
22 Malignancy and Topical Use of Pimecrolimus. *JAMA Dermatol*. 2015;151(6):594-9.
- 23 161. Deleuran M, Vestergaard C, Vølund A, Thestrup-Pedersen K. Topical Calcineurin Inhibitors, Topical
24 Glucocorticoids and Cancer in Children: A Nationwide Study. *Acta dermato-venereologica*. 2016 96(6):834-
25 5.
- 26 162. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of
27 crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment
28 of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol*. 2016;75(3):494-503 e4. Epub
29 2016/07/16.
- 30 163. Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT. A Phase 2, Randomized, Controlled,
31 Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to
32 Moderate Atopic Dermatitis. *J Drugs Dermatol*. 2015;14(12):1394-9. Epub 2015/12/15.
- 33 164. Hanifin JM, Ellis CN, Frieden IJ, Fölster-Holst R, Stein Gold LF, Secci A, et al. OPA-15406, a novel,
34 topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and
35 adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind,
36 placebo-controlled study. *J Am Acad Dermatol*. 2016 75:297-305.
- 37 165. Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M, et al. Efficacy of a novel
38 phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-
39 controlled study. *The Journal of dermatological treatment*. 2016;27(5):467-72.
- 40 166. Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. Topical tofacitinib for
41 atopic dermatitis: a phase IIa randomized trial. *Br J Dermatol*. 2016 175(5):902-11.
- 42 167. Patrizi A, Savoia F, Giacomini F, Tabanelli M, Gurioli C. The effect of summer holidays and sun
43 exposure on atopic dermatitis. *G Ital Dermatol Venereol*. 2009;144(4):463-6.
- 44 168. Legat FJ, Wolf P. Cutaneous sensory nerves: mediators of phototherapeutic effects? *Front Biosci*
45 (Landmark Ed). 2009;14:4921-31.
- 46 169. Gambichler T, Kreuter A, Tomi NS, Othlinghaus N, Altmeyer P, Skrygan M. Gene expression of
47 cytokines in atopic eczema before and after ultraviolet A1 phototherapy. *Br J Dermatol*. 2008;158(5):1117-
48 20. Epub 2008/03/28.
- 49 170. Dotterud LK, Wilsgaard T, Vorland LH, Falk ES. The effect of UVB radiation on skin microbiota in
50 patients with atopic dermatitis and healthy controls. *Int J Circumpolar Health*. 2008;67(2-3):254-60. Epub
51 2008/09/05.

- 1 171. Hong SP, Kim MJ, Jung MY, Jeon H, Goo J, Ahn SK, et al. Biopositive effects of low-dose UVB on
2 epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. *J*
3 *Invest Dermatol.* 2008;128(12):2880-7. Epub 2008/06/27.
- 4 172. Vahavihu K, Ylianttila L, Salmelin R, Lamberg-Allardt C, Viljakainen H, Tuohimaa P, et al.
5 Heliotherapy improves vitamin D balance and atopic dermatitis. *Br J Dermatol.* 2008;158(6):1323-8.
- 6 173. Morita A, Krutmann J. Ultraviolet A radiation-induced apoptosis. *Methods Enzymol.* 2000;319:302-
7 9.
- 8 174. Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M, et al. Evidence that singlet oxygen-
9 induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. *J*
10 *Exp Med.* 1997;186(10):1763-8.
- 11 175. Grabbe J, Welker P, Humke S, Grewe M, Schopf E, Henz BM, et al. High-dose ultraviolet A1 (UVA1),
12 but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. *J*
13 *Invest Dermatol.* 1996;107(3):419-22.
- 14 176. Grewe M, Gyufko K, Krutmann J. Interleukin-10 production by cultured human keratinocytes:
15 regulation by ultraviolet B and ultraviolet A1 radiation. *J Invest Dermatol.* 1995;104(1):3-6.
- 16 177. Harari M, Shani J, Seidl V, Hristakieva E. Climatotherapy of atopic dermatitis at the Dead Sea:
17 demographic evaluation and cost-effectiveness. *International journal of dermatology.* 2000;39(1):59-69.
- 18 178. Vocks E, Borelli S, Rakoski J. Climatotherapy in atopic dermatitis. *Allergologie.* 1994;17:208–13.
- 19 179. Larko O, Swanbeck G. Is UVB treatment of psoriasis safe? A study of extensively UVB-treated
20 psoriasis patients compared with a matched control group. *Acta dermato-venereologica.* 1982;62(6):507-
21 12.
- 22 180. Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M. No evidence for increased skin cancer
23 risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective
24 study. *Acta dermato-venereologica.* 2004;84(5):370-4.
- 25 181. Becker D, Langer E, Seemann M, Seemann G, Fell I, Saloga J, et al. Clinical efficacy of blue light full
26 body irradiation as treatment option for severe atopic dermatitis. *PLoS One.* 2011;6(6):e20566. Epub
27 2011/06/21.
- 28 182. Mavilia L, Mori M, Rossi R, Campolmi P, Puglisi Guerra A, Lotti T. 308 nm monochromatic excimer
29 light in dermatology: personal experience and review of the literature. *G Ital Dermatol Venereol.*
30 2008;143(5):329-37. Epub 2008/10/04.
- 31 183. Wollenschlager I, Hermann J, Ockenfels HM. [Targeted UVB-308 nm (NUVB) therapy with excimer
32 laser in the treatment of atopic dermatitis and other inflammatory dermatoses]. *Hautarzt.*
33 2009;60(11):898-906. UVB-308-nm- (NUVB-)Therapie mittels Excimer-Laser bei atopischer Dermatitis und
34 weiteren inflammatorischen Dermatosen.
- 35 184. Syed S, Weibel L, Kennedy H, Harper JJ. A pilot study showing pulsed-dye laser treatment improves
36 localized areas of chronic atopic dermatitis. *Clin Exp Dermatol.* 2008;33(3):243-8.
- 37 185. Diffey BL, Farr PM, Oakley AM. Quantitative studies on UVA-induced erythema in human skin. *Br J*
38 *Dermatol.* 1987;117(1):57-66.
- 39 186. Gilchrist BA, Soter NA, Hawk JL, Barr RM, Black AK, Hensby CN, et al. Histologic changes associated
40 with ultraviolet A--induced erythema in normal human skin. *J Am Acad Dermatol.* 1983;9(2):213-9.
- 41 187. Dittmar HC, Pflieger D, Schopf E, Simon JC. [UVA1 phototherapy. Pilot study of dose finding in acute
42 exacerbated atopic dermatitis]. *Hautarzt.* 2001;52(5):423-7. UVA1-Phototherapie. Pilotstudie zur
43 Dosisfindung bei der bei akut exazerbierten atopischen Dermatitis.
- 44 188. von Kobyletzki G, Pieck C, Hoffmann K, Freitag M, Altmeyer P. Medium-dose UVA1 cold-light
45 phototherapy in the treatment of severe atopic dermatitis. *J Am Acad Dermatol.* 1999;41(6):931-7.
- 46 189. Kowalzik L. UVA1 for atopic dermatitis: medium dose superior to low dose. *J Am Acad Dermatol.*
47 2001;44(3):548.
- 48 190. Tzaneva S, Seeber A, Schwaiger M, Honigsmann H, Tanew A. High-dose versus medium-dose UVA1
49 phototherapy for patients with severe generalized atopic dermatitis. *J Am Acad Dermatol.* 2001;45(4):503-
50 7.
- 51 191. Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of the clinical significance of
52 systematic reviews on atopic eczema published in 2006 and 2007. *Clin Exp Dermatol.* 2008;33(6):685-8.

192. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. *Br J Dermatol*. 2009;160(3):652-8. Epub 2009/01/06.
193. Pugashetti R, Lim HW, Koo J. Broadband UVB revisited: is the narrowband UVB fading limiting our therapeutic options? *The Journal of dermatological treatment*. 2010;21(6):326-30.
194. Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology* : JEADV. 2013;27(2):e239-42.
195. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. *Int Arch Allergy Immunol*. 2001;124(1-3):326-31.
196. Kamata Y, Tominaga M, Takamori K. Itch in Atopic Dermatitis Management. *Curr Probl Dermatol*. 2016;50:86-93.
197. Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB, Jr. Relieving the pruritus of atopic dermatitis: a meta-analysis. *Acta dermato-venereologica*. 2012;92(5):455-61.
198. Herzog JL, Solomon JA, Draelos Z, Fleischer A, Jr., Stough D, Wolf DI, et al. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opioid antagonist nalmeferine in subjects with atopic dermatitis. *J Drugs Dermatol*. 2011;10(8):853-60.
199. Schommer A, Matthies C, Petersen I, Augustin M. Effektivität einer Polidocanol-Harnstoff-Kombination bei trockener, juckender Haut. *Ergebnisse einer methodisch geprüften Anwendungsbeobachtung. Akt Dermatol* 2007;33:33–8.
200. Hauss H, Proppe A, Matthies C. Vergleichende Untersuchungen zu Behandlung von trockener, juckender Haut mit einer Zubereitung aus Harnstoff und Polidocanol sowie mit einer Linolsäure-haltigen Fettcreme. *Ergebnisse aus der Praxis. Dermatosen Beruf Umwelt*. 1993;41:184–8.
201. Weisshaar E, Forster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema. *Skin Pharmacol*. 1997;10(4):183-90.
202. Weisshaar E, Heyer G, Forster C, Handwerker HO. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. *Arch Dermatol Res*. 1998;290(6):306-11.
203. Reimann S, Luger T, Metze D. [Topical administration of capsaicin in dermatology for treatment of itching and pain]. *Hautarzt*. 2000;51(3):164-72. *Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz*.
204. Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. *Br J Dermatol*. 2014;170(3):501-13.
205. Doherty V, Sylvester DG, Kennedy CT, Harvey SG, Calthrop JG, Gibson JR. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. *BMJ*. 1989;298(6666):96.
206. Henz BM, Metzenauer P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. *Allergy*. 1998;53(2):180-3.
207. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. *Allergy*. 1994;49(1):22-6.
208. La Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double-blind study of cetirizine in atopic eczema in children. *Ann Allergy*. 1994;73:117–22.
209. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. *Br J Dermatol*. 1990;122(4):545-51.
210. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziński Z, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. *Dermatology*. 2002;205(1):40-5.
211. Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. *Ann Allergy*. 1993;70(2):127-33.

- 1 212. Chunharas A, Wisuthsarewong W, Wananukul S, Viravan S. Therapeutic efficacy and safety of
2 loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. J
3 Med Assoc Thai. 2002;85(4):482-7.
- 4 213. Kawakami T, Kaminishi K, Soma Y, Kushimoto T, Mizoguchi M. Oral antihistamine therapy influences
5 plasma tryptase levels in adult atopic dermatitis. J Dermatol Sci. 2006;43(2):127-34.
- 6 214. van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, Jupiter A, Mattered U, Weisshaar E. No high level
7 evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a
8 Cochrane systematic review. Syst Rev. 2014;3:25.
- 9 215. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a
10 topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized,
11 multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol. 2003;148(6):1212-21.
- 12 216. Simons FE, Early Prevention of Asthma in Atopic Children Study G. Safety of levocetirizine treatment
13 in young atopic children: An 18-month study. Pediatr Allergy Immunol. 2007;18(6):535-42.
- 14 217. Simons FE. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very
15 young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. The Journal
16 of allergy and clinical immunology. 1999;104(2 Pt 1):433-40. Epub 1999/08/19.
- 17 218. Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic
18 urticaria and atopic dermatitis. J Am Acad Dermatol. 1989;21(1):135-6.
- 19 219. Burch JR, Harrison PV. Opiates, sleep and itch. Clin Exp Dermatol. 1988;13(6):418-9.
- 20 220. Banerji D, Fox R, Seleznick M, Lockey R. Controlled antipruritic trial of nalmefene in chronic urticaria
21 and atopic dermatitis. The Journal of allergy and clinical immunology. 1988;81:81: 252.
- 22 221. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor
23 antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol.
24 1999;41(4):533-9.
- 25 222. Malekzad F, Arbabi M, Mohtasham N, Toosi P, Jaberian M, Mohajer M, et al. Efficacy of oral
26 naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. Journal of the European
27 Academy of Dermatology and Venereology : JEADV. 2009;23(8):948-50.
- 28 223. Stander S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, et al. Treatment of
29 chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an
30 open-labelled, two-arm proof-of-concept study. Acta dermato-venereologica. 2009;89(1):45-51.

Consensus based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children

Part II

Wollenberg A²¹, Barbarot S²², Bieber T²³, Christen-Zaech S²⁴, Deleuran M²⁵, Fink-Wagner A²⁶, Gieler U²⁷, Girolomoni G²⁸, Lau S²⁹, Muraro A³⁰, Czarnecka-Operacz M³¹, Schäfer T³², Schmid-Grendelmeier P³³, Simon D³⁴, Szalai Z³⁵, Szepletowski JC³⁶, Taïeb A³⁷, Torrelo A³⁸, Werfel T³⁹, Ring J⁴⁰

For the European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients' Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS)

Correspondence to:
Prof. Dr. med. Dr. h.c. Andreas Wollenberg
Department of Dermatology and Allergology
Ludwig-Maximilian University
Frauenlobstr. 9-11, D-80337 Munich
Email: wollenberg@lrz.uni-muenchen.de

²¹ Department Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany and Klinik Thalkirchner Straße, Munich, Germany

²² Department of Dermatology, Centre Hospitalier Universitaire CHU Nantes, Nantes, France

²³ Department of Dermatology and Allergy, and Christine Kühne-Center for Allergy Research and Education, University Bonn, Bonn, Germany

²⁴ Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

²⁵ Department Dermatology, Aarhus University Hospital, Aarhus, Denmark

²⁶ EFA corporate Relations and Fundraising Manager and Co-Founder of GAAPP, Konstanz, Germany

²⁷ Dept. of Dermatology and Dept. of Psychosomatics and Psychotherapy, University of Gießen and Marburg GmbH, Gießen, Germany

²⁸ Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy

²⁹ Pediatric Pneumology and Immunology, Universitätsmedizin Berlin, Germany

³⁰ Centro di Specializzazione Regionale per lo Studio e la Cura delle Allergie e delle Intolleranze Alimentari presso l'Azienda Ospedaliera, Università di Padova, Italy

³¹ Department of Dermatology, Medical University, Poznan, Poland

³² Dermatological Practice, Immenstadt, Germany

³³ Allergy Unit, Department of Dermatology, University of Zurich, Switzerland and Christine Kühne Center for Allergy research and Education CK-CARE, Davos, Switzerland

³⁴ Department Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

³⁵ Department of Dermatology, Heim Pál Children's Hospital, Budapest, Hungary

³⁶ Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland

³⁷ Department of Dermatology & Pediatric Dermatology, Hôpital St André, Bordeaux, France

³⁸ Department of Dermatology, Hospital Niño Jesus, Madrid, Spain

³⁹ Department Dermatology and Allergy, Hannover Medical School, Hannover, Germany

⁴⁰ Department Dermatology and Allergy Biederstein, Technische Universität München, Munich, Germany and Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos

Declaration of Conflict of Interest

A. Wollenberg has been an advisor, speaker or investigator for ALK Abelló, Almirall, Anacor, Astellas, Beiersdorf, Bencard, Bioderma, Chugai, Galderma, Glaxo SmithKline, Hans Karrer, LEO Pharma, L'Oreal, Maruho, MedImmune, Novartis, Pfizer, Pierre Fabre, Regeneron and Sanofi.

S.Barbarot has been an advisor, speaker or investigator for Bioderma, La Roche Posay, Sanofi-Genzyme, Novalac, Ferring, Abbvie, Novartis, Janssen.

T. Bieber has been advisor, speaker or investigator for Abbvie, Allmirall, Anacor, Astellas, Bayer, Celgene, Chugai, Daiichi-Sankyo, Galderma, Glaxo SmithKline, Leo Pharma, Novartis, Pfizer, Pfizer, Pierre-Fabre, L'Oréal, La Roche-Posay, Regeneron, and Sanofi.

S. Christen-Zaech has been an advisor, speaker or investigator for Galderma, L'Oreal, La RochePosey, Pierre Fabre, Permamed, Procter and Gamble, and Sanofi-Genzyme.

M. Deleuran has been an advisor, speaker or investigator for AbbVie, Leo Pharma, MEDA, Pierre-Fabre, L'Oréal, La Roche-Posay, Pfizer, Regeneron and Sanofi.

A. Fink-Wagner has been working with, or an advisor or speaker for ALTANA, Novartis, Nycomed, Hoffmann-La Roche and Teva.

U. Gieler has been has been advisor or speaker for Allmirall, Astellas, Bayer, Celgene, Galderma, Glaxo SmithKline, Leo Pharma, Lilly, Novartis, Pfizer, Pierre-Fabre, La Roche-Posay and Sanofi - Aventis.

G. Girolomoni has been an advisor, speaker or investigator for AbbVie, Abiogen, Allmirall, Amgen, Bayer, Biogen, Boehringer Ingelheim, Celgene, Eli-Lilly, Galderma, Hospira, Janssen, Leo Pharma, Menlo therapeutics, Merck, MSD, Mundipharma, Novartis, Otsuka, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi and Sun Pharma

S. Lau has received grants from Allergopharma and Symbiopharm, and a honorarium from Merck as member of a drug monitoring committee, ALK and DBV Technologies.

A. Muraro has has been a speaker for Meda, Nestlé and Stallergenes.

M. Czarnecka-Operacz has been an advisor, speaker or investigator for Allergopharma, Allmiral, Bioderma, Berlin Chemie, Mennarini, Novartis, Pierre Fabre, Galderma, Janssen and Leo Pharma.

T. Schäfer has been speaker for Abbott, Bencard, Dr Pfleger, Norvatis and Syneron-Candela.

P. Schmid-Grendelmeier has been an advisor or speaker for ALK-Abello, Allergopharma, La Roche-Posay, MEDA, Novartis, Sanofi and Stallergenes.

D. Simon has been an advisor, speaker or investigator for Roche, Novartis, Galderma, Glaxo SmithKline, Merz Pharma (Schweiz), Almirall, Sanofi, and Eli Lilly.

Z. Szalai has been advisor for Pfizer, speaker or investigator for Bayer, Novartis, Pierre Fabre, Sanofi, Leo.

J.C. Szepletowski has been a Consultant and Advisor for AbbVie, Celgene, Dignity Sciences, Leo Pharma, Novartis, Pierre-Fabre and Sandoz; Investigator for AbbVie, Actelion, Amgen, GSK, Janssen, Merck, Novartis, Regeneron, Takeda, Trevi; Speaker for AbbVie, Actavis, Astellas, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly.

A. Taïeb has been an advisor for Anacor, Bioderma, Chugai, Galderma, Roche and Pierre Fabre.

1
2 A. Torrelo has been advisor, speaker or investigator for AbbVie, Anacor, Astellas, Bayer, Beiersdorf
3 AG, Galderma, Meda, Novartis, Pierre Fabre.

4
5 T. Werfel has received support for research projects from AbbVie, Astellas, Janssen/JNJ, Meda,
6 Regeneron/Sanofi, Takeda, Ziarco, and has been an advisor for AbbVie, Allmiral, LEO Pharma, Lilly,
7 MSD, Novartis, Regeneron/Sanofi, Roche, Stallergen and Ziarco.

8
9 J. Ring has been advisor, speaker or investigator for ALLERGIKA, ALK Abello, Almirall-Hermal,
10 Anacor, Astellas, Bencard/Allergy Therapeutics, Galderma, GSK-Stiefel, LEO Pharma, Meda, MSD,
11 Novartis, Phadia-ThermoFisher, and Sanofi.
12

1 List of Abbreviations

2	AAD	American Academy of Dermatology
3	AD	Atopic dermatitis
4	AE	Atopic eczema
5	AEGIS	3-trimethylsilylpropyl-dimethyloctadecyl ammonium chloride
6	AH	Antihistamines
7	AGREE	Appraisal of Guidelines Research and Evaluation
8	APT	Atopy patch test
9	ASIT	Allergen-specific Immunotherapy
10	AZA	Azathioprine
11	BB-UVB	Broadband ultraviolet B
12	BCC	Basal Cell Carcinoma
13	BO	Borage oil
14	CAM	Complementary alternative medicine
15	CAP-FEIA	CAP Fluorescence Immunoassay
16	CHM	Chinese herbal medicine
17	DBPC	Double-blind placebo-controlled
18	DBPCFC	Double-blind placebo-controlled food challenge
19	DHA	Docosahexaenoic acid
20	EADV	European Academy of Dermatology and Venereology
21	EASI	Eczema Area and Severity Score, a signs score
22	EAT	Enquiring About Tolerance
23	EC	Eczema coxsackium
24	EC-MPS	Enteric-coated mycophenolate sodium
25	EDF	European Dermatology Forum
26	EFA	European Federation of Allergy and Airways Diseases Patients'
27		Associations
28	EH	Eczema herpeticum
29	EPO	Evening primrose oil
30	ETFAD	European Task Force on Atopic Dermatitis
31	EU	European Union
32	EV	Eczema vaccinatum
33	FA	Food allergy
34	FTU	Fingertip unit
35	GAAPP	Global Allergy and Asthma Patient Platform
36	HBD	Human- β -defensin
37	HDM	House Dust Mite
38	HTA	Health Technology Assessment
39	H1R	Histamin 1 receptor
40	IA	Immunoabsorption
41	ICAM1	Intercellular Adhesion Molecule 1
42	IGA	Investigators Global Assessment, a signs score
43	IgE	Immunoglobulin E
44	IgG	Immunoglobulin G
45	IL	Interleukin
46	IVIG	Intravenous immunoglobulins
47	IFN- α	Interferon alpha
48	IFN- γ	Interferon gamma

1	JAK	Janus kinase
2	LEAP	Learning Early About Peanut Allergy
3	LTC4	Leukotriene C4
4	LTD4	Leukotriene D4
5	LTE4	Leukotriene E4
6	MCV	Molluscum contagiosum virus
7	MMF	Mycophenolat Mofetil
8	MTX	Methotrexate
9	mTLSS	modified Total Lesion Symptom Score
10	NB-UVB	Narrow band Ultraviolet B
11	OFC	Oral food challenge
12	OTC	Over the counter
13	PDE 4	Phosphodiesterase 4
14	PE	Patient education
15	PO-SCORAD	Patient-oriented Scoring of Atopic Dermatitis
16	PUVA	Psoralen and ultraviolet A
17	RCT	Randomized controlled trial
18	ROS	Reactive oxygen species
19	SASSAD	Six Area Six Signs Atopic Dermatitis score
20	SCC	Squamous Cell Carcinoma
21	SCIT	Subcutaneous Immunotherapy
22	SCORAD	Scoring of Atopic Dermatitis, a composite score
23	SLIT	Sublingual Immunotherapy
24	SPT	Skin prick test
25	TCI	Topical calcineurin inhibitors
26	TCS	Topical corticosteroids
27	TPMT	Thiopurine methyltransferase
28	TSH	Thyroid-stimulating hormone
29	Th1	T helper 1 cells
30	Th2	T helper 2 cells
31	Th17	T helper 17 cells
32	UV-light	Ultraviolet light
33	VOCs	Volatile organic compounds
34	VZV	Varicella-zoster Virus
35	QoL	Quality of life
36	TSLP	Thymic stromal lymphopoietin
37		

Abstract

The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) was evaluated using the national standard Appraisal of Guidelines Research and Evaluation (AGREE). The consensus process consisted of a nominal group process and a Delphi procedure. This second part of the guideline covers antimicrobial therapy, systemic treatment, allergen specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions, whereas the first part covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy.

Management of AE must consider the individual clinical variability of the disease. Systemic immuno-suppressive treatment with cyclosporine, methotrexate, azathioprine and mycophenolic acid are established options for severe refractory cases, and widely available. Biologicals targeting the T helper 2 pathway such as dupilumab may be a safe and effective, disease modifying alternative when available. Oral drugs such as JAK inhibitors and Histamin4 receptor antagonists are in development. Microbial colonization and superinfection may cause disease exacerbation and can require additional antimicrobial treatment. Allergen-specific immunotherapy with aeroallergens may be considered in selected cases. Psychosomatic counselling is recommended especially in stress-induced exacerbations. Therapeutic patient education ("Eczema school") is recommended for children and adult patients.

General measures, basic emollient treatment, bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and anti-pruritic therapy have been addressed in the first part of the guideline.

Key words: Atopic eczema, atopic dermatitis, management, therapy, guideline

1	Table of contents
2	
3	Part I
4	Introduction
5	Method of guideline formation
6	Patient perspective
7	General measures and avoidance strategies
8	Basic emollient treatment and bathing
9	Dietary intervention
10	Topical anti-inflammatory therapy
11	Phototherapy
12	Antipruritic therapy
13	
14	Part II
15	Antimicrobial therapy
16	Systemic anti-inflammatory treatment
17	Other systemic treatment
18	Allergen specific immunotherapy
19	Complementary medicine
20	Psychosomatic counselling
21	Educational interventions
22	Conclusion and future options
23	

Antimicrobial therapy

In patients with AE, the inflammatory micro-milieu initiated by TSLP, IL-4 and IL-13 may downregulate the cutaneous antimicrobial peptides such as cathelicidin LL-37, dermcidin, human β -defensins HBD-1, HBD-2, and HBD-3 (1, 2). This is one of the reasons why these patients are more susceptible to secondary skin infections, which tend to generalize (2). The understanding of colonization and infection in AE has largely increased by structured investigation of the human microbiome in the context of AE. Flares of AE are significantly associated with a *S. aureus*-caused loss of diversity in the cutaneous microbiome, which is not significant if patients have followed a proactive therapy regimen before the flare (3).

Anti-bacterial

In up to 90% of AE patients even the normal looking skin is extensively colonized by *Staphylococcus aureus*. This bacterium is a major trigger of AE, as it leads to inflammation through the release of superantigen toxins, which enhance T cell activation of superantigen specific and allergen-specific T cells, expression of IgE anti-staphylococcal antibodies and as it increases expression of IL-31 which leads to pruritus (4). Scratching favors binding of *S. aureus* to the skin, and the increased amount of *S. aureus* derived ceramidase aggravates the skin barrier defect. Moreover, superantigen production increases expression of alternative glucocorticoid receptors that do not bind to topical corticosteroids, which leads to resistance (5). Biofilm formation by AE-associated staphylococci most certainly also plays a major role in the occlusion of sweat ducts and leads to inflammation and pruritus (6). Recent investigations have shown that besides *S. aureus* the dysbalance of skin microbiome may play an important role in AE pathophysiology (7, 8). New developments in emollients are the incorporation of active compounds that repair the barrier function or influence the microbiome of AE with bacterial lysates from *Aquaphilus dolomiae* or *Vitreoscilla filiformis* species (9). A better understanding of the skin microbiome in AE is a promising direction for the development of new treatment strategies.

A systematic review of 26 studies including 1229 participants showed no clear beneficial evidence of antiseptic bath additives or soaps, or of antimicrobial agents added to topical therapies in non-infected atopic dermatitis. Nevertheless, if there is no response to topical glucocorticosteroids or calcineurin inhibitors, or evident infection, the use of topical antiseptics can be considered, and these are preferred over topical antibiotics with regard to the development of bacterial resistance (10). Sodium hypochlorite 0.005% is not only antiseptic but enhances epidermal thickness and proliferation (11). Its intermittent use showed a significant decrease of AE severity (12). Systemic antibiotics should only be used in case of apparent and extensive bacterial superinfection. On the basis of current resistance spectra, cephalexin, or another first-generation cephalosporin can be recommended. Children with AE seem to have a much lower rate of community-acquired methicillin resistant *S. aureus* infection compared to the general pediatric population (13). In any case treatment with emollient and corticosteroids or topical calcineurin inhibitors should be continued.

Underestimated sources of bacteria are cream and ointment containers, of which up to 53% are contaminated, up to 25% with *S. aureus*. Thus the following recommendations seem to be useful (14): 1.) Keep open moisturizers in refrigerator; 2.) Use pumps or pour bottles rather than jars; 3.) Avoid direct contact with hands and decant; 4.) Avoid sharing personal hygiene items.

Antimicrobial textiles

Silver-impregnated textiles have shown significant antimicrobial activity, as well as improvement of localized SCORAD in an unblinded, side-to-side controlled clinical trial (15). In patients with uninfected AE, the use of silver impregnated textile compared to cotton underwear did not reduce AE severity (16-18). However, some functional textiles (silver-coated, acid-coated and silk textiles) as well as Chitosan, a natural biopolymer with immunomodulatory and antimicrobial properties, may possibly improve AE manifestations, as they decrease skin colonization by *S. aureus*, and they reduce itch (19). Some of these newer options are still under investigation and there seem to be some concern about the safety of silver-coated textiles in infants and toddlers. AEGIS-coated silk textiles did not show clinical benefit in a well-controlled, multicenter clinical trial (20).

Anti-viral

Viral infections including herpes simplex, varicella zoster, molluscum contagiosum, smallpox and coxsackie viruses occur more frequently in AE patients than in healthy individuals, with a tendency to disseminated, widespread disease (21).

Eczema herpeticum (EH), a disseminated herpes simplex virus infection, is a potentially serious complication of AE that requires immediate medical action. Patients, mostly children, present with disseminated vesicles, fever and lymphadenopathy and can develop complications such as keratoconjunctivitis, meningitis and encephalitis. Predisposing factors of EH are early onset of AE, severe or untreated forms of AE, filaggrin deficiency and high total serum-IgE level (21). Pre-treatment with topical corticosteroids does not seem to imply an increased risk of developing EH whereas topical calcineurin inhibitor may do so and should be discontinued immediately (22). Mainstay of EH therapy is a systemic treatment with aciclovir or valaciclovir, in a majority of cases administered intravenously (23). Treatment should be started immediately once the clinical diagnosis is made (24).

Varicella-zoster virus (VZV) infection in an immunocompetent child is usually a mild, self-limited disease. This infection is, however, known to facilitate secondary local or systemic bacterial infection, which is cause for particular concern in AE children. Earlier studies demonstrated the safety and efficacy of VZV vaccination in these children who appear to benefit from this vaccination (25). Moreover, in children with AE, common childhood immunization in the first year is not associated with an increased risk of more severe AE or allergic sensitization; also immune response to VZV vaccine is comparable to healthy children (26). Therefore parents of atopic children should be encouraged to fully immunize their children.

Molluscum contagiosum virus (MCV) infection is in general benign and self-limited, but in patients with AE dissemination is frequent and therefore treatment is recommended. A large

variety of topical treatments have been reported such as cantharidin, potassium hydroxide, tretinoin cream, topical cidofovir, and others (27). Physical therapies including cryotherapy and curettage are also effective, but not always well tolerated in pediatric patients (28). Topical treatment of AE with TCS may be continued during MCV infection.

Eczema vaccinatum (EV) is a complication of smallpox vaccination known to occur in AE patients. The vaccinia virus disseminates and causes an extensive rash and severe systemic illness with a mortality rate estimate at 5-40% (29). Therefore smallpox vaccination is contraindicated in patients with a history of or currently active AE (30). The existence of an attenuated vaccine and three antiviral drugs, in addition to vaccinia immunoglobulin, provides means of preventing or treating EV (31, 32). Should a smallpox outbreak necessitate an emergency mass vaccination, the choice of vaccination strategies, such as ring or mass vaccination, has to be determined by policymakers.

Eczema coxsackium (EC) is a disseminated form of coxsackie virus infection mostly occurring in children with active AE lesions. The coxsackie virus A6 strain leads to atypical disease manifestations, which are classified as diffuse form (lesions extended to the trunk), acral form (lesions with a mainly acral distribution), or eczema coxsackium (disseminated lesions on preexisting eczematous areas) (33). Symptomatic treatment includes use of topical steroids and wet wrap therapy (34, 35).

Regional vaccination programs should be followed by all AE patients as recommended. The denial of vaccination because of diagnosed AE is a misconception possibly leading to fatal consequences (see chapter: general measures).

Anti-fungal

Despite its role as a commensal on healthy human skin, *Malassezia* spp. is attributed a pathogenic role in AE, as it may interact with the local skin immune response and barrier function. The precise mechanisms by which *Malassezia* spp. may contribute to the pathogenesis of AE are not fully understood and remain to be elucidated (36). Several randomized, placebo controlled trials investigated the benefit of topical or systemic antifungal treatment for AE patients (37, 38). The ambiguous results of these clinical trials might be attributed to a selection bias. It can be speculated that antifungal therapies are more effective in certain subgroup of AE. It seems for example that antifungal therapy shows beneficial effects in patients with a head-neck-type distributed AE and detectable IgE-mediated sensitization against *Malassezia* (39). It has also been shown that sensitization against this skin-colonizing yeast can correlate with disease activity (40). The most common class of antifungal drugs prescribed for AE patients are azoles such as ketoconazole and itraconazole which have also some anti-inflammatory properties (38). Due to a better benefit side effect ratio imidazole derivatives (fluconazole or itraconazole) should be prescribed instead of ketoconazole for systemic treatment. In summary, antifungal treatment with either topical ketoconazole or ciclopiroxolamine or systemic itraconazole or fluconazole can be considered for those patients who suffer from head–neck dermatitis, particularly for those who are characterized by clear IgE-sensitization to *Malassezia* spp.

1 **Summary of evidence**

2 Oral antibiotics have no benefit on the skin condition in AE as long as skin lesions are not
3 obviously superinfected. (1b)

4 A Cochrane review showed no clear beneficial evidence to antiseptic substances in non-
5 infected AE. (4)

6 Topical glucocorticosteroids and calcineurin inhibitors reduce the colonization rate of *S.*
7 *aureus* in AE. (4)

8 Antiseptic textiles have a moderate clinical effect on AE. (2b)

9 AEGIS-coated silk garments do not show clinical benefit over standard care (2b).

10 VZV vaccination is safe, efficacious and beneficial for children with atopic dermatitis. (2a)

11 An antifungal therapy may be efficient in some AE patients, mainly in those suffering from
12 the „head and neck“-variant of AE or with demonstrated IgE-sensitization to *Malassezia spp.*
13 (2b)

14 **Recommendations**

15 A short course of systemic antibiotics, such as cephalosporin, may be considered in AE
16 patients clinically infected with *S. aureus*. (2b, B)

17 The long-term application of topical antibiotics is not recommend due to the risk of increasing
18 resistances and sensitizations. (2, D)

19 Treatment with topical antiseptic drugs – including antiseptic baths e.g. with diluted sodium
20 hypochlorite - should be considered, if clinical signs of bacterial superinfection are present.
21 (4,C)

22 Treatment with topical antiseptic drugs – including sodium hypochlorite 0.005% baths – may
23 be considered in patients with treatment resistant, chronic course of AE. (2b,B)

24 Eczema herpeticum should be treated without delay using systemic antiviral therapy, such
25 as systemic aciclovir. (4,D)

26 VZV vaccination is recommended for children with atopic dermatitis. Parents of atopic
27 children should be encouraged to fully immunize their children. (2a,B)

28 Topical or systemic antifungal therapy may be effective in some AE patients, mainly in those
29 suffering from the „head and neck“ variant of AE or with demonstrated IgE-sensitization to
30 *Malassezia spp.* (2b,B)

Systemic anti-inflammatory treatment

Immunosuppressive treatment

Oral glucocorticosteroids

Oral glucocorticosteroids are used in many European countries for treatment of AE. Well known side effects limit their use especially for long-term treatment. Funding of expensive clinical trials in the near future is unlikely.

Controlled clinical trial data demonstrating efficacy: There is one controlled trial available that demonstrates lower efficacy of therapy with systemic prednisolone compared to ciclosporine in severe adult AE patients (41). Broad experience from clinical use by many experts indicates some efficacy, as well as prompt rebound after withdrawal.

Summary of evidence

Short term treatment with oral glucocorticosteroids is moderately effective. (1b)

Systemic steroids have a largely unfavourable risk/benefit ratio for treatment of AE. (1b)

Recommendations

Short-term (up to 1 week) treatment with oral glucocorticosteroids may be an option to treat an acute flare in exceptional cases of AE. Restrictive use, largely limited to adult patients with severe AE, is recommended. (-, D)

The daily dose should be adjusted to and not exceed 0,5 mg/kg body weight. (-, D)

Long-term use of oral glucocorticosteroids in AE patients is not recommended. The indication for oral steroids in children should be handled even more cautiously than in adults. (-, D)

Cyclosporine A

Cyclosporine is licensed in many European countries for treatment of AE and is therefore considered to be the first line option for patients with severe disease who require systemic immunosuppressive treatment.

Controlled clinical trial data demonstrating efficacy

Cyclosporine vs. Placebo: A meta-analysis and review of pooled data from 15 RCTs (42) clearly demonstrated the efficacy of cyclosporine in AE with a 55% improvement on average after 6-8 weeks of treatment. Body surface area, erythema, sleep loss and glucocorticosteroid use were reduced in the cyclosporine group. Cyclosporine is more effective than placebo, but there is often prompt relapse if cyclosporine is stopped. All scores are back to pre-treatment values eight weeks after the end of cyclosporine therapy in most patients.

Cyclosporine dose finding study for AE treatment in adult patients: A fixed dosage cyclosporine regimen was evaluated in 106 adults with severe AE (43). Initial treatment was performed with 300 mg/d or 150 mg/d and reduced after two weeks to 50% of the initial daily dose until a final evaluation was performed after eight weeks. Clinical efficacy was detectable after two weeks in both treatment groups, but the higher dose was significantly more effective ($p < 0.05$). The authors recommended to start therapy with 150 mg/d, because this regimen showed a lower incidence of serum creatinine increase. It is recommended today to start with a higher dose of 4-5 mg/kg/day to obtain a good initial result unless the patient is old or suffers from relevant concomitant diseases (44). Some patients may tolerate low dose cyclosporine therapy for a longer time than the usually recommended therapy length of 2 years (45).

Continuous or intermittent cyclosporine therapy study of AE in children: Forty children aged 2-16 years were randomized to either a continuous long term or an intermittent short term cyclosporine regimen (46). Both groups showed significantly better results in clinical scores and quality of life assessments. Enhanced sustained improvement was seen in the continuously treated group. As the intermittent therapy was sufficient in some patients but associated with a lower cumulative cyclosporine dose, the authors recommended choosing the regimen on an individual basis.

Cyclosporine or UV Therapy for AE: Cyclosporine was tested against a combined UV/UVB regimen in a one year, open label, multicentre trial involving 72 patients (47). Cyclosporine therapy induced a significantly higher number of days in remission, as compared to UV therapy.

Compounding of Cyclosporine: Micro emulsions of cyclosporine show an earlier onset and higher peak value of efficacy compared to traditional formulations (48). The clinical efficacy evaluated after eight weeks of therapy was, however, identical for both formulations.

Drug safety profile of Cyclosporine: Patients receiving cyclosporine should be monitored for blood pressure and renal parameters, as cyclosporine is known to induce structural and organic kidney damage. Nephrotoxic effects are more likely to occur if the daily dose exceeds 5 mg/kg body weight, serum creatinine values are elevated or elderly patients are treated. Life vaccination is contraindicated during cyclosporine therapy.

Summary of evidence

Many RCTs indicate the efficacy of cyclosporine versus placebo in AE. (1a)

Cyclosporine is also effective in children and adolescent AE patients. (2b)

Self-willed reduction of the recommended cyclosporine dose may reduce the clinical efficacy of cyclosporine and is not recommended. (2b)

A micro emulsion of cyclosporine has the advantage of an earlier onset and peak level of clinical efficacy, which may be useful in short-term treatment. (1b)

Long-term intermittent cyclosporine therapy for one year is more effective than an intermittent UVA/UVB therapy following a 2-3 times weekly regimen. (1b)

Recommendations

Cyclosporine may be used in chronic, severe cases of AE in adults. Treatment should not exceed a two-year continuous regimen. Careful monitoring for potential severe side effects must be performed. (1a, A)

Cyclosporine may be used (off label) in children and adolescent patients showing a refractory or severe course of disease. A detailed patient monitoring, especially of the renal status, is advisable. (2b, B)

The duration of cyclosporin therapy is guided by clinical efficacy and tolerance of the drug. Both short-term and long-term therapy may be useful in AE. (-, D)

Common side effects of cyclosporine (e.g. nephrotoxicity, hypertension) argue against a long-term treatment of AE with cyclosporine. Therefore, an interval of 3-6 months is usually recommended. (-,D)

Cessation of therapy or switch to another systemic drug should be attempted after two years of therapy, although many patients tolerate much longer therapy with low dose cyclosporine. (-,D).

An initial daily dose of 5 mg/kg/d, divided upon two single doses, is recommended. A dose reduction of 0.5-1.0 mg/kg/d every two weeks is recommended, once clinical efficacy is reached. (-,D)

Dose reduction should be considered according to clinical efficacy. Long term treatment prescribing the lowest clinically useful dose may be advisable in selected cases. (-,D)

Since an intermittent dosage regimen (e.g. "weekend therapy") will lead to lower cumulative doses of cyclosporine and is effective in some AE patients, an individualized dosage regimen is recommended for underage patients. (-,D)

Cyclosporine trough levels do not need to be assessed routinely during therapy. (-,D)

Though there are no controlled studies available regarding the efficacy of vaccination during cyclosporine therapy, there is no evidence for a failure during cyclosporine either. Hence, a cessation of therapy of 2 weeks before and 4-6 weeks after vaccination may be advisable. Clinically, there is no evidence for this recommendation. (-,D)

A combination therapy of cyclosporine with UV-therapy is not recommended, effective UV protection should be used. (-,D)

Azathioprine (AZA)

Azathioprine is used (off label) for many years for treatment of AE in adult patients. Funding of expensive clinical trials in the near future is unlikely.

Controlled clinical trial data demonstrating efficacy: Efficacy of AZA was tested in a randomized, controlled, 6 month, crossover clinical trial involving 37 patients aged 17 to 73 years (49). The drop-out rate was high (12 patients on AZA, 4 patients on placebo). AZA (2.5 mg/kg/d) or placebo was given for three months each in a crossover design. The SASSAD skin severity score was reduced by 26% in the AZA group and 3% in the placebo

group ($p < 0.01$). Pruritus, sleep loss and fatigue improved significantly during AZA, but not during placebo treatment.

Another randomized double blind, placebo controlled, 12 weeks, clinical trial involved 63 outpatients with AE (50). Following a low dose introduction phase, azathioprine was dosed in 42 patients according to the results of a thiopurine methyltransferase (TPMT) polymorphism, which may be indicative for the myelotoxicity of azathioprine – the other 21 patients received placebo. Patients with a normal TPMT activity were treated with 2.5 mg/kg/d AZA, whereas patients with a reduced TPMT activity (heterozygous phenotype) received 1.0 mg/kg/d AZA. The AZA regimen was more effective in AE, as the disease activity dropped by 37% in the azathioprine group and by 20% in the placebo group. None of the patients showed myelotoxic symptoms.

A prospective, randomized controlled trial showed equal clinically relevant improvement of AZA 1.5-2.5 mg/kg/day compared to methotrexate 10-22.5 mg/week after 12 weeks of treatment in adults with severe AE. Both treatments were safe in the short term (51).

Twelve children with severe, recalcitrant AE were treated with oral AZA and followed prospectively. AZA therapy was associated with clinical improvement in all but 1 patient. There were few adverse effects (52).

A retrospective, uncontrolled study investigated 48 children and adolescents aged 6 to 16 years diagnosed with severe AE (53). After three months of therapy, 28 patients showed very good and 13 patients showed good improvement of their symptoms, while 7 patients showed little or no improvement. None of the patients showed myelotoxic symptoms, TPMT activity was determined in all patients before treatment. All patients were started on 2mg/kg/d AZA and the dose was increased to 3mg/kg/d in 14 patients due to insufficient clinical response. The mean time to achieve clinical response was 4 weeks.

A retrospective, uncontrolled study in a heterogeneous group of 17 children and adults with a mean age of 16 years showed significant improvement of SCORAD after 3 and 6 months of AZA, and significant reduction of total serum IgE levels (54).

Safety profile of azathioprine The authors of the Berth-Jones study concluded, that AZA would be an effective and clinically useful drug for treatment of severe AE, but would be associated with a high rate of unwanted drug effects (49). Leukocyte counts and liver enzymes must be controlled during therapy. The higher dose caused gastrointestinal symptoms in 14 patients; leukopenia in 2 and elevated liver enzymes in 8 patients. Long-term efficacy and safety data in AE patients are sparse, but AZA increased the risk of non-melanoma skin cancer and lymphoma in inflammatory bowel disease patients (55).

Summary of evidence

AZA is effective for treatment of severe AE in adults. (1b)

One small prospective clinical trial in children showed efficacy of AZA. (4)

Recommendations

AZA may be used (off label) in adult AE patients, if cyclosporine is either not effective or contraindicated. (1b,A)

AZA may also be used (off label) in children. (4, C)

Patients should be screened for TPMT activity before starting AZA therapy to reduce the risk for bone marrow toxicity by dose adaptation. The suggested dose range is 1-3mg/kg bw/d. (1b,A)

Alternatively, an initial AZA dose of 50mg/day in adults and a slow increase of the dose under close monitoring of full blood and liver function count is possible. (-, D)

In pregnant women, AZA should only be used on strict indication. (-, D)

AZA should not be combined with UV therapy, effective UV protection should be used. (-, D)

Mycophenolate Mofetil (MMF)

MMF is an immunosuppressant drug licensed in many European countries for the treatment of systemic lupus erythematosus and prevention of transplant rejection.

Controlled clinical trial data demonstrating efficacy: There is one controlled trial with enteric-coated mycophenolate sodium (EC-MPS) vs. Cyclosporine A as long-term treatment showing almost equal efficacy (56). Some case reports or uncontrolled clinical trial data from adults indicate that it would be clinically effective in AE (57, 58). There is one uncontrolled retrospective report involving 14 children indicating efficacy in this age group, with MMF 40-50 mg/kg/d in younger children and 30-40 mg/kg/d in adolescents (59) and another including 12 children (60). A fixed dose of 2g MMF per day for adults is common practice in Europe (24).

Drug safety profile of MMF: Gastrointestinal adverse events such as nausea or diarrhoea are the most relevant side effect of MMF. They are most common during initiation of treatment and tend to disappear during long-term treatment. Leukopenia or thrombocytopenia may also occur. Recent data indicate that MMF should be discontinued 6 weeks before a planned pregnancy (61).

Summary of evidence

Positive case reports and uncontrolled clinical trial data indicate that MMF may be effective in AE. (4)

There is no randomized clinical trial data for use of MMF in children or adolescents. (-)

MMF and EC-MPS are both teratogenic substances. (3a)

Recommendations

MMF may be used (off label) for treatment of AE in adults in a dose up to 3 g/d, if cyclosporine is not effective or not indicated. (4,C)

MMF may be used for treatment of AE in children or adolescents. (4, C)

As MMF and EC-MPS are both teratogenic, men and women of childbearing potential must use effective contraception during therapy. (3a, B)

Methotrexate (MTX)

The immunosuppressant MTX is frequently used in psoriasis, but there is little published data on its use in AE. Some clinicians have used this drug in AE with good responses since many years. MTX can be given by oral, intravenous or subcutaneous application. Funding of expensive clinical trials in the near future is unlikely.

Controlled clinical trial data demonstrating efficacy: A randomized trial with MTX vs. Azathioprine showed comparable effects in severe AE (51).

Forty children with severe AE were randomly assigned to receive either methotrexate 7.5 mg weekly or cyclosporin 2.5 mg/kg daily for 12 weeks. At week 12, patients in the methotrexate group had a mean reduction in SCORAD which was not statistically different from the cyclosporin treated group. Both drugs were associated with minor adverse effects, none of which required changing the treatment regimen (62).

An open 24 week dose escalation clinical trial involving 12 adult patients investigated the efficacy of increasing doses MTX (63). The starting dose of 10 mg/week was increased weekly in steps of 2.5 mg/week until clinical efficacy was seen. The skin score SASSAD improved by 52% after 24 weeks. The median dose administered was 15 mg MTX/week. Improvement remained stable in 9 patients 12 weeks after end of treatment.

An uncontrolled, retrospective report involving 20 adult AE patients treated with 10 mg/week to 25 mg/week MTX showed response in 16 patients after 8-12 weeks (64). First improvement was observed after a period ranging from 2 weeks to 3 months (mean 9.95 w +/- 3.17). Treatment was more effective in adult onset AE than in childhood onset.

Forty Children with severe AE were randomly assigned to receive either methotrexate 7.5 mg weekly or cyclosporin 2.5 mg/kg daily for 12 weeks. At week 12, patients in the methotrexate group had a mean reduction in SCORAD which was not statically different from the cyclosporin treated group. Both drugs were associated with minor adverse effects, none of which required changing the treatment regimen (62).

Safety profile of MTX:

All available drug safety data for MTX is largely derived from clinical experience from other low dose indications for MTX, indicating liver toxicity and teratogenicity as main areas of concern. There is no AE specific safety data available for MTX.

Summary of evidence

An open, uncontrolled clinical trial, as well as broad clinical experience, indicate that MTX may be effective in AE. (4)

MTX is a teratogenic substance. (3a)

Recommendations

MTX may be used (off label) for treatment of AE in both adults and children. (4,C)

The recommended dosing regimen is similar or slightly lower compared to psoriasis. (D,-)

As MTX is teratogenic, men and women of child bearing potential must use effective contraception during therapy. (3a,B)

Biological agents

Biological agents (Biologics) have been used in dermatology for more than 10 years for other inflammatory skin diseases, especially psoriasis, but so far no registered biologics for AE are available in Europe. Biologics present a relatively new group of therapeutics created by using biological processes that include recombinant therapeutic proteins such as antibodies or fusion proteins. Biologics specifically target inflammatory cells and/or mediators respectively. In AE, biologics may be helpful in reducing inflammation by modulating the number, activation and function of immune cells or the action of cytokines or disease relevant antibodies. Several case reports, pilot studies and retrospective analyses on the effect of biologics in patients with moderate to severe AE refractory to topical and/or systemic therapy have been published, and randomized, placebo-controlled studies evaluating the efficacy and safety of a few biologics in AE are now available.

Approved biologic therapy

Dupilumab

Dupilumab, a fully human monoclonal antibody that blocks the common α -chain of the receptor for interleukin-4 and interleukin-13, has been approved as first line treatment for moderate-to-severe adult AE in the USA in March 2017 and in Europe in September 2017. Dupilumab has previously shown efficacy in patients with asthma and elevated eosinophil levels and now also in AE (65). Randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe AE were performed. In 4-week monotherapy studies, dupilumab resulted in rapid and dose-dependent significant improvements in pathophysiological and clinical parameters. Side-effect profiles were not dose-limiting and mostly mild side effects were observed. In a 12 week double-blind study where topical corticosteroids were combined with dupilumab or placebo, the group treated with dupilumab had significantly better effect on both AE activity and pruritus (65). The positive outcome for dupilumab treated moderate to severe adult AE patients was confirmed in a double blind, placebo controlled study involving 380 randomly assigned to different dosages of dupilumab or placebo (66). Recently, the two identical phase III SOLO studies in adults have completed the clinical development program for dupilumab, again confirming the efficacy of dupilumab monotherapy on skin signs and symptoms, and overall improvement of the QoL in AE. A significant proportion of patients achieved an IGA score of clear and almost clear and at least a 75% improvement in EASI score (67). The LIBERTY AD CHRONOS studies indicate maintenance of efficacy over 1 year of continued treatment with dupilumab (68). The safety profile of dupilumab was good, with conjunctivitis being the only adverse event that was observed more frequently with dupilumab than with placebo. In view of all trials published so far, about 1/3 of all treated patients are clear or almost clear in IGA from their AE. Up to 70% of patients achieve an EASI 75 or higher skin improvement, and it takes about 4 weeks to reach the full clinical outcome. Skin signs, QoL, and symptoms including pruritus significantly improved as early as 2 weeks after treatment initiation. Several ongoing studies involving both children and adolescents will show if these subgroups of the AE population may experience equally positive effects, expanding the treatment indication for dupilumab even further.

Summary of evidence

A number of large, randomized, placebo controlled clinical trials indicate that dupilumab is effective in AE, with the response maintained for at least 1 year of continuous treatment in the majority of patients. (1b)

Dupilumab-treated AE patients did not show systemic side effects in clinical studies, but showed a higher incidence of conjunctivitis. (1b)

Recommendations

Dupilumab is recommended as a disease modifying drug for patients with moderate to severe AE, in whom topical treatment is not sufficient and other systemic treatment is not advisable. (1,a)

Dupilumab should be combined with daily emollients and may be combined with topical anti-inflammatory drugs as needed. (2,b)

Upcoming biologic therapy

Nemolizumab

Nemolizumab, a humanized monoclonal antibody directed against the IL-31 receptor A, has shown efficacy in patients with moderate to severe AE (69). There was a significant improvement in the primary endpoint pruritus, as well as in the objective signs of the AE with, however, less efficacy. Nemolizumab is currently not approved for any indication.

Summary of evidence

A randomized, placebo controlled clinical trial indicates that nemolizumab is effective in treating pruritus in AE patients. (1b)

Nemolizumab-treated AE patients did not show systemic side effects in clinical studies, but showed a higher incidence of peripheral edema. (1b)

Off label use of other traditional Biologicals

Rituximab

The depletion of B cells by an anti-CD20 antibody, rituximab (2x 1000 mg), resulted in a rapid reduction of skin inflammation in all patients with a sustained effect over 5 months in five of six patients. These results may suggest a pathogenic role of B cells in AE, although CD20 may also play a role in some DC-T cell mediated reactions (70). A report on two cases of severe AE receiving rituximab could not confirm these findings (71).

Mepolizumab

Inflammation in AE is characterized by a T helper 2 cytokine expression including interleukin (IL) –5 and eosinophil infiltration. Upon short-term therapy with the anti-IL-5 antibody mepolizumab (2 x 750 mg), a moderate improvement of clinical symptoms was observed, although a rapid depletion of eosinophils in the peripheral blood was noted (72). The patients were not stratified for eosinophilia in this study. Mepolizumab had no effect on atopy patch

test reactions (73). Based on the promising results in AE and the experiences in bronchial asthma therapy, long-term trials with anti-IL-5 antibodies are now performed.

Omalizumab

Most AE patients have elevated serum IgE levels, but the pathogenic role of IgE in AE remains unknown. In a placebo-controlled study in 20 patients, omalizumab administered for 16 weeks failed to improve AE symptoms and itch despite a depletion of free serum IgE and reduction of IgE receptor saturation (74). Other studies reported that accompanying AE significantly improved in patients receiving omalizumab because of severe bronchial asthma (75-77). First explorative open label trials did not indicate good efficacy (78). An open label study on 20 adult patients with severe AE have indicated an increased efficacy of omalizumab in patients with wild type filaggrin status and high levels of phosphatidylcholines (79). An open label study involving 7 treatment refractory, pediatric AE patients treated with omalizumab for 12 to 68 months showed significant improvement of their AE (80). By contrast, a recent small, randomised, trial including 8 children with severe treatment refractory AE treated for 24 weeks with omalizumab or placebo showed no significant clinical differences between the two groups (81) and this was confirmed in another similar study (82). In summary, the data concerning omalizumab are conflicting, and omalizumab cannot be recommended for treatment of AE.

Ustekinumab

By blocking IL-12 and IL-23, ustekinumab can regulate Th1, Th17 and also Th22 pathways, which are reportedly active in AE. Results regarding the use of ustekinumab in severe AE have, however, been conflicting and only case reports have been published so far. Some have reported significant improvement of AE (83) and some have not (84). The first two randomised controlled trials comprising 79 and 33 patients in total have been completed, and results are quite uniform showing no significant decrease in severity scores (85, 86).

Other substances

Some older biologics such as infliximab or efalizumab, which are outdated for use in atopic dermatitis or withdrawn from the market, are not discussed anymore in this version of the guideline.

On the other hand, a number of highly interesting substances are in progress and may soon be registered for treatment of AE. Therefore, the committee decided to produce a table in the addendum on potential new biologics or small molecules for AE “in the pipeline”, which will be continuously updated by the guideline committee. Substances to be included in this table will be, among others, the anti-IL 13 antibody tralokinumab, the anti-TSLP antibody tezepelumab, and the Janus kinase (JAK) inhibitor upadacitinib.

Summary of evidence

None of the traditional biologics has been approved for the therapy of AE in Europe. At present, the use of traditional biologics in AE should be tried only in patients with severe AE refractory to other topical and/or systemic treatment. Beside the lack of efficacy and safety data in AE, the potential side effects must be taken into account before using biologics. On

the other hand, treatment with biologics may provide important information on pathogenetic mechanisms in AE. Today, the imminent availability of Th2-blocking biologics has further reduced the clinical need for experimental therapy with traditional biologics. (-)

Recommendations

A therapy of AE with traditional biologics (rituximab, omalizumab or ustekinumab) cannot be recommended. (4, C)

A therapy of AE with mepolizumab may be tried in selected cases unresponsive to standard therapy. (-, D)

Other systemic treatment

Alitretinoin

Alitretinoin is a retinoid binding both retinoid and rexinoid receptors, thus delivering anti-inflammatory and anti-proliferative effects. It is licensed in some European countries for the treatment of chronic hand eczema irrespectively of its pathogenesis.

Controlled clinical trial data demonstrating efficacy

There is one large, multicenter randomized, placebo controlled clinical trial involving 1032 patients with chronic hand eczema, about one third of which are probably atopic hand eczema patients (87). Improvement of eczema symptoms was seen in 75% of the patients. The response rate of hyperkeratotic hand eczema (49%) and pulpitis sicca type patients (44%) was higher than the dyshidrosiform subtype of hand eczema (33%). The patient group suffering from atopic hand eczema has not been analyzed separately, and extrapalmar symptoms have not been assessed in this trial.

Six patients with AE and prominent hand involvement have been treated with alitretinoin for twelve weeks in an uncontrolled, open label trial (88). Palmar and extrapalmar lesions improved during the trial, as shown by the mTLSS hand eczema score and the SCORAD.

Drug safety profile of alitretinoin

As alitretinoin is highly teratogenic, all females of childbearing potential must adhere to a strict birth control program. Headache is the most frequent clinical side effect of alitretinoin especially in the first two weeks of treatment. Serum lipid and TSH elevation may also occur.

Summary of evidence

Direct evidence from an uncontrolled clinical trial, as well as indirect evidence from a large, double blinded, placebo controlled clinical trial indicates that alitretinoin may be effective in atopic hand eczema. (4)

Alitretinoin is a teratogenic substance. (-)

There is no trial data for its use in children or adolescents. (-)

Recommendations

Alitretinoin may be used for atopic hand eczema in adult patients of non-child-bearing potential unresponsive to topical steroid therapy. (1b,A)

Alitretinoin might lead to an improvement of both extrapalmar and hand lesions in AE patients. (4,C)

Apremilast

Apremilast is a small molecule phosphodiesterase (PDE) 4 inhibitor that has been approved for the treatment of psoriasis arthritis and moderate to severe plaques psoriasis. Blocking PDE4 increases intracellular adenosine monophosphate levels resulting in a downregulation of proinflammatory cytokines such as IL-2, IL-5, IL-13 and increased production of the regulatory cytokine IL-10. A pilot study investigating the effect of apremilast in patients with

moderate to severe AE has demonstrated moderate improvement of skin lesions, pruritus and QoL (89), but the drug development program of apremilast for AE has been stopped.

Recommendations

Apremilast may be used in selected cases unresponsive to standard therapy for treatment of AE. (-,D)

Tofacitinib

So far only one small open label trial with the oral JAK inhibitor tofacitinib citrate has been performed in 6 patients with moderate to severe, treatment refractory AE. After 8-29 weeks of treatment they had a mean SCORAD reduction of 66 %. No adverse events were observed (90).

Recommendations

There is not enough evidence to support the use of tofacitinib in AE. (4,C)

Immunoadsorption

Immunoadsorption (IA) has been used in patients with AE and high serum-IgE levels based on the assumption that a reduction of IgE might result in a reduction of disease activity. An investigator initiated open-label pilot study in patients with severe AE recalcitrant to topical and systemic therapy showed that IA resulted in a significant decrease of SCORAD three weeks after the first cycle of 5 IA and a further improvement after the second cycle one month apart, and in parallel a reduction of skin-bound IgE (91). A recent study confirmed these results and showed long-term clinical effect of IA in AE patients (92). Another pilot study in severe AE showed a beneficial effect of immunoadsorption together with subcutaneous application of omalizumab; the serum levels of free IgE and the SCORAD decreased significantly (93).

Recommendations

Immunoadsorption might be considered for patients with severe AE and high serum IgE levels if the technology is available. (4, C)

Mast cell stabilizers

Mast cell stabilizers inhibit mast cell degranulation and thus prevent the release of histamine and other mediators. Oral cromolyn, ketotifen and pemirolast are used for asthma and other allergic diseases, but have not shown any significant effect for the treatment of AE. In the last five years, studies investigating these substances in AE have not been published.

Recommendations

Mast cell stabilizers are not recommended for the treatment of AE. (-)

Leukotriene antagonists

Montelukast is a cysteinyl-leukotriene receptor antagonist that blocks the action of LTD₄, LTC₄ and LTE₄. It has been used at doses of 10 mg daily (5 mg/day in children below 12 years), with some reduction in SCORAD indexes (94, 95). A systematic review stated that limited evidence exists to recommend montelukast for the treatment of AE (96). Studies on leukotriene antagonist zafirlukast for the treatment of AE have not been reported in the last five years.

Recommendations

There is not enough evidence to support the use of leukotriene antagonists in AE. (2a,B)

Intravenous Immunoglobulin

Intravenous immunoglobulins (IVIG) are considered as immunomodulatory substances, but not as immunosuppressive agents. IVIG have been tried for both adults and children with severe, treatment refractory AE, but clinical trials did not indicate a high efficacy or quick onset of action despite the high cost of treatment (97, 98). IVIG may be considered as a last resort treatment in severe, treatment refractory AE in children only. It is likely that the availability of novel biologics for AE may further reduce the indication for IVIG in AE.

Recommendations

The use of IVIG in AE is not recommended. (4,D)

H1R-blocking antihistamines

Traditional histamine 1 receptor (H1R) blocking antihistamines have been used for decades, in an attempt to relieve pruritus in patients with AE. However, only a few randomized controlled trials have been conducted and they have in the majority shown only a weak or no effect in decreasing pruritus (99-104). According to a Cochrane search, randomized controlled trials investigating the efficacy of antihistamine monotherapy in AE patients are lacking (105).

The first generation of sedative antihistamines such as hydroxyzine, clemastine fumarate, doxylamine, and dimetinden maleate may allow better pattern in acute situations with exacerbations of AE (evidence level D). Concerning the newer non-sedating antihistamines, studies using loratadine, cetirizine or fexofenadine demonstrated no or only a weak relief of pruritus in AE (106-108). A significant, but clinically small, antipruritic effect of fexofenadine

60 mg twice daily has been described (109). An effect on itch of a high dosage of 20 to 40 mg cetirizine daily has been observed, but this effect was primarily attributed to sedation (107).

The corticosteroid sparing effect of cetirizine in infants with severe AE has been attributed to its decreasing effect on pruritus (110). A recent study reported a beneficial effect of the non-sedating H1 antihistamine olopatadine in AE patients by decreasing nocturnal scratching without affecting sleep quality (111). Possible mechanisms of action of second generation antihistamines are a reduction of the urticarial component of AE, and blocking histamine interaction with bradykinine, downregulation of transcription factors resulting in a decrease of proinflammatory cytokine production (112).

In general, antihistamines are safe to use, also for a long period of time (113), and the major advantage seems to be relief of the symptoms of co-morbidities such as allergic asthma, rhino-conjunctivitis, urticarial dermographism and urticaria. Topical antihistamines have no effect on itch beyond that of their cooling vehicles.

H4R-blocking antihistamines

Amongst the 4 histamine receptors described in humans, the histamine 4 receptor (H4R) blocking antihistamines represent an additional promising treatment for AE (114). Clinical trials have been performed with H4R blocking agents, but the results are not published yet.

Recommendations

There is not enough evidence to support the general use of both first and second generation H1R-antihistamines for treatment of pruritus in AE. These may be tried for treatment of pruritus in AE patients, if standard treatment with TCS and emollients is not sufficient. (1b, A)

Long term use of sedative antihistamines in childhood may affect sleep quality and is therefore not recommended. (-,D)

Allergen-specific immunotherapy

Allergen-specific immunotherapy (ASIT) has been investigated for treatment of AE, the two relevant therapeutic regimens are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).

Introduction to allergen-specific immunotherapy for AE

Some efficacy of allergen-specific immunotherapy (ASIT) in AE has been shown in a number of case reports and smaller cohort studies (115, 116), and more recently in a larger multicenter trial with subcutaneous house dust mite immunotherapy (117). These data showed that ASIT can be used for treatment of allergic rhinitis or mild asthma also in AE patients, since the AE was obviously not worsened and sometimes even improved during or after ASIT. A few prospective studies have been performed which address the question if AE alone may be an indication for ASIT.

Even if the results of the studies are interpreted very carefully with regard to the therapeutic effects of ASIT, it is remarkable that exacerbations of the skin disease during treatment were rare, while the treatment was well tolerated in most patients. The same was true for studies in patients with coexistent AE who were treated with ASIT for respiratory atopic diseases and experienced not more often flares of eczematous skin lesions. The role of allergens in the pathophysiology of AE has been proven in controlled studies on allergen avoidance and atopy patch testing (118-120). In respiratory atopic diseases, ASIT plays an important role not only for treatment, but also for the prevention of further sensitizations and progress to more severe respiratory disease (change from rhinitis to bronchial asthma).

Hypothetically, patients with a positive atopy patch test and corresponding history of eczema flares may be candidates for ASIT with the eliciting allergen. The performed studies point to the safety of ASIT also in AE, if the treatment is performed according to the guidelines. However, the final judgement on the efficacy of ASIT in this diagnosis is still not possible due to the lack of large, controlled and randomized clinical trials with modern allergen vaccines (116).

Evidence from controlled clinical trials

Experience in a pair of monozygotic twins with AE (with spring and summer exacerbations) treated either with grass pollen ASIT or placebo in a double-blind fashion showed significant improvement and decrease of serum IgE in the patient treated with ASIT (121). Several open uncontrolled study designs also demonstrated advantages of ASIT in patients with AE, these data were often published in national or non-anglosaxon journals. Some investigators in the 1970s and 80s also showed improvement of AE in controlled trials (116).

Subcutaneous immunotherapy (SCIT)

A double-blind controlled trial of ASIT with *Dermatophagoides pteronyssinus* in children with AE failed to demonstrate superiority over placebo after a standard 8-months' course of treatment with tyrosin-adsorbed house dust mite extracts in 24 house dust mite-allergic children with AE (122). However, in a second study phase children were randomly allocated

1 to continue with active treatment or placebo for a further 6 months. The placebo effect was
2 high, and the numbers were too small to permit confident conclusions, but the clinical scores
3 suggested that prolonged ASIT may be effective with regards to several objective
4 parameters of AE severity (122).

5 A small placebo-controlled study showed AE improvement in 13 of 16 ASIT treated AE
6 patients, whereas only 4 of 10 placebo-treated AE patients improved (123). Similar results
7 were reported for AE lesions under ASIT with house dust mite extracts (124, 125). Oral ASIT
8 for *D. pter* was not effective in a controlled study enrolling 60 children with AE which were
9 followed for three years (126). Conventional s.c. ASIT (n=41; 76% improved) and sublingual
10 ASIT (SLIT; n=48; 64% improved) showed some efficacy, with adverse drug reactions
11 occurring in 15-20% of both groups (127). A controlled study applying SLIT with house dust
12 allergens was performed in 56 children with AE aged 5 to 16 years, but the outcome of this
13 intervention was positive only in patients with mild to moderate AE, but not with severe AE
14 (128).

15 A pilot study reported the improvement of AE together with changes in T cell subpopulations
16 induced by IFN gamma pretreatment before ASIT with house dust mite allergens. Patients
17 receiving placebo, IFN gamma only or ASIT only showed no treatment effect (129).

18 A large randomized, assessor-blinded clinical trial investigated 89 patients with AE showing
19 a sensitization to house dust mite (CAP-FEIA ≥ 4) (117). Patients were injected weekly with
20 three different doses of HDM allergen extract. With higher allergen doses, a beneficial
21 SCORAD decrease occurred after 8 weeks compared to a control group with an “active
22 placebo” consisting of very low allergen dose. The effect was maintained over one year and
23 was accompanied by lower glucocorticosteroid use.

24 A smaller DBPC study involving 20 patients with HDM- or grass pollen sensitization also
25 showed objective and subjective symptom relief accompanied by immunological changes
26 under ASIT (130).

27 Another large, randomized double-blind placebo controlled study investigated 168 adult AE
28 patients for 18 months. The study did not reveal efficacy in the AE patients studied, but a
29 subgroup analysis showed statistical significance of SCORAD reduction in subgroup of
30 severe AE patients with SCORAD > 50 (131). Longer treatment duration was associated
31 with higher efficacy. The best outcome was observed during September to February, which
32 may be due to the use of indoor heating and subsequent high HDM exposure.

33 A systematic review and meta-analysis of randomized controlled trials published until
34 December 2012 assessed the efficacy of immunotherapy for AE. 8 randomized controlled
35 trials that comprised a total of 385 subjects were analyzed. It has been found that ASIT has
36 a significant positive effect on AE patients (odd ratio [OR], 5.35;95% CI, 1.61-17.77; number
37 needed to treat 3;95% CI, 2-9). ASIT showed also significant efficacy in long-term treatment
38 (OR, 6.42;95% CI, 1.31-7.48) for severe atopic dermatitis (OR, 3.13;95% CI, 1.31-7.48), and
39 when administered subcutaneously (OR, 4.27;95% CI, 1.36-13.39). This meta-analysis
40 provides moderate level evidence for the efficacy of SCIT in AE. However, these findings
41 are based on an analysis of a small number of patients, with considerable heterogeneity
42 among trials (132).

43 ***Sublingual immunotherapy (SLIT)***

1 A first 18 months, placebo controlled study investigating the effects of SLIT on AE found a
2 significant decrease of the SCORAD starting from month 9 (128).

3 Another study analyzed 107 patients undergoing SLIT for 12 months. A total of 84 patients
4 finished the trial, compared to the placebo group (53,85%), the treatment group (77,78%)
5 showed improvement in symptoms (133).

6 Another group of authors has investigated SLIT in AE patients allergic to HDM in a murine
7 model (134). The mouse model induced by *Der f* allergen extract reflected the typical
8 hallmarks of AE in humans. In the *Der f* allergens-sensitized mice, SLIT treatment with *Der*
9 *f* vaccine significantly inhibited AE symptoms through correction of Th2 and Th1 cytokine
10 predominance, therefore according to the authors SLIT could be considered as an
11 alternative treatment for patients with extrinsic AE.

12 13 **Summary of evidence**

14 There is conflicting evidence regarding ASIT in AE, with more recent literature being more
15 in favour of it. ASIT may have positive effects in selected, highly sensitized patients with AE.
16 (2a)

17 The best evidence so far is available for ASIT with house dust mite allergens. (2a)

18 There is no contraindication for performing ASIT in patients with respiratory allergic diseases
19 (allergic rhinoconjunctivitis, mild allergic bronchial asthma) and concomitant AE. (2b)

20 **Recommendations**

21 ASIT is currently not recommended as a general treatment option for AE. (2a, B)

22 ASIT may be considered for selected patients with house dust mite, birch or grass pollen
23 sensitization, who have severe AE, and a history of clinical exacerbation after exposure to
24 the causative allergen or a positive corresponding atopy patch test. (2a, B)

25

Complementary and alternative medicine in atopic eczema

There is evidence of growing interest of so-called complementary alternative medicine (CAM) as treatment for AE (135-137). CAM has been defined as “diagnosis, treatment or prevention which complements mainstream medicine by contributing to a common whole, by satisfying a demand not met by orthodoxy or by diversifying the conceptual frameworks of medicine” (136). This chapter summarises available RCT-based evidence on CAM for AE.

Essential fatty acids

The most commonly used preparations in the treatment of AE are polyunsaturated fatty acids, evening primrose oil (EPO), borage oil (BO), or animal and fish oil. A systematic review published in 2016 showed conflicting results on EPO (138-141). Four smaller trials (142-145), as well as two larger trials (146, 147) and an Indian study on EPO (148) also gave conflicting results.

Negative results were obtained in a trial on eicosapentaenoic acids from Germany (149)

A study from Berlin compared the daily administration of 5,4 g docosahexaenoic acid (DHA) in 21 patients who completed the trial with an isoenergetic control of fatty acids (N=23) over 8 weeks. The SCORAD dropped significantly in the DHA group, however, significant differences to control were not observed (150).

In a comparison of dietary hempseed oil with olive oil, some parameters of skin physiology and symptoms improved under hempseed oil, but obviously without significant difference to the control group (151).

A RCT in 20 hospitalised patients with AE comparing infusions of fish oil to soybean oil revealed marked improvements within one week in both groups but a significantly greater effect in those treated with fish oil (152). Some smaller RCTs have also indicated a beneficial effect (153-155), although the largest and well reported trial did show a difference between the fish oil and the placebo (156).

EPO has also been used as topical treatment. Although a pilot study has indicated some beneficial effects (157), further studies were unable to establish a dose response relationship (158). Additional studies could not prove a beneficial effect on skin barrier function (159). Large trials on that issue, however, are lacking.

In one pilot study, the addition of gamma-linolenic acid to emollients was able to decrease elevated TEWL in atopic eczema (160).

The most recent Cochrane review on EPO and BO included 19 studies on EPO and 8 on BO (161). The authors concluded that EPO and BO lack effect on AE and that further studies would be hard to justify.

Summary of evidence

There is partly conflicting, mostly negative evidence regarding the efficacy of oral or topical applications of unsaturated fatty acids in the treatment of AE. (1a)

Recommendations

Oral application of unsaturated fatty acids is not recommended for treatment of AE. (1a, A)
Topical application of unsaturated fatty acids as an ingredient in emollients may be tried in selected cases. (D,-)

Phytotherapy

Detailed background information on herbal therapy in dermatology is published (162). Two RCTs investigated the efficacy and safety of topical chamomile preparation (163) and a hypericum extract cream for AE (164).

The chamomile cream was moderately superior to 0.5% hydrocortisone cream regarding pruritus, erythema and desquamation, but not different to the vehicle cream. The cream containing hypericum extract standardized to 1.5% hyperforin was compared to the corresponding vehicle cream in a half side comparison in 18 patients with mild to moderate AE. The modified SCORAD index improved over 4 weeks with both therapies, but the improvement was significantly higher under active treatment. A further study compared a topical preparation of Mahonia aquifolium, Viola tricolor and Centella asiatica with the vehicle cream in 88 patients and could not find significant differences (165). A subgroup analysis revealed superiority of the plant preparation under dry and cool weather conditions.

Plant extracts are well known to induce contact sensitisation and subsequent contact allergy (166, 167). It was demonstrated that so called “phytocosmetic creams” containing a mixture of plant extracts may also contain triamcinolone acetonide as an active ingredient (168).

The concerns regarding side effects of phytotherapy with crude plant extracts must not be generalized to emollients containing protein free oat plantlet extracts (169, 170). (see section “Emollients plus” in chapter “Basic therapy”).

Summary of evidence

Beside many negative results, there is only one small RCT indicating a beneficial effect of hypericum cream as a topical phytotherapy. (1b)

Topical use of crude plant extracts may cause contact sensitization and contact dermatitis. (1a, A)

Recommendations

Topical use of crude plant extracts is not recommended for treatment of AE. (1b, C)

Chinese herbal medicine (CHM)

Chinese herbs are part of the traditional Chinese medicine which consists of Chinese herbs administered orally or topically, acupuncture, diet and exercise (171, 172). CHM is promoted as treatment for AE, taken orally as decoction, usually consisting of about 10 different herbs. The first positive RCTs of CHM in the treatment of AE outside China were published by Sheehan in 1992 (173). Serious adverse effects including fatal hepatitis have been reported by independent investigators following these trials (171, 174-176). Further trials on

Zemaphyte®, a commercial product of Chinese herbs, revealed conflicting results (177, 178).

The oral application of a combination of *Eleutherococcus*, *Achillea millefolium*, and *Lamium album* was not superior to placebo after two weeks (179).

The most recent Cochrane review on CHM included 28 studies encompassing 2306 patients (180). When compared to placebo CHM showed higher clinical effectiveness (RR 2.09, 95% CI 1.32 to 3.32) in 2 studies. The total effectiveness rate in CHM groups was found to be superior (RR 1.43, 95% CI 1.27 to 1.61) when compared to conventional therapy in 21 studies. The authors assessed most studies at high risk of bias and found substantial inconsistency between studies. Therefore it was concluded that there is no conclusive evidence that CHM could reduce the severity of AE. A similar result was achieved by the systematic review of Tan and co-workers (181). The most recent RCT showed significant effects of CHM on SCORAD and QoL scores when compared to the placebo group (182).

Summary of evidence

There is no conclusive evidence to support the use of Chinese herbs in the treatment of AE. (1a)

Recommendations

The use of Chinese herbs is not recommended for treatment of AE. (1a, A)

Acupuncture/Acupressure

Acupuncture has been studied considering allergen-induced itch as primary endpoint but not systematically or within randomised controlled trials as a treatment for AE. Case series of patients including those with AE indicate some beneficial effects but studies implying a rigorous methodology are needed (183-186). There is initial evidence from a small pilot trial that acupressure might be helpful in reducing pruritus and lichenification in AE patients (187).

Summary of evidence

There is absence of evidence to support the use of acupuncture or acupressure in the treatment of AE. (-)

Recommendations

The use of acupuncture or acupressure is not recommended for treatment of AE. (-, D)

Autologous blood therapy

One RCT compared the intramuscular re-injection of 1 to 3 ml autologous blood over 5 weeks to the injection of the equivalent amount of sterile saline solution (188). Patients were recruited via press advertisement and finally 30 subjects participated. Over a 9 weeks period, AE severity measured by SASSAD dropped significantly in the verum group from 23.2 to 10.4 and did not change in the placebo group (21.0 to 22.5). Significant differences were not observed in health related quality of life and the subjective assessment of pruritus

skin appearance and sleep quality. The data suggest a beneficial effect of autologous blood therapy with respect to the signs score. This finding should be confirmed in larger trials and different settings.

Summary of evidence

There is very limited evidence supporting the use of autologous blood therapy in the treatment of AE. (2b)

Recommendations

The use of autologous blood therapy is not recommended for the treatment of AE. (2b, B)

Bioresonance

One RCT has been published so far, comparing bioresonance with a sham (inactive pseudo-) procedure in 36 children with AE attending a specialized rehabilitation unit in Davos, Switzerland (189). After 4 weeks, AE severity had improved in both groups with slight superiority of the active group but without statistical significance. Further studies under more usual outpatient conditions are needed.

Summary of evidence

Current evidence from a single trial does not indicate a substantial clinical effect of bioresonance for treatment of AE. (2b)

Recommendations

The use of bioresonance for treatment of AE is not recommended. (2b, B)

Homoeopathy

Homeopathy is a system of alternative medicine created in 1796 by Samuel Hahnemann, based on his doctrine of like cures like. Large case series illustrating the therapeutic benefits of homeopathy have been published as papers or books (190, 191). A recent uncontrolled trial of 17 patients with longstanding AE in Japan revealed a marked improvement after the introduction of homoeopathic treatment (192). A classical randomised placebo controlled trial was initiated in Germany including 60 patients (193), showing no difference between placebo and verum homeopathy in the outcome of AE (194).

Summary of evidence

There is absence of evidence to support the use of homeopathy in the treatment of AE. (2b)

Recommendations

The use of homeopathy is not recommended for treatment of AE. (2b, B)

Massage therapy / aroma therapy

The effect of additional massage therapy for AE, applied daily for 20 minutes over a one month period compared to standard therapy alone, was investigated in a randomised trial in

20 children (195). Greater degrees of improvement in anxiety scores, tactile defensiveness and coping index were reported by parents of children in the active group. Furthermore clinical signs such as scaling and excoriation improved significantly in the massage group. Appropriate statistical comparisons between groups, however, were not performed. A further small cross-over trial in 8 children compared massage with essential oils (aroma therapy) to conventional massage (196). Both treatment groups improved significantly without significant differences between groups. Given the small sample size, conclusions on the beneficial effects of additional aroma therapy cannot be drawn.

Summary of evidence

There is insufficient evidence to support the use of massage / aroma therapy in the treatment of AE. (4)

Recommendations

The use of massage / aroma therapy is not recommended for treatment of AE. (4, C)

Salt baths and thermal spring water balneotherapy

Salt bath has been used for a long time to control chronic inflammatory skin diseases, especially psoriasis. Based on this experience and anecdotal evidence, salt was recently recommended also in the treatment of AE. The efficacy of salt bath alone, however, has not been studied systematically in AE. In the current reports, salt baths were investigated as part of a complex climatotherapy or in combination with UV-therapy (197-204). From these studies it cannot be concluded that salt baths provide a consistent and significant clinical effect on AE. Conventional balneotherapy with or without synchronous UV therapy has been shown to be effective in AE but was not considered as CAM in this chapter. Balneotherapy with thermal spring water has been shown to be beneficial in children with mild to moderate AE with an effect similar to mid-potency topical corticosteroids (205).

Summary of evidence

There is insufficient evidence to support the use of salt baths in the treatment of AE. (4)

Cohort studies indicate that thermal spring water balneotherapy with or without phototherapy may be effective in mild to moderate AE (2a, 2b)

Recommendations

The use of salt baths is not generally recommended for treatment of AE. (4, C)

Thermal spring water balneotherapy may be considered in mild to moderate AE (B, 2a, 2b)

Vitamins and minerals

A total of 6 trials were identified investigating vitamins or minerals in the treatment of AE (206-211). A placebo-controlled study from Italy studied oral vitamin E (400 IU) in 96 patients (210). Greater clinical improvement was reported for the vitamin E group but without

1 results of statistical tests. Similarly, a smaller study of 49 patients comparing vitamin E plus
2 vitamin B2 to vitamin E or vitamin B2 alone revealed a superiority of the combination
3 treatment with respect to the physician's assessed overall usefulness and global rating
4 (208). A further trial in 60 adults with AE compared selenium or selenium plus vitamin E vs.
5 placebo over a 12 weeks period (207). The AE severity score fell in all 3 study arms without
6 significant differences. A Hungarian study compared multi-vitamin supplementation in 2090
7 pregnancies to trace element supplementation in 2032 pregnancies over a 17 month period
8 (206). AE occurred more frequently in the multi-vitamin group (0.7% vs. 0.2%). Although this
9 unexpected result could be a chance finding as suggested by the authors, detailed studies
10 in the prospective setting are needed. A small trial has investigated the zinc supplementation
11 vs. placebo in 15 children over a 2 month period (212). The severity score increased in both
12 study groups without significant differences. There is one published RCT comparing
13 pyridoxine (vitamin B₆) vs. placebo in 41 children over a 4 weeks period (209). The median
14 severity score increased in the pyridoxine group whereas an improvement was observed in
15 the placebo group. None of the differences were statistically significant.

16 Following a pilot study on vitamin D (211) more RCTs on that subject were published
17 recently. Thereby vitamin D supplementation showed statistically significant improvement in
18 clinical scores in 20 i.e. 60 adults (213, 214) and 107 children (215), whereas another trial
19 in 60 adults failed to prove significant effects by vitamin D supplementation (216). Vitamin
20 D supplementation of mothers during lactation did also not improve facial eczema in 164
21 children studied (217). A further RCT in 45 adults patient showed equal and significant
22 reduction of the SCORAD score by vitamin D or E supplementation (34.8%, 35.7% resp.)
23 and an even higher reduction by the combination of both vitamins (64.3%) (218).

24 25 **Summary of evidence**

26 There is preliminary evidence that vitamins, especially vitamin E and D, may be useful in the
27 treatment of AE. (1b)

28 **Recommendations**

29 There is not enough evidence to recommend vitamin supplementation for routine use in AE
30 patients. (2b, B)

31 **Topical Vitamin B12 in avocado oil**

32 There are two smaller studies with half-side comparisons, which indicate a mild beneficial
33 effect of a preparation containing 0.07% vitamin B12 in avocado oil compared to a placebo
34 preparation (219, 220).

35 **Summary of evidence**

36 There is preliminary evidence that a topical preparation of Vitamin B12 in avocado oil may
37 be useful in the treatment of AE. (2b)

38 **Recommendations**

39 There is not enough evidence to recommend topical preparations of Vitamin B12 in avocado
40 oil for routine use in AE. (2b, B)

1
2 **Harms of CAM**
3 Contrary to widespread assumptions of the public, CAM is not free of side effects. Dietary
4 regimens involving strong restrictions can lead to harmful sequels in terms of
5 malnourishment. Therapeutic procedures involving organic material from plants or animals
6 can be associated with severe toxic or allergic reactions. Finally, patient's and parent's
7 adherence to assumingly effective CAM may delay or hinder a severely affected patient's
8 access to effective or even lifesaving therapy.

9

Psychosomatic counseling

Psychological and emotional factors influence the clinical course of AE, which is mirrored in the German term “neurodermitis”. Interventions including patient education, eczema action plans, and a quick return for a follow-up visit improve adherence (221). The reason for treatment failure in more than one-half of patients referred to specialist centers is that the treatment is not being administered. Doctors often have insufficient time to educate patients and their caregivers about the correct application of ointments and creams, and this adversely affects compliance. Many countries have patient organizations and support groups that provide useful supplementary literature (222).

Poor adherence to treatment

Poor adherence to treatment is a major factor limiting treatment outcomes (223), and may have different causes: *Stress* can elicit severe exacerbations of eczematous skin lesions (224-226). The *itch-scratch cycle* is especially vulnerable to psychological influences and can show a tendency to self-perpetuation (227-229). *Psychosomatic disease* in the sense of anxiety or depression can be a co-morbidity of AE (228, 230). *Intrafamilial psychodynamics* are also well-known factors influencing the clinical course of AE (231, 232).

Educational interventions

A Cochrane review analyzed ten RCTs of psychological or educational interventions, in addition to conventional therapy, for AE in children (233). One study of a psychological intervention used biofeedback and hypnotherapy as relaxation techniques versus discussion only. Three of the four educational studies identified significant improvements in disease severity in the intervention groups. The fourth trial evaluated long-term outcomes and found a statistically significant improvement ($P < 0.01$) in disease severity and parental quality of life over 12 months in all studied age groups (three months to 18 years). Heterogeneity in outcome measures and inadequate methodology limited data synthesis in this review. The psychological and educational interventions were delivered by nurses or multidisciplinary teams (234). Quality of life (QoL) is severely impaired in AE patients (235), as shown in a recent review: Statistically significant improvements in QoL of AE patients by patient education were reported in five studies, whereas the severity of skin disease improved significantly in three studies out of ten studies evaluated. In conclusion, patient education appears to be effective in improving QoL and in reducing the perceived severity of skin disease (236-238). (See chapter: Educational interventions for AE)

Psychotherapeutic approaches

Most psychological training programs include relaxation techniques (239), habit training for social competence and communication as well as coping behavior and improvement of self-control with regard to disrupting the itch-scratch cycle.

Psychosomatic counseling: Randomized controlled trials compared the use of topical corticosteroid alone with steroids together with a behavioral therapy program which led to a significantly pronounced improvement of skin condition and itch-scratch behavior (240).

Behavioral therapy: Behavioral therapy against itch was studied, showing a significant improvement in symptoms after one year (241-243). Especially habit reversal techniques improve itch in atopic dermatitis (244).

Autogenic training: Together with cognitive behavioral therapy was studied in a standardized educational program (see chapter “Education”) (245).

Relaxation: Relaxation methods may be more effective in reducing disease severity than discussion only (246).

Parents who had negative treatment experiences in the past and possessed only poor coping abilities with regard to scratch control benefitted the most from the training program. The outcome of the education measure was independent of parents' schooling, vocational level and income (247). Another publication stated that there is currently only limited research evidence on the effect of educational and psychological approaches when used alongside medicines for the treatment of childhood eczema (233). It is well possible that there is limited research activity in this area of intervention, thus providing limited evidence of the measurable effects of interventions.

Summary of evidence

Psychosomatic counseling can be a helpful adjuvant procedure in the management of patients with AE including psychotherapeutical approaches and behavioral therapy techniques. (3b)

Relaxation techniques may cause significant improvements in disease severity. (1a)

Individual psychotherapeutic approaches can be helpful in individual patients. (-)

Psychological and psychosomatic interventions are an essential and helpful part of educational programs. (1a)

Recommendations

Psychosomatic counseling, psychotherapeutical approaches, behavioural therapy techniques, autogenic training, relaxation techniques, psychological and psychosomatic interventions are recommended in selected patients. (1a, A)

The indication should be confirmed by specialists in the field of psychodermatology. (-, D)

Educational interventions for atopic eczema

Adherence to treatment and poor quality of life (QoL) are key issues in patients with AE (248). Patient education (PE) interventions can help patients and their families to better understand their disease and cope with treatment in order to maintain or even improve QoL and treatment adherence. The aim of PE is not simply to provide information by leaflets in the waiting rooms, but entails the transfer of skills (e.g. self- management of the disease, treatment adaptation) from a trained healthcare professional to the patient or their parents. Additionally, PE should aim to reduce doctor's visits, facilitate a better partnership between the doctor and the patient/parents and restore family dynamics. PE should also lead to a decrease of the long-term costs of AE treatment. A recent study showed that parents with negative treatment experiences in the past and poor coping abilities regarding scratch control benefitted most from PE programs (247).

High-quality PE programs should ideally be evidence-based, tailored to a patient's individual educational and cultural background (rather than being standardized in form and content), and have well-defined content and activities (233, 236, 249).

Educational service delivery models

There are different types of PE programs running all around the world. These differ in number and certification of the educators, number of participants, age of patients, teaching techniques, duration and frequency of interventions (233, 250). Thus, because the content of the PE programs varies greatly, comparison between studies is difficult. For example, while the intervention by Staab (237) entailed 2-h sessions, involving a trained multidisciplinary team, once a week for 6 weeks, the intervention by Shaw et al (251) involved a trained medical student running a single 15-min session. Most of the published intervention programs are structured as follows:

Multidisciplinary age related structured group training educational programs (eczema school): There is evidence that structured age related programs are significantly improving severity score, improving coping behavior, parents handling their affected children and increasing disease knowledge. (237, 241, 252-255). A recent multidisciplinary eczema school program tailored to the adult situation showed also high efficacy (238).

Eczema workshops: Eczema workshops may improve the disease severity of patients with AE (256, 257). There is also a greater adherence to eczema management (coping behavior, parent's handling their affected children) in the eczema school, compared with the standard dermatologist-led clinic (254).

Nurse-led eczema workshop: There is evidence that the benefits of nurse interventions are the reduction in the severity of the condition and the better use of topical therapies. There is a reduction in referrals to general practitioners or dermatologists, disease knowledge and self-management techniques are improving (254, 256, 258, 259). The relative effectiveness of nurse led programs compared to multidisciplinary age related, structured programs is unclear.

Structured lay-led self-management education training programs: They lead to a small statistically-significant reduction in disease status (pain/ itch, disability, fatigue) and a small, statistically-significant improvement in depression and psychological well-being but there was no difference in quality of life (260). There is no evidence that such programs improve psychological health (261, 262).

E-health during follow-up of patients with AE

E-health intervention follows the initial diagnosis and treatment with face-to-face contact. This is just as effective as usual face-to-face care with regard to quality of life and severity of disease. However, when costs are considered, e-health is likely to result in substantial cost savings. Therefore, e-health is a valuable service for patients with AE. (263, 264).

Forms of educational intervention tools

Depending of cultural backgrounds and health care systems, a wide variety of tools are used in PE programs (practical demonstrations sessions as florescent cream advices (265), written action plans (266), lectures, question and answer sessions, leaflets, online videos etc.) but there is no evidence that a specific tool is more efficient than another (233).

Summary of evidence

PE programs for AE in children and adults are efficient and established already in many countries. The multidisciplinary age related structured group training educational programs (eczema school) have the most evidence-based benefit. (1a)

Eczema workshops lead to an improvement in severity scores, there is greater adherence in eczema-management, itch-scratching cognition, and there is additional psychological benefit. (2a, 2b)

Nurse led programs result in more effective use of topical therapies. (3b)

Nurse led programs result in an improvement of severity scores. (2a)

Nurse led programs may be sparing doctor's time. (2b)

There is some evidence that a direct-access, online model for follow-up dermatologic care is equivalent to classical in-person care for patients with AE. (2a)

There is no evidence of change in severity scores due to lay-led self-management education programs, which have weak effect in improvement although the disease knowledge is increasing (-)

Recommendations

PE programs for AE in children and adults are recommended as an adjunct to conventional therapy of AE. (1a, A)

Conclusion and Outlook

The complex pathophysiology of AE explains why the therapeutic strategies also comprise multiple aspects and are complex in nature. Although there is a strong genetic preposition, patients with AE must not be desperate. Labelling AE as “incurable” is not correct, since the eczema with its symptoms can very well be treated and may disappear totally. Adequate treatment needs the cooperation of the well-informed patient with the physician and time; educational programs are extremely helpful.

In the recent past, new medications resulting from immunological research have been licensed for AE. The appearance of biologics specific for immune mediators and receptors are extremely promising and will be available soon for patients in many European countries and the rest of the world.

Tables

Table 1 Grades of evidence

1a) Meta-analysis of randomized clinical trials (RCT)

1b) Single RCTs

2a) Systematic review of cohort studies

2b) Single cohort studies and RCTs of limited quality

3a) Systematic review of case control studies

3b) Single case control study

4) Case series, case cohort studies or cohort studies of limited quality

Recommendations (see Table 2) were classified based on the grade of evidence.

Table 2 Classification of strength of recommendation

Recommendation strength	Evidence grade
A	1a, 1b
B	2a, 2b, 3a, 3b
C	4
D	Expert opinion

Table 3 Language of recommendations

Wording in standard situations	Free text explanation
must be used	This intervention should be done in all patients, unless there is a real good reason not to do it
should be used	Most expert physicians would do it this way, but some would prefer other possible action
may be used	It would be correct to do this intervention, but it would also be correct not to do it; the choice depends largely on the specific situation
is possible	Most expert physicians would do something else, but it would not be wrong to do it
may be used in selected patients only	This intervention is not adequate for most patients, but for some patients there may be a reason to do it
is not recommended	Most expert physicians would not choose this intervention, but some specific situation may justify its use
must not be used	This intervention is inadequate in most situations

Table 4: Systemic drugs for treatment of severe atopic eczema

	cyclosporine	methotrexate	azathioprine	mycophenolic acid	corticosteroids	dupilumab
overall recommendation	++ acute flare intervention	++ long term maintenance	can be used long term	++ little toxicity	outdated ♦	long term maintenance
time to respond (weeks) #	2	8-12	8-12	8-12	1-2	4-6
time to relapse (weeks)	< 2	> 12	>12	> 12	< 2	> 8
most important side effects	serum creatinine ↑ blood pressure ↑	hematological liver enzymes gastro-intestinal	↑ hematological ↑ liver enzymes ↑ gastro-intestinal	hematological skin infections gastro-intestinal	Cushing's osteoporosis diabetes	conjunctivitis
starting dose adult	4-5 mg/kg/day ♦	5-15 mg/week	50 mg/day ♦	MMF 1-2 g/day (EC-MPA 1.44 g/day)	0.2-0.5 mg/kg/day	600 mg loading dose
maintenance dose adult	2.5-3 mg/kg/day	most often 15/week; can increase to max 25 mg/week	2-3 mg/kg/day*	MMF 2-3 g/day** (EC-MPA 1.44 g/day)	not for maintenance ♦	300 mg/ 2 weeks
starting dose children	5 mg/kg/day	10–15 mg/m ² /week	25-50 mg/day	MMF 20–50 mg/kg/day	0.2-0.5 mg/kg/day	no data yet
maintenance dose children	2.5-3 mg/kg/day	increase 2.5-5mg/week, decrease 2.5mg/week to effective/lowest effective dose	2-3 mg/kg/day*	increase daily total dose by 500 mg every 2–4 weeks up to 30-50 mg/kg/day	not for maintenance ♦	no data yet
pregnancy	possible	teratogenic, absolutely contra-indicated	conflicting data, possible with strict indication	teratogenic, absolutely contra-indicated	possible	no data yet

fathering	possible	little information, conflicting data, contra-indicated	little information, possible with strict indication	conflicting data	possible	no data yet
------------------	----------	--	--	------------------	----------	-------------

* TPMT heterozygote 1-1.5 mg/kg/day ♦ see full text # time to reach most of expected full response

MMF: mycophenolate mofetil; EC-MPS: enteric-coated mycophenolic sodium

Table 5: Upcoming systemic drugs for treatment of atopic eczema

	Substance code	Target	Substance class	Development phase	Registration status	Trial data	Adverse drug effect signals	Recommendation
Nemolizumab	CD-14152 (formerly CIM-331)	IL31R alpha	IL31 blocker	III		♦	peripheral edema?	
Tralokinumab	CAT-354	IL13	Th2 blocker	III				
Lebrikizumab	TNX-650	IL13	Th2 blocker	II				
Tezepelumab	MEDI-9929	TSLP	TSLP blocker	II				
Upadacitinib	ABT-494	JAK1	JAK inhibitor	II				
	PF-04965842	JAK1	JAK inhibitor	III				
	ZPL-389 (formerly PF-03893787)	H4R	H4R blocker	II				

♦ see full text

References

1. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *The New England journal of medicine*. 2002;347(15):1151-60.
2. Weidinger S, Novak N. Atopic dermatitis. *Lancet*. 2016;387(10023):1109-22.
3. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res*. 2012;22(5):850-9. Epub 2012/02/09.
4. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Luscher-Firzlaff J, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. *The Journal of allergy and clinical immunology*. 2012;129(2):426-33, 33 e1-8.
5. Schlievert PM, Case LC, Strandberg KL, Abrams BB, Leung DY. Superantigen profile of *Staphylococcus aureus* isolates from patients with steroid-resistant atopic dermatitis. *Clin Infect Dis*. 2008;46(10):1562-7.
6. Allen HB, Vaze ND, Choi C, Hailu T, Tulbert BH, Cusack CA, et al. The presence and impact of biofilm-producing staphylococci in atopic dermatitis. *JAMA Dermatol*. 2014;150(3):260-5.
7. Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. *Curr Allergy Asthma Rep*. 2015;15(11):65.
8. Kong HH, Segre JA. Skin microbiome: looking back to move forward. *J Invest Dermatol*. 2012;132(3 Pt 2):933-9. Epub 2011/12/23.
9. Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, et al. Effects of nonpathogenic gram-negative bacterium *Vitreoscilla filiformis* lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. *Br J Dermatol*. 2008 159:1357-63.
10. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce *Staphylococcus aureus* in the management of atopic eczema: an updated Cochrane review. *Br J Dermatol*. 2011;164:12-26.
11. Leung TH, Zhang LF, Wang J, Ning S, Knox SJ, Kim SK. Topical hypochlorite ameliorates NF-kappaB-mediated skin diseases in mice. *J Clin Invest*. 2013;123(12):5361-70.
12. Huang JT, Abrams M, Tloutan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics*. 2009;123(5):e808-14. Epub 2009/05/01.
13. Matiz C, Tom WL, Eichenfield LF, Pong A, Friedlander SF. Children with atopic dermatitis appear less likely to be infected with community acquired methicillin-resistant *Staphylococcus aureus*: the San Diego experience. *Pediatric dermatology*. 2011;28(1):6-11.
14. Chiu LS, Chow VC, Ling JM, Hon KL. *Staphylococcus aureus* carriage in the anterior nares of close contacts of patients with atopic dermatitis. *Arch Dermatol*. 2010;146(7):748-52.
15. Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, Abeck D. Silver-coated textiles reduce *Staphylococcus aureus* colonization in patients with atopic eczema. *Dermatology*. 2003;207(1):15-21.
16. Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. *Pediatr Allergy Immunol*. 2013;24(6):603-13.
17. Vlachou C, Thomas KS, Williams HC. A case report and critical appraisal of the literature on the use of DermaSilk in children with atopic dermatitis. *Clin Exp Dermatol*. 2009;34(8):e901-3.
18. Jaeger T, Rothmaier M, Zander H, Ring J, Gutermuth J, Anliker MD. Acid-coated textiles (pH 5.5-6.5) - a new therapeutic strategy for atopic eczema? *Acta dermato-venereologica*. 2015;95:659-63.
19. Lopes C, Soares J, Tavaría F, Duarte A, Correia O, Sokhatska O, et al. Chitosan Coated Textiles May Improve Atopic Dermatitis Severity by Modulating Skin Staphylococcal Profile: A Randomized Controlled Trial. *PLoS One*. 2015;10(11):e0142844.
20. Thomas KS, Bradshaw LE, Sach TH, Batchelor JM, Lawton S, Harrison EF, et al. UK Dermatology Clinical Trials Network's CLOTHES Trial Team. Silk garments plus standard care compared with standard care for treating eczema in children: A randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial). *PLoS Med*. 2017;14(4):e1002280.

21. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. *J Am Acad Dermatol*. 2003;49(2):198-205. Epub 2003/08/02.
22. Wollenberg A. Eczema herpeticum. *Chem Immunol Allergy*. 2012;96:89-95.
23. Ong PY, Leung DY. Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review. *Clin Rev Allergy Immunol*. 2016;51(3):329-37.
24. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2016;30(5):729-47. Epub 2016/03/24.
25. Kreth HW, Hoeger PH, Members of the VZVADsg. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. *Eur J Pediatr*. 2006;165(10):677-83.
26. Schneider L, Weinberg A, Boguniewicz M, Taylor P, Oettgen H, Heughan L, et al. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. *The Journal of allergy and clinical immunology*. 2010;126(6):1306-7 e2.
27. Osier E, Eichenfield LF. The utility of cantharidin for the treatment of molluscum contagiosum. *Pediatric dermatology*. 2015;32(2):295.
28. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. *The Journal of allergy and clinical immunology*. 2003;112(4):667-74. Epub 2003/10/18.
29. Rush J, Dinulos JG. Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts. *Curr Opin Pediatr*. 2016;28(2):250-7.
30. Wollenberg A, Engler R. Smallpox, vaccination and adverse reactions to smallpox vaccine. *Curr Opin Allergy Clin Immunol*. 2004;4:271-5.
31. Reed JL, Scott DE, Bray M. Eczema vaccinatum. *Clin Infect Dis*. 2012;54(6):832-40.
32. Darso U, Sbornik M, Rombold S, Katzer K, von Sonnenburg F, Behrendt H, et al. Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2016;30(11):1971-7. Epub 2016/10/25.
33. Neri I, Dondi A, Wollenberg A, Ricci L, Ricci G, Piccirilli G, et al. Atypical Forms of Hand, Foot, and Mouth Disease: A Prospective Study of 47 Italian Children. *Pediatric dermatology*. 2016. Epub 2016/06/14.
34. Lynch MD, Sears A, Cookson H, Lew T, Laftah Z, Orrin L, et al. Disseminated coxsackievirus A6 affecting children with atopic dermatitis. *Clin Exp Dermatol*. 2015;40(5):525-8.
35. Johnson VK, Hayman JL, McCarthy CA, Cardona ID. Successful treatment of eczema coxsackium with wet wrap therapy and low-dose topical corticosteroid. *J Allergy Clin Immunol Pract*. 2014;2(6):803-4.
36. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The Role of *Malassezia* spp. in Atopic Dermatitis. *J Clin Med*. 2015;4(6):1217-28.
37. Kaffenberger BH, Mathis J, Zirwas MJ. A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. *J Am Acad Dermatol*. 2014;71(3):480-3.
38. Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2004;18(4):445-9.
39. Brodska P, Panzner P, Pizinger K, Schmid-Grendelmeier P. IgE-mediated sensitization to *malassezia* in atopic dermatitis: more common in male patients and in head and neck type. *Dermatitis*. 2014;25(3):120-6.
40. Glatz M, Buchner M, von Bartenwerffer W, Schmid-Grendelmeier P, Worm M, Hedderich J, et al. *Malassezia* spp.-specific immunoglobulin E level is a marker for severity of atopic dermatitis in adults. *Acta dermato-venereologica*. 2015;95(2):191-6.
41. Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. *Br J Dermatol*. 2010;162(3):661-8. Epub 2009/10/30.

- 1 42. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a
2 systematic review and meta-analysis. *Journal of the European Academy of Dermatology and Venereology* :
3 *JEADV*. 2007;21(5):606-19. Epub 2007/04/24.
- 4 43. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of
5 cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. *J Am*
6 *Acad Dermatol*. 2000;42(4):653-9.
- 7 44. van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum
8 Creatinine Levels During and After Long-term Treatment with Cyclosporin A in Patients with Severe Atopic
9 Dermatitis. *Acta dermato-venereologica*. 2015;doi: 10.2340/00015555-2125. Epub 2015/04/29.
- 10 45. van der Schaft J, Politiek K, van den Reek JM, Christoffers WA, Kievit W, de Jong EM, et al. Drug
11 survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. *Br J*
12 *Dermatol*. 2015;172(6):1621-7. Epub 2015/02/17.
- 13 46. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood
14 atopic dermatitis: short course versus continuous therapy. *Br J Dermatol*. 2000;142(1):52-8.
- 15 47. Granlund H, Erkkö P, Remitz A, Langeland T, Helsing P, Nuutinen M, et al. Comparison of
16 cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. *Acta*
17 *dermato-venereologica*. 2001;81(1):22-7.
- 18 48. Zurbriggen B, Wuthrich B, Cachelin AB, Wili PB, Kagi MK. Comparison of two formulations of
19 cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot
20 study. *Dermatology*. 1999;198(1):56-60.
- 21 49. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult
22 atopic dermatitis: a double-blind, placebo-controlled, crossover trial. *Br J Dermatol*. 2002;147(2):324-30.
- 23 50. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for
24 moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet*.
25 2006;367(9513):839-46.
- 26 51. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of
27 methotrexate versus azathioprine for severe atopic eczema. *The Journal of allergy and clinical immunology*.
28 2011;128(2):353-9.
- 29 52. Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response
30 and thiopurine monitoring. *J Am Acad Dermatol*. 2013;68(1):29-35.
- 31 53. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic
32 eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. *Br J*
33 *Dermatol*. 2002;147(2):308-15.
- 34 54. Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC. Efficacy and tolerability at 3 and 6 months
35 following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. *The Journal of*
36 *dermatological treatment*. 2009;20(3):141-5.
- 37 55. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk
38 for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
39 *Gastroenterology*. 2011;141(5):1621-28 e1-5. Epub 2011/06/29.
- 40 56. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA.
41 Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with
42 severe atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol*. 2011;64(6):1074-84.
- 43 57. Ballester I, Silvestre JF, Perez-Crespo M, Lucas A. [Severe adult atopic dermatitis: treatment with
44 mycophenolate mofetil in 8 patients]. *Actas Dermosifiliogr*. 2009;100(10):883-7. Tratamiento de la
45 dermatitis atópica grave del adulto con mofetil micofenolato en 8 pacientes.
- 46 58. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis.
47 *Clin Exp Dermatol*. 2007;32:23-7.
- 48 59. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic
49 dermatitis: experience in 14 patients. *Br J Dermatol*. 2007;157:127-32.
- 50 60. Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with
51 azathioprine and mycophenolate mofetil. *Pediatric dermatology*. 2011;28(6):689-94.
- 52 61. King RW, Baca MJ, Armenti VT, Kaplan B. Pregnancy outcomes related to mycophenolate exposure
53 in female kidney transplant recipients. *Am J Transplant*. 2017;17:151-60.

- 1 62. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in
2 the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr*.
3 2013;172(3):351-6. Epub 2012/12/12.
- 4 63. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of
5 methotrexate for moderate-to-severe adult atopic eczema. *Br J Dermatol*. 2007;156(2):346-51.
- 6 64. Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, et al. Low-dose methotrexate
7 treatment for moderate-to-severe atopic dermatitis in adults. *Journal of the European Academy of*
8 *Dermatology and Venereology : JEADV*. 2010;24(1):43-9.
- 9 65. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in
10 adults with moderate-to-severe atopic dermatitis. *The New England journal of medicine*. 2014;371(2):130-
11 9. Epub 2014/07/10.
- 12 66. Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in
13 adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a
14 randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet*. 2016;387(10013):40-52. Epub
15 2015/10/12.
- 16 67. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of
17 Dupilumab versus Placebo in Atopic Dermatitis. *The New England journal of medicine*. 2016;375(24):2335-
18 48. Epub 2016/10/04.
- 19 68. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term
20 management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical
21 corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3
22 trial. *Lancet*. 2017;389(10086):2287-303. Epub 2017/05/10.
- 23 69. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-Interleukin-31
24 Receptor A Antibody for Atopic Dermatitis. *The New England journal of medicine*. 2017;376(9):826-35.
- 25 70. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves
26 atopic eczema. *The Journal of allergy and clinical immunology*. 2008;121:122-8.
- 27 71. Sedivá A, Kayserová J, Vernerová E, Poloucková A, Capková S, Spísek R, et al. Anti-CD20 (rituximab)
28 treatment for atopic eczema. *The Journal of allergy and clinical immunology*. 2008;121:1515-6.
- 29 72. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized
30 monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. *Allergy*. 2005;60(5):693-6.
31 Epub 2005/04/09.
- 32 73. Oldhoff JM, Darsow U, Werfel T, Bihari IC, Katzer K, Laifaoui J, et al. No effect of anti-interleukin-5
33 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. *Int Arch Allergy Immunol*.
34 2006;141(3):290-4.
- 35 74. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion
36 of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study.
37 *J Dtsch Dermatol Ges*. 2010;8(12):990-8. Epub 2010/08/04.
- 38 75. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment
39 of atopic dermatitis: a pilot study. *Allergy Asthma Proc*. 2008;29(5):530-7.
- 40 76. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in
41 patients with atopic dermatitis. *J Am Acad Dermatol*. 2006;55(1):168-70.
- 42 77. Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG. Effectiveness of
43 omalizumab in a patient with severe asthma and atopic dermatitis. *Monaldi Arch Chest Dis*. 2008;69(2):78-
44 80. Epub 2008/10/08.
- 45 78. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, et al. Low-dose anti-IgE therapy in
46 patients with atopic eczema with high serum IgE levels. *The Journal of allergy and clinical immunology*.
47 2007;120:1223-5.
- 48 79. Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R, et al. Increased
49 efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels
50 of phosphatidylcholines. *Allergy*. 2014;69(1):132-5.
- 51 80. Lacombe Barrios J, Begin P, Paradis L, Hatami A, Paradis J, Des Roches A. Anti-IgE therapy and
52 severe atopic dermatitis: a pediatric perspective. *J Am Acad Dermatol*. 2013;69(5):832-4.

- 1 81. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of
2 omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical
3 trial. *Int Arch Allergy Immunol*. 2013;162(1):89-93. Epub 2013/07/03.
- 4 82. Doerthe AA, Wang J. Immunologic effects of omalizumab in children with severe refractory atopic
5 dermatitis: a randomized, placebo-controlled clinical trial. *Pediatrics*. 2014;134(3):160.
- 6 83. Fernandez-Anton MC, Alfageme Roldan F, Ciudad Blanco C, Suarez Fernandez R. Ustekinumab in
7 the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. *Actas*
8 *Dermosifiliogr*. 2014;105(3):312-23. Ustekinumab en el tratamiento de la dermatitis atopica severa.
9 Nuestra experiencia en 4 pacientes. Informe preliminar.
- 10 84. Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic
11 dermatitis - a report of two patients. *Journal of the European Academy of Dermatology and Venereology* :
12 *JEADV*. 2016;30(3):522-3.
- 13 85. Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of
14 ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. *Experimental dermatology*.
15 2017;26(1):28-35. Epub 2016/06/16.
- 16 86. Saeki H, Kabashima K, Tokura Y, Murata Y, Shiraishi A, Tamamura R, et al. Efficacy and safety of
17 ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-
18 controlled, phase II study. *Br J Dermatol*. 2017;177(2):419-27. Epub 2017/03/25.
- 19 87. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of
20 oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical
21 corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. *Br J Dermatol*.
22 2008;158(4):808-17.
- 23 88. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A. Treatment of atopic eczema with oral
24 alitretinoin. *Br J Dermatol*. 2010;162(1):217-8.
- 25 89. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor
26 (apremilast) for atopic dermatitis in adults. *Arch Dermatol*. 2012;148(8):890-7. Epub 2012/04/18.
- 27 90. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase
28 inhibitor tofacitinib citrate. *J Am Acad Dermatol*. 2015;73(3):395-9.
- 29 91. Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M, et al. Improvement of
30 treatment-refractory atopic dermatitis by immunoabsorption: a pilot study. *The Journal of allergy and*
31 *clinical immunology*. 2011;127:267-70.
- 32 92. Kasperkiewicz M, Sufke S, Schmidt E, Zillikens D. IgE-specific immunoabsorption for treatment of
33 recalcitrant atopic dermatitis. *JAMA Dermatol*. 2014;150(12):1350-1.
- 34 93. Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchian V, et al. Targeting IgE in Severe
35 Atopic Dermatitis with a Combination of Immunoabsorption and Omalizumab. *Acta dermato-*
36 *venereologica*. 2016;96(1):72-6. Epub 2015/06/11.
- 37 94. Broshtilova V, Gantcheva M. Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist
38 montelukast in the treatment of atopic dermatitis. *Dermatol Ther*. 2010;23(1):90-3.
- 39 95. Holme H, Winckworth LC. Montelukast can reduce the severity and extent of atopic dermatitis. *J*
40 *Paediatr Child Health*. 2013;49(5):412-5.
- 41 96. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments
42 for moderate-to-severe atopic dermatitis: a systematic review. *The Journal of allergy and clinical*
43 *immunology*. 2014;133(2):429-38.
- 44 97. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long-term Efficacy of Intravenous Immunoglobulin Therapy
45 for Moderate to Severe Childhood Atopic Dermatitis. *Allergy Asthma Immunol Res*. 2011;3(2):89-95. Epub
46 2011/04/05.
- 47 98. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial
48 of intravenous immunoglobulin in adults with severe atopic dermatitis. *Br J Dermatol*. 2002;147(3):518-22.
49 Epub 2002/09/05.
- 50 99. Doherty V, Sylvester DG, Kennedy CT, Harvey SG, Calthrop JG, Gibson JR. Treatment of itching in
51 atopic eczema with antihistamines with a low sedative profile. *BMJ*. 1989;298(6666):96.
- 52 100. Henz BM, Metzenauer P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor
53 antagonists in pruritic dermatoses. *Allergy*. 1998;53(2):180-3.

- 1 101. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with
2 atopic dermatitis. A multi-crossover-designed study. *Allergy*. 1994;49(1):22-6.
- 3 102. La Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double-blind study of cetirizine
4 in atopic eczema in children. *Ann Allergy*. 1994;73:117–22.
- 5 103. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative
6 antihistamine in atopic dermatitis. *Br J Dermatol*. 1990;122(4):545-51.
- 7 104. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiedzinski Z, et al. Chlorpheniramine
8 is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal
9 itching and scratching component. *Dermatology*. 2002;205(1):40-5.
- 10 105. van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, Jupiter A, Mattered U, Weisshaar E. No high level
11 evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a
12 Cochrane systematic review. *Syst Rev*. 2014;3:25.
- 13 106. Chunharas A, Wisuthsarewong W, Wananukul S, Viravan S. Therapeutic efficacy and safety of
14 loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. *J*
15 *Med Assoc Thai*. 2002;85(4):482-7.
- 16 107. Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E, et al. Dose ranging
17 study: cetirizine in the treatment of atopic dermatitis in adults. *Ann Allergy*. 1993;70(2):127-33.
- 18 108. Kawakami T, Kaminishi K, Soma Y, Kushimoto T, Mizoguchi M. Oral antihistamine therapy influences
19 plasma tryptase levels in adult atopic dermatitis. *J Dermatol Sci*. 2006;43(2):127-34.
- 20 109. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a
21 topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized,
22 multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol*. 2003;148(6):1212-21.
- 23 110. Diepgen TL, Early Treatment of the Atopic Child Study G. Long-term treatment with cetirizine of
24 infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the
25 ETAC trial) over 18 months. *Pediatr Allergy Immunol*. 2002;13(4):278-86. Epub 2002/10/23.
- 26 111. Yamanaka K, Motomura E, Noro Y, Umeda K, Morikawa T, Umeda-Togami K, et al. Olopatadine, a
27 non-sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic
28 dermatitis. *Experimental dermatology*. 2015;24(3):227-9.
- 29 112. Church MK, Maurer M. H1 -Antihistamines and itch in atopic dermatitis. *Experimental dermatology*.
30 2015;24(5):332-3.
- 31 113. Simons FE, Early Prevention of Asthma in Atopic Children Study G. Safety of levocetirizine treatment
32 in young atopic children: An 18-month study. *Pediatr Allergy Immunol*. 2007;18(6):535-42.
- 33 114. Thurmond RL. The histamine H4 receptor: from orphan to the clinic. *Front Pharmacol*. 2015 6:65.
- 34 115. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy
35 represent a therapeutic option for patients with atopic dermatitis? *The Journal of allergy and clinical*
36 *immunology*. 2006;118(6):1292-8.
- 37 116. Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. *Curr Allergy Asthma*
38 *Rep*. 2011;11(4):277-83.
- 39 117. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific
40 immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-
41 centre, randomized, dose-response study. *Allergy*. 2006;61(2):202-5.
- 42 118. Darsow U, Behrendt H, Ring J. Gramineae pollen as trigger factors of atopic eczema: evaluation of
43 diagnostic measures using the atopy patch test. *Br J Dermatol*. 1997;137(2):201-7.
- 44 119. Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema
45 with the atopy patch test: a randomized, double-blind multicenter study. *Atopy Patch Test Study Group. J*
46 *Am Acad Dermatol*. 1999;40(2 Pt 1):187-93.
- 47 120. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-
48 mite allergen avoidance on atopic dermatitis. *Lancet*. 1996;347(8993):15-8.
- 49 121. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic
50 twins. *Br J Dermatol*. 1982;107(5):597-602.
- 51 122. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to *Dermatophagoides*
52 *pteronyssinus* in children with atopic eczema. *Clinical and experimental allergy : journal of the British*
53 *Society for Allergy and Clinical Immunology*. 1992;22(4):440-6.

123. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. *Ann Allergy*. 1974;32(6):321-30.
124. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to *Dermatophagoides pteronyssinus* in children with asthma. *Lancet*. 1978;2(8096):912-5.
125. Zachariae H, Cramers M, Herlin T, Jensen J, Kragballe K, Ternowitz T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. *Acta Derm Venereol Suppl* (Stockh). 1985;114:48-54.
126. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, et al. Use of a specific oral hyposensitization therapy to *Dermatophagoides pteronyssinus* in children with atopic dermatitis. *Allergol Immunopathol* (Madr). 1994;22(1):18-22.
127. Mosca M, Albani-Rocchetti G, Vignini MA, Ubezio S, Nume AG, Di Silverio A. La vaccinoterapia sublinguale nella dermatite atopica. *Ital Dermatol Venereol*. 1993;128:79–83.
128. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. *The Journal of allergy and clinical immunology*. 2007;120(1):164-70.
129. Noh G, Lee KY. Pilot study of IFN-gamma-induced specific hyposensitization for house dust mites in atopic dermatitis: IFN-gamma-induced immune deviation as a new therapeutic concept for atopic dermatitis. *Cytokine*. 2000;12(5):472-6.
130. Silny W, Czarnecka-Operacz M. Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Dermatitis. Ergebnisse einer placebokontrollierten Doppelblindstudie. *Allergologie*. 2006;29:171–83.
131. Novak N, Bieber T, Hoffmann M, Folster-Holst R, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. *The Journal of allergy and clinical immunology*. 2012;130(4):925-31 e4. Epub 2012/09/06.
132. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. *The Journal of allergy and clinical immunology*. 2013;132(1):110-7.
133. Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with *Dermatophagoides farinae* drops in patients with atopic dermatitis. *International journal of dermatology*. 2014;53(5):650-5.
134. Liu L, Guo D, Liang Q, Ding S, Wu B, Zhang L, et al. The efficacy of sublingual immunotherapy with *Dermatophagoides farinae* vaccine in a murine atopic dermatitis model. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2015;45(4):815-22.
135. Artik S, Ruzicka T. Complementary therapy for atopic eczema and other allergic skin diseases. *Dermatol Ther*. 2003;16(2):150-63.
136. Ernst E, Resch K, Mills S. Complementary medicine – a definition. *Br J Gen Pract* 1995;45:506.
137. Happle R. The essence of alternative medicine. A dermatologist's view from Germany. *Arch Dermatol*. 1998;134(11):1455-60.
138. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess*. 2000;4(37):1-191.
139. Morse PF, Horrobin DF, Manku MS, Stewart JC, Allen R, Littlewood S, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response. *Br J Dermatol*. 1989;121(1):75-90.
140. Bamford JT, Gibson RW, Renier CM. Atopic eczema unresponsive to evening primrose oil (linoleic and gamma-linolenic acids). *J Am Acad Dermatol*. 1985;13(6):959-65.
141. Nankervis H, Thomas KS, Delamere FM, Barbarot S, Rogers NK, Williams HC. Scoping systematic review of treatments for eczema. Southampton (UK)2016.
142. Bahmer FA, Schafer J. [Treatment of atopic dermatitis with borage seed oil (Glandol)--a time series analytic study]. *Kinderarztl Prax*. 1992;60(7):199-202. Die Behandlung der atopischen Dermatitis mit Borretschsamen-Öl (Glandol)--eine zeitreihenanalytische Studie.
143. Borrek S, Hildebrandt A, Forster J. [Gamma-linolenic-acid-rich borage seed oil capsules in children with atopic dermatitis. A placebo-controlled double-blind study]. *Klin Padiatr*. 1997;209(3):100-4.

- 1 Gammalinolensaure-reiche Borretschsamenol-Kapseln bei Kindern mit Atopischer Dermatitis. Eine placebo-
2 kontrollierte Doppelblind-Studie.
- 3 144. Buslau M, Thaci D. Atopic dermatitis: borage oil for systemic therapy. *Z Dermatol.* 1996;182: 131–2.
- 4 145. Valsecchi R, Di Landro A, Pansera B, Reseghetti A. Gammalinolenic acid in the treatment of atopic
5 dermatitis *Journal of the European Academy of Dermatology and Venereology : JEADV.* 1996;7:77–9.
- 6 146. Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG, et al. Double-blind,
7 multicentre analysis of the efficacy of borage oil in patients with atopic eczema. *Br J Dermatol.*
8 1999;140(4):685-8.
- 9 147. Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, et al. Efficacy and tolerability of
10 borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel
11 group trial. *BMJ.* 2003;327(7428):1385.
- 12 148. Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in atopic dermatitis: a
13 randomized placebo-controlled trial. *Indian J Dermatol Venereol Leprol.* 2008;74(5):447-52.
- 14 149. Ring J, Kunz B. Unsaturated fatty acids in the treatment of atopic eczema. In: Ruzicka T, Ring J,
15 Przybilla B, editors. *Handbook of Atopic Eczema.* Berlin: Springer; 1991. p. 429–34.
- 16 150. Koch C, Dolle S, Metzger M, Rasche C, Jungclas H, Ruhl R, et al. Docosahexaenoic acid (DHA)
17 supplementation in atopic eczema: a randomized, double-blind, controlled trial. *Br J Dermatol.*
18 2008;158(4):786-92.
- 19 151. Callaway J, Schwab U, Harvima I, Halonen P, Mykkanen O, Hyvonen P, et al. Efficacy of dietary
20 hempseed oil in patients with atopic dermatitis. *The Journal of dermatological treatment.* 2005;16(2):87-
21 94.
- 22 152. Mayser P, Mayer K, Mahloudjian M, Benzing S, Kramer HJ, Schill WB, et al. A double-blind,
23 randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis.
24 *JPEN J Parenter Enteral Nutr.* 2002;26(3):151-8.
- 25 153. Bjorneboe A, Soyland E, Bjorneboe GE, Rajka G, Drevon CA. Effect of dietary supplementation with
26 eicosapentaenoic acid in the treatment of atopic dermatitis. *Br J Dermatol.* 1987;117(4):463-9.
- 27 154. Bjorneboe A, Soyland E, Bjorneboe GE, Rajka G, Drevon CA. Effect of n-3 fatty acid supplement to
28 patients with atopic dermatitis. *J Intern Med Suppl.* 1989;731:233-6.
- 29 155. Gimenez-Arnau A, Barranco C, Alberola M, Wale C, Serrano S, Buchanan MR, et al. Effects of linoleic
30 acid supplements on atopic dermatitis. *Adv Exp Med Biol.* 1997;433:285-9.
- 31 156. Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, et al. Dietary supplementation with very
32 long-chain n-3 fatty acids in patients with atopic dermatitis. A double-blind, multicentre study. *Br J*
33 *Dermatol.* 1994;130(6):757-64.
- 34 157. Anstey A, Quigley M, Wilkinson J. Topical evening primrose oil as treatment for atopic eczema. *J*
35 *Dermatol Treat.* 1990;1:199–201.
- 36 158. Ferreira M, Fiadeiro T, Silva M, Soares A. Topical gamma-linolenic acid therapy in atopic dermatitis.
37 A clinical and biometric evaluation. *Allergo J* 1998;7:213–6.
- 38 159. Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening primrose oil on epidermal
39 barrier function in atopic dermatitis as a function of vehicle. *Arzneimittelforschung.* 1999;49(7):635-42.
- 40 160. Goebel AS, Knie U, Abels C, Wohlrab J, Neubert RH. Dermal targeting using colloidal carrier systems
41 with linoleic acid. *European journal of pharmaceuticals and biopharmaceuticals : official journal of*
42 *Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV.* 2010;75(2):162-72. Epub 2010/02/23.
- 43 161. Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and
44 borage oil for eczema. *The Cochrane database of systematic reviews.* 2013(4):CD004416.
- 45 162. Bedi MK, Shenefelt PD. Herbal therapy in dermatology. *Arch Dermatol.* 2002;138(2):232-42.
- 46 163. Patzelt-Wenczler R, Ponce-Poschl E. Proof of efficacy of Kamillosan(R) cream in atopic eczema. *Eur J*
47 *Med Res.* 2000;5(4):171-5.
- 48 164. Schempp CM, Hezel S, Simon JC. [Topical treatment of atopic dermatitis with Hypericum cream. A
49 randomised, placebo-controlled, double-blind half-side comparison study]. *Hautarzt.* 2003;54(3):248-53.
- 50 Behandlung der subakuten atopischen Dermatitis mit Johanniskraut-Creme. Eine randomisierte,
51 placebokontrollierte Doppelblindstudie im Halbseitendesign.

165. Klovekorn W, Tepe A, Danesch U. A randomized, double-blind, vehicle-controlled, half-side comparison with a herbal ointment containing *Mahonia aquifolium*, *Viola tricolor* and *Centella asiatica* for the treatment of mild-to-moderate atopic dermatitis. *Int J Clin Pharmacol Ther*. 2007;45(11):583-91.
166. Ernst E. Adverse effects of herbal drugs in dermatology. *Br J Dermatol*. 2000;143(5):923-9.
167. Giordano-Labadie F, Schwarze HP, Bazex J. Allergic contact dermatitis from camomile used in phytotherapy. *Contact Dermatitis*. 2000;42(4):247.
168. Bircher AJ, Niederer M, Hohl C, Surber C. Stealth triamcinolone acetonide in a phytocosmetic cream. *Br J Dermatol*. 2002;146(3):531-2.
169. Mandeau A, Aries MF, Boe JF, Brenk M, Crebassa-Trigueros V, Vaissiere C, et al. Rhealba(R) oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inflammatory mediators. *Planta medica*. 2011;77(9):900-6. Epub 2011/01/18.
170. Stalder JF, Tennstedt D, Deleuran M, Fabbrocini G, de Lucas R, Haftek M, et al. Fragility of epidermis and its consequence in dermatology. *Journal of the European Academy of Dermatology and Venereology* : JEADV. 2014;28 Suppl 4:1-18. Epub 2014/06/17.
171. Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. *Arch Dermatol*. 1998;134(11):1388-93.
172. Vender RB. Alternative treatments for atopic dermatitis: a selected review. *Skin Therapy Lett*. 2002;7(2):1-5.
173. Sheehan MP, Rustin MH, Atherton DJ, Buckley C, Harris DW, Brostoff J, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. *Lancet*. 1992;340(8810):13-7.
174. Mostefa-Kara N, Pauwels A, Pines E, Biour M, Levy VG. Fatal hepatitis after herbal tea. *Lancet*. 1992;340(8820):674.
175. Wang L, Lu L. Analysis of 162 reported cases of side effects of Chinese medical material. *J Beijing Clin Pharm*. 1992;5:50-5.
176. Perharic L, Shaw D, Leon C, De Smet PA, Murray VS. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. *Vet Hum Toxicol*. 1995;37(6):562-6.
177. Latchman Y, Banerjee P, Poulter LW, Rustin M, Brostoff J. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). *Int Arch Allergy Immunol*. 1996;109(3):243-9.
178. Fung AY, Look PC, Chong LY, But PP, Wong E. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. *International journal of dermatology*. 1999;38(5):387-92.
179. Shapira MY, Raphaelovich Y, Gilad L, Or R, Dumb AJ, Ingber A. Treatment of atopic dermatitis with herbal combination of *Eleutherococcus*, *Achillea millefolium*, and *Lamium album* has no advantage over placebo: a double blind, placebo-controlled, randomized trial. *J Am Acad Dermatol*. 2005;52(4):691-3.
180. Gu S, Yang AW, Xue CC, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. *The Cochrane database of systematic reviews*. 2013(9):CD008642.
181. Tan HY, Zhang AL, Chen D, Xue CC, Lenon GB. Chinese herbal medicine for atopic dermatitis: a systematic review. *J Am Acad Dermatol*. 2013;69(2):295-304.
182. Liu J, Mo X, Wu D, Ou A, Xue S, Liu C, et al. Efficacy of a Chinese herbal medicine for the treatment of atopic dermatitis: a randomised controlled study. *Complement Ther Med*. 2015;23(5):644-51.
183. Chung-Jen C, Hsin-Su Y. Acupuncture, electrostimulation, and reflex therapy in dermatology. 2003;16:87-92.
184. Adaskevich VP. Clinical efficacy and immunoregulatory and neurohumoral effects of MM therapy in patients with atopic dermatitis. *Crit Rev Biomed Eng*. 2000;28(5-6):11-21.
185. Pfab F, Huss-Marp J, Gatti A, Fuqin J, Athanasiadis GI, Irnich D, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. *Allergy*. 2010;65(7):903-10.
186. Pfab F, Kirchner MT, Huss-Marp J, Schuster T, Schalock PC, Fuqin J, et al. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient- and examiner-blinded, randomized, placebo-controlled, crossover trial. *Allergy*. 2012;67(4):566-73.

- 1 187. Lee KC, Keyes A, Hensley JR, Gordon JR, Kwasny MJ, West DP, et al. Effectiveness of acupressure on
2 pruritus and lichenification associated with atopic dermatitis: a pilot trial. *Acupuncture in medicine : journal*
3 *of the British Medical Acupuncture Society*. 2012;30(1):8-11. Epub 2011/12/31.
- 4 188. Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E. Randomized, double-blind, placebo-
5 controlled trial of autologous blood therapy for atopic dermatitis. *Br J Dermatol*. 2003;148(2):307-13.
- 6 189. Schoni MH, Nikolaizik WH, Schoni-Affolter F. Efficacy trial of bioresonance in children with atopic
7 dermatitis. *Int Arch Allergy Immunol*. 1997;112(3):238-46.
- 8 190. Ernst E. The usage of complementary therapies by dermatological patients: a systematic review. *Br*
9 *J Dermatol*. 2000;142(5):857-61.
- 10 191. Eichler R, Frank H. Die Homoöpathische Behandlung der Neurodermitis bei Kindern und
11 Jugendlichen. Stuttgart,: Haug; 2002.
- 12 192. Itamura R, Hosoya R. Homeopathic treatment of Japanese patients with intractable atopic
13 dermatitis. *Homeopathy*. 2003;92(2):108-14.
- 14 193. Remy W, Rakoski J, Siebenwirth J, Ulm K, Wiesenauer M. Classical homeopathic treatment in
15 atopic dermatitis. Study protocol. *Allergologie*. 1995;18: 246–52.
- 16 194. Siebenwirth J, Lüdtke R, Remy W, Rakoski J, Borelli S, Ring J. Wirksamkeit von klassisch-
17 homöopathischer Therapie bei atopischem Ekzem. *Forsch Komplement Med* 2009;16:315–23.
- 18 195. Schachner L, Field T, Hernandez-Reif M, Duarte AM, Krasnegor J. Atopic dermatitis symptoms
19 decreased in children following massage therapy. *Pediatric dermatology*. 1998;15(5):390-5.
- 20 196. Anderson C, Lis-Balchin M, Kirk-Smith M. Evaluation of massage with essential oils on childhood
21 atopic eczema. *Phytother Res*. 2000;14(6):452-6.
- 22 197. Halevy S, Sukenik S. Different modalities of spa therapy for skin diseases at the Dead Sea area. *Arch*
23 *Dermatol*. 1998;134:1416–20.
- 24 198. Harari M, Shani J, Seidl V, Hristakieva E. Climatotherapy of atopic dermatitis at the Dead Sea:
25 demographic evaluation and cost-effectiveness. *International journal of dermatology*. 2000;39(1):59-69.
- 26 199. Shani J, Seidl V, Hristakieva E, Stanimirovic A, Burdo A, Harari M. Indications, contraindications and
27 possible side-effects of climatotherapy at the Dead-Sea. *International journal of dermatology*.
28 1997;36(7):481-92.
- 29 200. Giryas H, Friger M, Sarov B. Treatment of atopic dermatitis in the Dead Sea area: biology and
30 therapy of inflammatory skin diseases. *International Symposium at the Dead Sea Dead Sea Israel*. 1997.
- 31 201. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Landthaler M, Hofstadter F, Stolz W. Dead Sea
32 treatment - principle for outpatient use in atopic dermatitis: safety and efficacy of synchronous
33 balneophototherapy using narrowband UVB and bathing in Dead Sea salt solution. *European journal of*
34 *dermatology : EJD*. 2002;12(6):543-8.
- 35 202. Dittmar HC, Pflieger D, Schempp CM, Schopf E, Simon JC. [Comparison of balneophototherapy and
36 UVA/B mono-phototherapy in patients with subacute atopic dermatitis]. *Hautarzt*. 1999;50(9):649-53.
37 Vergleichsstudie Solebader plus UVA/B versus UVA/B- Monotherapie bei Patienten mit subakuter
38 atopischer Dermatitis.
- 39 203. Zimmermann J, Utermann S. [Photo-brine therapy in patients with psoriasis and neurodermatitis
40 atopica]. *Hautarzt*. 1994;45(12):849-53. Photosoletherapie bei Patienten mit Psoriasis und Neurodermitis
41 atopica.
- 42 204. Adachi J, Sumitsuzi H, Endo K, Fukuzumi T, Aoki T. [Evaluation of the effect of short-term
43 application of deep sea water on atopic dermatitis]. *Arerugi*. 1998;47(1):57-60.
- 44 205. Farina S, Gisondi P, Zanoni M, Pace M, Rizzoli L, Baldo E, et al. Balneotherapy for atopic dermatitis
45 in children at Comano spa in Trentino, Italy. *The Journal of dermatological treatment*. 2011;22(6):366-71.
46 Epub 2011/01/25.
- 47 206. Czeizel AE, Dobo M. Postnatal somatic and mental development after periconceptional
48 multivitamin supplementation. *Arch Dis Child*. 1994;70(3):229-33.
- 49 207. Fairris GM, Perkins PJ, Lloyd B, Hinks L, Clayton BE. The effect on atopic dermatitis of
50 supplementation with selenium and vitamin E. *Acta dermato-venereologica*. 1989;69(4):359-62.
- 51 208. Hakagawa R, Ogino Y. Effects of combination therapy with vitamins E and B2 on skin diseases.
52 Double blind controlled clinical trial. *Skin Res*. 1989;31:856–81.

209. Mabin DC, Hollis S, Lockwood J, David TJ. Pyridoxine in atopic dermatitis. *Br J Dermatol.* 1995;133(5):764-7.
210. Tsourelis-Nikita E, Hercogova J, Lotti T, Menchini G. Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels. *International journal of dermatology.* 2002;41: 146–50.
211. Sidbury R, Sullivan AF, Thadhani RI, Camargo CA, Jr. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. *Br J Dermatol.* 2008;159(1):245-7.
212. Ewing CI, Gibbs AC, Ashcroft C, David TJ. Failure of oral zinc supplementation in atopic eczema. *Eur J Clin Nutr.* 1991;45(10):507-10.
213. Udompataikul M, Huajai S, Chalermchai T, Taweetchotipatr M, Kamanamool N. The Effects of Oral Vitamin D Supplement on Atopic Dermatitis: A Clinical Trial with *Staphylococcus aureus* Colonization Determination. *J Med Assoc Thai.* 2015;98 Suppl 9:S23-30.
214. Amestejani M, Salehi BS, Vasigh M, Sobhkhiz A, Karami M, Alinia H, et al. Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. *J Drugs Dermatol.* 2012;11(3):327-30.
215. Camargo CA, Jr., Ganmaa D, Sidbury R, Erdenedelger K, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. *The Journal of allergy and clinical immunology.* 2014;134(4):831-5 e1.
216. Hata TR, Audish D, Kotol P, Coda A, Kabigting F, Miller J, et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology : JEADV.* 2014;28(6):781-9.
217. Norizoe C, Akiyama N, Segawa T, Tachimoto H, Mezawa H, Ida H, et al. Increased food allergy and vitamin D: randomized, double-blind, placebo-controlled trial. *Pediatr Int.* 2014;56(1):6-12.
218. Javanbakht MH, Keshavarz SA, Djalali M, Siassi F, Eshraghian MR, Firooz A, et al. Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. *The Journal of dermatological treatment.* 2011;22(3):144-50.
219. Stucker M, Pieck C, Stoerb C, Niedner R, Hartung J, Altmeyer P. Topical vitamin B12--a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. *Br J Dermatol.* 2004;150(5):977-83.
220. Januchowski R. Evaluation of topical vitamin B(12) for the treatment of childhood eczema. *J Altern Complement Med.* 2009;15(4):387-9.
221. Feldman SR, Vrijens B, Gieler U, Piaserico S, Puig L, van de Kerkhof P. Treatment Adherence Interventions Studies in Dermatology and Guidance on How to support Adherence. *Am J Clin Dermatol.* 2017;18:253-71.
222. Arkwright PD, Motala C, Subramanian H, Spergel J, Schneider LC, Wollenberg A, et al. Management of difficult-to-treat atopic dermatitis. *J Allergy Clin Immunol Pract.* 2013;1(2):142-51. Epub 2014/02/26.
223. Bass AM, Anderson KL, Feldman SR. Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review. *J Clin Med.* 2015;4(2):231-42.
224. Kupfer J, Gieler U, Braun A, Niemeier V, Huzler C, Renz H. Stress and atopic eczema. *Int Arch Allergy Immunol.* 2001;124:354–5.
225. Chang HY, Suh DI, Yang SI, Kang MJ, Lee SY, Lee ES, et al. Prenatal maternal distress affects atopic dermatitis in offspring mediated by oxidative stress. *The Journal of allergy and clinical immunology.* 2016;138(2):468-75.
226. Peters EM, Michenko A, Kupfer J, Kummer W, Wiegand S, Niemeier V, et al. Mental stress in atopic dermatitis - neuronal plasticity and the cholinergic system are affected in atopic dermatitis and in response to acute experimental mental stress in a randomized controlled pilot study. *PLoS One.* 2014;9(12):e113552.doi.
227. Raap U, Werfel T, Jaeger B, Schmid-Ott G. [Atopic dermatitis and psychological stress]. *Hautarzt.* 2003;54(10):925-9. Atopische Dermatitis und psychischer Stress.
228. Gieler U. Psychosomatic and psychobiological aspects of atopic eczema. In: Ring J, Przybilla B, Ruzicka T, editors. *Handbook of Atopic Eczema.* Berlin: Springer; 2006. p. 544–56.

- 1 229. Koblenzer CS, Koblenzer PJ. Chronic intractable atopic eczema. Its occurrence as a physical sign of
2 impaired parent-child relationships and psychologic developmental arrest: improvement through parent
3 insight and education. *Arch Dermatol.* 1988;124(11):1673-7.
- 4 230. Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The Psychosocial Burden of
5 Skin Diseases: A Cross-Sectional Multicenter Study among dermatological out-patients in 13 European
6 Countries. *J Invest Dermatol.* 2015;135:984-91.
- 7 231. Gieler U, Effendy I. Psychosomatische Aspekte in der Dermatologie. *Akt Dermatol* 1984;10:103–60.
- 8 232. Ring J, Palos E, Zimmermann F. [Psychosomatic aspects of parent-child relations in atopic eczema in
9 childhood. I. Psychodiagnostic test procedures in parents and children in comparison with somatic
10 findings]. *Hautarzt.* 1986;37(10):560-7. Psychosomatische Aspekte der Eltern-Kind-Beziehung bei
11 atopischem Ekzem im Kindesalter.
- 12 233. Ersner SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. Psychological and
13 educational interventions for atopic eczema in children. The Cochrane database of systematic reviews.
14 2014(1):CD004054.
- 15 234. Norris S, Ortiz DD, Sullo E. FPIN's Clinical Inquiries. Complementary and alternative therapies for
16 atopic dermatitis. *Am Fam Physician.* 2012;85(8):817-23.
- 17 235. Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. *Br J Dermatol.*
18 1996;135(4):509-15.
- 19 236. de Bes J, Legierse CM, Prinsen CA, de Korte J. Patient education in chronic skin diseases: a
20 systematic review. *Acta dermato-venereologica.* 2011;91(1):12-7.
- 21 237. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured
22 educational programmes for the management of atopic dermatitis in children and adolescents:
23 multicentre, randomised controlled trial. *BMJ.* 2006;332(7547):933-8. Epub 2006/04/22.
- 24 238. Heratizadeh A, Werfel T, Wollenberg A, Abraham S, Plank-Habibid S, Schnopp C, et al. Effects of
25 structured patient education in adult atopic dermatitis – multi-center randomized controlled trial. *The*
26 *Journal of allergy and clinical immunology.* 2017;140:845-53.
- 27 239. Bae BG, Oh SH, Park CO, Noh S, Noh JY, Kim KR, et al. Progressive Muscle Relaxation Therapy for
28 Atopic Dermatitis: Objective Assessment of Efficacy. *Acta dermato-venereologica.* 2012;92:57-61.
- 29 240. Noren P, Melin L. The effect of combined topical steroids and habit-reversal treatment in patients
30 with atopic dermatitis. *Br J Dermatol.* 1989;121(3):359-66.
- 31 241. Evers AW, Duller P, de Jong EM, Otero ME, Verhaak CM, van der Valk PG, et al. Effectiveness of a
32 multidisciplinary itch-coping training programme in adults with atopic dermatitis. *Acta dermato-*
33 *venereologica.* 2009;89(1):57-63.
- 34 242. Schut C, Mollanazar NK, Kupfer J, Gieler U, Yosipovitch G. Psychological Interventions in the
35 Treatment of Chronic Itch. *Acta dermato-venereologica.* 2016;96:157-61.
- 36 243. Niebel Ge, editor. Behavioral Medicine of Chronic Dermatological Disorders – Interdisciplinary
37 Perspectives on Atopic Dermatitis and its Treatment. Bern: Huber; 1990.
- 38 244. Daunton A, Bridgett C, Goulding JM. Habit reversal for refractory atopic dermatitis: a review. *Br J*
39 *Dermatol.* 2016 174(3):657-9.
- 40 245. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and
41 dermatological approaches to relapse prevention. *J Consult Clin Psychol.* 1995;63(4):624-35.
- 42 246. Farasat H. Cochrane Review update: psychological and educational interventions for atopic eczema
43 in children. *Community Pract.* 2014;87(9):11-2.
- 44 247. Breuer K, Matteredne U, Diepgen TL, Fartasch M, Gieler U, Kupfer J, et al. Predictors of benefit from
45 an atopic dermatitis education programme. *Pediatr Allergy Immunol.* 2014;25(5):489-95.
- 46 248. Batchelor JM, Ridd MJ, Clarke T, Ahmed A, Cox M, Crowe S, et al. The Eczema Priority Setting
47 Partnership: a collaboration between patients, carers, clinicians and researchers to identify and prioritize
48 important research questions for the treatment of eczema. *Br J Dermatol.* 2013;168(3):577-82.
- 49 249. Barbarot S, Bernier C, Deleuran M, De Raeve L, Eichenfield L, El Hachem M, et al. Therapeutic
50 patient education in children with atopic dermatitis: position paper on objectives and recommendations.
51 *Pediatric dermatology.* 2013;30(2):199-206. Epub 2013/03/07.
- 52 250. Stalder JF, Bernier C, Ball A, De Raeve L, Gieler U, Deleuran M, et al. Therapeutic patient education
53 in atopic dermatitis: worldwide experiences. *Pediatric dermatology.* 2013;30(3):329-34. Epub 2013/02/15.

- 1 251. Shaw M, Morrell DS, Goldsmith LA. A study of targeted enhanced patient care for pediatric atopic
2 dermatitis (STEP PAD). *Pediatric dermatology*. 2008;25(1):19-24.
- 3 252. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: the impact of an
4 educational intervention. *Pediatric dermatology*. 2006;23(5):428-36.
- 5 253. Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, et al. Itch intensity
6 evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life,
7 coping behaviour and SCORAD severity in 823 children. *Acta dermato-venereologica*. 2008;88(3):234-9.
- 8 254. Kupfer J, Gieler U, Diepgen TL, Fartasch M, Lob-Corzilius T, Ring J, et al. Structured education
9 program improves the coping with atopic dermatitis in children and their parents-a multicenter,
10 randomized controlled trial. *J Psychosom Res*. 2010;68(4):353-8. Epub 2010/03/24.
- 11 255. Pustišek N, Šitum M, Vurnek Živković M, Ljubojević Hadžavdić S, Vurnek M, Niseteo T. The
12 significance of structured parental educational intervention on childhood atopic dermatitis: a randomized
13 controlled trial. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2016 30:806-
14 12.
- 15 256. Moore EJ, Williams A, Manias E, Varigos G, Donath S. Eczema workshops reduce severity of
16 childhood atopic eczema. *Australas J Dermatol*. 2009;50(2):100-6.
- 17 257. Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, et al. ETFAD/EADV eczema task
18 force 2009 position paper on diagnosis and treatment of atopic dermatitis. *Journal of the European
19 Academy of Dermatology and Venereology : JEADV*. 2010;24(3):317-28. Epub 2009/09/08.
- 20 258. Courtenay M, Carey N. A review of the impact and effectiveness of nurse-led care in dermatology. *J
21 Clin Nurs*. 2007;16(1):122-8.
- 22 259. Schuttelaar ML, Vermeulen KM, Drukker N, Coenraads PJ. A randomized controlled trial in children
23 with eczema: nurse practitioner vs. dermatologist. *Br J Dermatol*. 2010;162(1):162-70.
- 24 260. Foster G, Taylor SJ, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by
25 lay leaders for people with chronic conditions. *The Cochrane database of systematic reviews*.
26 2007(4):CD005108.
- 27 261. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge,
28 therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical
29 therapies by a specialist dermatology nurse. *Br J Dermatol*. 2003;149(3):582-9.
- 30 262. Laurant M, Reeves D, Hermens R, al. e. Substitution of doctors by nurses in primary care. *Cochrane
31 Libr* 2004.
- 32 263. van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, van der Zalm A, de Bruin-Weller MS, Pasmans
33 SG, et al. E-health in caring for patients with atopic dermatitis: a randomized controlled cost-effectiveness
34 study of internet-guided monitoring and online self-management training. *Br J Dermatol*.
35 2012;166(5):1060-8. Epub 2012/01/25.
- 36 264. Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical outcomes in
37 adults with atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol*. 2011;64(3):502-7.
- 38 265. Ulf E, Maroti M, Serup J. Fluorescent cream used as an educational intervention to improve the
39 effectiveness of self-application by patients with atopic dermatitis. *The Journal of dermatological
40 treatment*. 2013;24(4):268-71.
- 41 266. Shi VY, Nanda S, Lee K, Armstrong AW, Lio PA. Improving patient education with an eczema action
42 plan: a randomized controlled trial. *JAMA Dermatol*. 2013;149(4):481-3.